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Sͤummary
Epigenetic changes are a key regulator of gene expression in different cancer histotypes. 
After investigating the differentially expressed genes upon treatment with a demethylating 
agent, e.g. DAC, we performed pathways enrichment analysis and investigated the map of 
Transcription Factors and microRNAs regulating the epigenetically modified genes. Our 
results  revealed  several  oncogenic  signalling  pathways  that  are  altered  upon  DAC 
treatment, thus depicting a breast cancer specific pathway landscape. Also, the regulatory 
maps that  have been reported offer a contribution to the understanding of the potential 
molecular mechanisms induced by DAC therapy.
1 Background
The transformation of normal cell into cancer is a complex process. Initially thought to be exclusively a 
consequence of genetic modifications in key tumor-related genes that regulate important processes, 
such  as  cell  proliferation,  cell-cycle  arrest,  DNA repair  and  other  homeostatic  functions,  recent 
advances in the field of epigenetics have provided new insights of global epigenetic modifications that 
promote cancer development and progression [1- 8]. 
The epigenetic therapy was born thanks to reversible nature of the epigenetic changes that alter gene 
expression in many tumor histotypes [9, 10]. There are several drugs with anti-tumorigenic effect that 
regulate the epigenetic status of cells, including the 5-Aza-2'-deoxycytidine (DAC, Dagogen) which is 
a potent demethylating agent known for anti-leukemic effect in the mouse model [11- 14], DAC acts to  
correct epigenetic defect including reactivation of tumor suppressor genes (TSG) [15],  silenced by 
epigenetic mechanisms in tumor tissues [2, 8]. Various phase II trials have demonstrated substantial 
activity for DAC in patients with relapsed or untreated Acute Myeloid Leukemia (AML) [16, 17]. A 
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combination of DAC with a chemotherapeutic agent (Carboplatin) in Patients with recurrent, Platinum-
resistant, Epithelial Ovarian Cancer (EOC), demonstrated a potent demethylating activity that justify 
further testing for clinical efficacy [18]. The DAC effect was evaluated in Breast cancer cell lines by 
gene expression analysis, using two concentration (5 µM and 10 µM) of DAC, suggesting a role of 
DAC tretment in different cellular processes relevant to TNF-α-dependent apoptosis  [19]. In colon 
cancer  cell  lines,  the  DAC  treatment  activates  a  set  of  hypermetilated  genes  and  promotes  a 
transcriptional down-regulation [20, 21]. 
The goal of our work is to investigate the effect of DAC treatment in MCF-7 Breast cancer cell lines,  
by performing gene expression profiling to identify epigenetically modified genes, and then to study 
their functionally enriched pathways. Moreover, we aim to build transcriptional and post-transcriptional 
regulatory networks with the goal to develop a novel anticancer target therapy. After Section 2 for 
Method description, the Results will be introduced in Section 3, and then discussed in Section 4.
2 Methods
2.1 DAC treatment and microarray data analysis
The MCF-7 cells were cultured in DMEM medium supplemented with 10% fetal bovine serum, 2 mM 
L-glutamine, at split ratio of 1:4 twice a week. After 24 hours of spit the culture medium was changed 
with media containing 2,5 µM 5-Aza-2-dC (DAC). The treated cells were collected after 48 hours of 
treatment  and  the  mRNA was  extracted  for  pelleted  cells  for  microarray  analysis.  For  cDNA 
microarray analysis: Total RNA samples were isolated from treated and untreated cells using TRIZOL 
reagent  (Invitrogen)  according  to  the  manufacturer’s  instructions.  Concentration  of  purified  RNA 
samples  were  determined  by  A260  measurement  and  the  quality  was  checked  by  Lab-on-a-chip 
analysis (total RNA nano biosizing assay, Agilent) with the Agilent 2100 Bioanalyzer. 
RNAs isolated from different tumor tissues, and transcribed in cDNAs, were used to carried out the 
microarray analysis. The cDNAs from treated breast cancer (BC) were labeled with cy5 red fluorescent  
dye and untreated BC with cy3 green fluorescent dye. Hybridization was done on a microarray chip 
called MWG Human Cancer Array containing 50-mer oligo probes for 1920 genes (1853 human genes 
associated with cancer, 27 control genes and 40 replicated genes). Spots of fluorescence intensity were 
read by dual  laser  scanner  (BioDiscovery)  and the values  were processed with dedicated software 
(Mavi Pro-2.6.0., MWG Biotech), by computing background subtraction, normalization to a number of 
housekeeping genes, and comparison with untreated cancers. 
In order to select deregulated genes, we considered the cy5/cy3 normalized ratio (NR), calculated for 
each gene and by taking the ratio of the intensity in cy5 (Ic5) and the normalized intensities in cy3 
(nIc3). Then, for simplicity and also to reduce variability, all ratio values were transformed in logarithm 
base 2. For inclusion of highly deregulated genes, we considered as up-regulated genes those with the 
log2 (NR) > 2.0, while values log2 (NR) < -2.0 were indicating down-regulated genes. 
2.2 Functional enrichment and pathways analysis
The analysis  of  the list  of significantly deregulated genes  is  based on the F-Census database  [22] 
(http://bioinfo.hrbmu.edu.cn/fcensus/Home.jsp), to extract information from highly inconsistent cancer 
gene data sources including CGC (Cancer Gene Census) [23], OMIM (Online Mendelian Inheritance in 
Man)  [24],  AGCOH(Atlas  of  Genetics  and  Cytogenetics  in  Oncology  and  Haematology)  [25], 
CancerGenes  [26], TSGDB (Tumor Suppressor Gene Database)  [27], TGDBs (Tumor Gene Family 
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Databases)  [28].  Then,  two  gene  lists  have  been  considered:  H-list  [29-  32] and  R-list  [33-  34] 
identified by two types of high-throughput techniques, and post-transcriptional regulation predicted by 
some  microRNA (miRNA)  target  prediction  algorithms  including TargetScan [35], PicTar [36], 
DIANA-microT [37] and MirTarget2 [38].
For bioinformatics and functional annotation, the tools that were considered were FatiGO, available in 
Babelomics [39,  40]  (http://babelomics.bioinfo.cipf.es),  DAVID Bioinformatics [41,  42] 
(http://david.abcc.ncifcrf.gov/gene2gene.jsp), and also over-representation analysis (ORA) available in 
ConsensusPathDB [43] (http://cpdb.molgen.mpg.de/). The tool combination was considered sufficient 
for the scopes of identifying the functional categories and biological pathways among the genes that 
were  differentially  expressed  between  treated  and  untreated  Breast  cancer. FatiGO,  Functional 
annotation  analysis  and  ORA analysis  are  tools  for  easy  and  interactive  querying  that  perform a 
functional  enrichment  analysis  by  comparing  two  lists  of  genes  (one  corresponds  to  the  list  of 
deregulated  genes  and  the  second  the  list  of  human  genome).  The  output  links  the  genes  to  the 
corresponding annotations, found in the databases (like GO terms, KEGG, Biocarta, Reactome etc.). 
Babelomics and David Bioinformatics contain an old version of data sources, while ConsensusPathDB 
contains the latest version of several databases also included in the previously listed tools.
2.3 Transcriptional and post-transcriptional regulatory network
The detection of Transcription Factors (TFs) predicted to regulate the list of significantly deregulated 
genes  upon DAC treatment  in  Breast  cancer,  was  performed using  the  web resource  TFactS [44] 
(http://www.tfacts.org/). TFactS database contains genes responsive to transcription factors, according 
to experimental evidence reported in literature. It reports two datasets: (i) A sign sensitive catalogue 
that indicates the type (up or down) of TF regulation exerted on its targets; (ii) A sign less catalogue 
that includes all regulatory interactions contained in sign sensitive and further interactions without the 
specific type of regulation.  TFactS takes as query the two lists of up and down regulated genes and 
compares it with sign sensitive catalogue of manually curated annotated target genes, and returns the 
lists of activated and inhibited transcription factors whose annotated target genes show a significant 
overlap with the query genes. We merged last versions of experimentally validated miRNA-target gene 
databases:  miRTarBase  V.2.4  [45]  (http://mirtarbase.mbc.nctu.edu.tw/),  miRecords  V.3 [46] 
(http://mirecords.biolead.org/),  and  miR2Disease  [47] (http://www.mir2disease.org/), to build a non-
redundant  dataset  of  miRNA-target  genes  regulatory  interactions  in  human.  We  used  this  non-
redundant dataset to predict the miRNA regulators among the list of significantly deregulated genes. 
We  used  Cytoscape  [48]  (http://www.cytoscape.org/),  to  show  the  transcriptional  and  post-
transcriptional  regulatory  network.  For  network  analysis,  we  used  a  tool  called 
“AdvancedNetworkMerged” that  provides  utilities  for  merging  networks  by set  operations  (union, 
intersection and difference). 
Table 1: Integrative Analysis Toolbox
Tools Scope & Use Web site
F-Census database To  extract  information  from  highly 
inconsistent cancer gene data sources
http://bioinfo.hrbmu.edu.cn/fcensus/Ho
me.jsp
FatiGO available in Babelomics Functional annotation analysis http://babelomics.bioinfo.cipf.es
DAVID Bioinformatics Functional annotation analysis http://david.abcc.ncifcrf.gov/gene2gene
.jsp
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ORA available in consensusPathDB Functional annotation analysis http://cpdb.molgen.mpg.de/
TFactS Detection  of  potential  Transcription 
Factors (TFs) 
http://www.tfacts.org/
miRTarBase V.2.4 Experimentally validated miRNA target 
genes
http://mirtarbase.mbc.nctu.edu.tw/
miRecords V.3 Experimentally validated miRNA target 
genes
http://mirecords.biolead.org/
miR2Disease Experimentally validated miRNA target 
genes
http://www.mir2disease.org/
Cytoscape Network visualization http://www.cytoscape.org/
AdvancedNetworkMerged Network analysis http://chianti.ucsd.edu/svn/csplugins/tru
nk/soc/jgao/NetworkMerge/
3 Results
3.1 Functional enrichment of differentially expressed genes after DAC treatment
Overall we have identified 336 differentially expressed genes upon DAC treatment. In particular, the 
application of the various tools yielded the following outcomes. The following points address the steps 
through which our results were obtained. After treatment of MCF-7 cell line, we performed the gene 
expression profiling to identify the epigenetically modified genes and found a total of 222 up-regulated 
genes with a log2 (NR) > 2 and integrated them with the information available in F-census (Table 1S), 
together with 114 down regulated genes with a log2 (NR) < -2 (Table 2S) after DAC treatment.
In  particular,  we found as  the  top  up-regulated  genes  the  following  genes  (Table  1S):  -CTAG1B 
(cancer/testis antigen 1B) is a member of cancer/testis (CT) antigens found expressed in  normal testis 
and in  many cancers  [49,  50].  Thanks  to  the  capacity  of  a  subset  of  these  antigens  to  activate  a 
spontaneous cellular immune responses in cancer patients  [51], this makes them ideal cancer antigen 
targets  for  tumor  immunotherapy,  especially  for  adult  T-cell  leukemia/lymphoma  (ATLL)  [52]; 
-RAB30 is  a  member  of  Ras-associated  binding  proteins  (Rabs),  that  are  involved  in  regulating 
different  steps  during exocytosis  [53]. In  particular  Rab30 is  Golgi-specific  Rabs,  required for  the 
structural integrity of the Golgi apparatus [54]; -MAGEA1 is also one of cancer/testis (CT) antigens, in 
particular  it  is  found  expressed  in  10% of  tumour  cells  in  conjunctival  melanomas  [55].  Its  up-
regulation upon DAC treatment makes it as potential candidate in combination with immunotherapy.
Then,  we  found  the  following  top  down-regulated  genes:  -CDKN2B,  a  cyclin-dependent  kinase 
inhibitor 2B (known also as p15, inhibits CDK4) and therefore a key regulator of biological processes 
to repress cell cycle progression by inhibition of cdk4 and cdk6 [56]. The observed down-regulation of 
the CDKN2B upon DAC treatment may represent a side effect of treatment and the balance between 
DNA methylation  and  demethylation  is  a  critical  regulator  of  the  methylation  status  of  cyclin-
dependent kinase inhibitor  [57]. In fact it is known that the demethylating agent functions, as DNA 
methyltransferase inhibitors and are able to incorporate into the genome during DNA replication, and to 
bind DNA methyltransferases that have the catalytic domain. This may lead to global hypomethylation 
and re-expression of both tumor suppressor genes and misregulation of proto-oncogenes [58]; - CDH6 
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(cadherin 6) is a membrane glycoprotein and a member of the cadherin superfamily type II involved in 
cell-cell adhesion, differentiation and morphogenesis. The aberrant expression of cadherin-6 correlates 
with a poor prognosis in patients with E-cadherin-absent Renal cell carcinomas (RCC) and could be a 
useful tool to estimate the malignancy potential of the tumor  [59]; -  CDH7 (cadherin 7) is another 
member of the cadherin superfamily type II. It was shown that CDH7 play a role in tumor development 
of  malignant  melanoma cells  by interacting  with  melanoma inhibitory activity  protein  (MIA)  and 
migration melanoma cell [60].
Using different functional enrichment analysis tools, we found a list of the over-represented functional 
categories and pathways among up and down-regulated gene. The results using FatiGO are reported in 
Table 3S and Table 4S. The results using functional enrichment analysis by David Bioinformatics are 
reported in Table 5S and Table 6S. The enriched pathways resulted from  ORA analysis available in 
consensusPathDB are reported in Table 7S and Table 8S. We then used the graphical tool available in 
consensusPathDB to select the most interesting pathways involved in up- and down-regulated genes 
(Figure 1 and 2). Based on the same data sources and listed tools, we obtained almost similar results. 
We next report the results obtained using ORA.
Figure 1: The over-represented pathways among the input list of 222 up-regulated genes upon DAC treatment. The 
node size indicates the size of the gene set. The node color corresponds to the p-value (deeper red means smaller P-value). 
The green node border  is used  to select the most interesting pathways. The  edge width indicates the size of the overlap 
between two nodes, while the edge color reppresents the number of shared genes in the pre-defined dataset. 
Figure  1  shows  the  most  interesting  pathways  regulated  upon  DAC  treatment,  for  which  also  a 
summary is reported in Table 2 together with the list of up-regulated genes in each specific pathway.
Table 2: The enriched pathways associated to up-regulated genes.
Pathways ID Genes p-value q-value
Atm signaling 
pathway
ATM; MDM2; RBBP8; JUN; TP73 3.23E-06 1.23E-03
Wnt Signaling 
Pathway and  
Pluripotency
WNT2B;  PRKCH;  PPP2R1B; 





STAT5B; PTPRU; RAF1; EPO 3.90E-04 1.25E-02
NF-kappa B 
signaling pathway 





JUN; GNA12; RAF1; GNA13; PAX8 1.87E-03 3.36E-02
p53 signaling 
pathway




cytokine  receptor 
interaction 
IFNW1;  TGFB3;  IL22;  EPO; 





NR2C2;  CEBPA;  RUNX2;  JUN; 
FHL2; AHR; MDM2
3.76E-03 4.07E-02
Integrated  breast 
cancer pathway











JUN; RIPK3; RAF1; APAF1; CFLAR 6.59E-03 4.90E-02
Our result show that the most enriched pathways associated to up-regulated genes is the atm signalling 
pathway. The activation of ATM (Ataxia telangiectasia mutated) and MDM2 (Mouse double minute 2), 
which represents an upstream components in atm pathway and DNA damage response mecchanism.
The mechanisms underlying the cytotoxicity of DAC treatment in gastric cancer AGScells was recently 
revealed, showing that ATM activation was associated with P53 phosphorylation and the cytotoxicity 
could be abolished using PI3K inhibitor  [61]. In our case the  ATM activation pathway is associated 
with the activation of p73 which is a member of p53 tumor suppressor family, important in regulation 
of cell cycle and apoptosis after DNA damage and found inactivated in many tumor histotypes [62, 63]. 
The methylation status  of p73 was shown to be common in patients with MDS and associated with 
poor  prognosis  [63,  64].  The  p73  play  also  a  key  role  in  p53  signalling  pathways  exerting  a 
anticarcinogenic effect  [65].  The reactivation of tumor surppressor rappresent one of  the  antitumor 
actions of demethylating agent therapy.  The activation of  the  Wnt Signalling Pathway and nuclear 
factor kappa B(NFKB) pathways are important for the control of self-renewal in normal stem cell and 
also in the biology of breast cancer stem cells  [66]. However the activation of NFKB pathway could 
leads to the production of cytokines that trigger Cytokine-cytokine receptor interaction, differentiation 
an proliferation signals, all of which contribute to chronic inflammation and malignant progression [67- 
69].  The  key  components  of  thyroid  stimulating  hormone  (TSH)  signalling  pathway  are  the  up 
regulation of guanine nucleotide binding protein GNA12 and GNA13, also known as G12 subfamily, 
which mediate G protein signaling and have been implicated in various biological and pathological 
processes [70]. 
The Jun transcription factor, known also as AP-1 or c-Jun, represents a key downstream effector of G12 
signaling pathway [71]. PAX8 is a nuclear protein, involved in regulation of thyroid-specific genes and 
development of thyroid follicular cell development. The inhibition of Pax8 may be a very attractive 
targeted therapy for  patients  with endometrial  cancer  [72].  RAF1 is  a protoncogene and functions 
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downstream of  the  Ras  family;  it is  activated  in  TSH and TNF alpha  signaling  pathway.  The  up 
regulation of RAF1 have been identified as predictive biomarker  and new target  for breast  cancer 
therapy [73]. 
Figure 2: The over-represented pathways among the input list of 114 down regulated genes upon DAC treatment. 
The node size indicates the size of the gene set. The node color corresponds to the p-value (deeper red means smaller P-
value). The green node border is used to select the most interesting pathways. The edge width indicates the size of the 
overlap between two nodes, while the edge color reppresents the number of shared genes in the pre-defined dataset.
Table 3: The enriched pathways associated to down-regulated genes.
Pathways ID Genes p-value q-value
Cytokine-cytokine 
receptor interaction 
IL2RA; IFNA8; IFNA1; 










IL2RA; IFNA8; IFNA1; 





IL2RA; IFNA1; IFNA8; 
IL2; IL26.
3.65E-03 7.52E-02
IL-2 signaling pathway IL2RA; IL2 4.34E-03 7.66E-02
Figure 2 shows the most interesting pathways regulated upon DAC treatment and a summary appears 
in Table 3 to show the list of down-regulated genes in each specific pathway. It is important to notice  
that  DAC treatment  in  MCF-7 cells  induces downregulation  of different  cytokines  and interferons 
genes that represent key regulators of the Cytokine-cytokine receptor interaction, PI3K-AKT signaling 
pathway, Jak-STAT signaling pathway and IL-2 signaling pathway. From Table 3, IL2RA and IL-2 are 
the common genes among all these pathways. The up-regulation of the interleukin-2 (IL-2) and its 
receptor alpha (IL2RA) are associated with the malignancy of the infiltrative human breast cancer [74] 
and it seems that their down-regulation upon DAC treatment could produce an anticancer effect.The 
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deregulation of these cytokines and interferons genes may suggest  a potential role as breast cancer 
biomarker or use as novel treatment in combination with DAC treatment.
3.2 Transcriptional and post-transcriptional regulatory networks
We built via a cytoscape tool called “AdvancedNetworkMerged” the union of transcriptional network 
resulted  from  TFactS analysis  (Table  9S),  and  the  miRNA regulatory  network  to  show  TFs  and 
miRNAs experimentally validated as candidate regulators of the epigenetically modified genes in BC 
(Figure 3). Then, we selected only TFs up-regulated upon DAC treatment,  according to our analysis, 
and we extracted the first neighbors of the selected TFs that resulted epigenetically modified (Figure 4).
The following box introduces the symbols of the next two figures.
Figure 3: The global network resulted from the union of transcriptional and post-transcriptional networks.  Node 
shape indicates the physical entity (ellipse for epigenetically modified genes, Hexagon for TFs and Diamond for miRNAs). 
Node color indicates the differentially expressed genes (red for up-regulated genes and green for down-regulated genes).  
Node border color indicate the significant TFs enriched (with p value<0.05) from TFactS analysis (red for activated TFs 
and green for inhibited TFs). The non-colored nodes correspond to TFs that regulate at least one target of the epigenetically 
modified genes.
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Gene DE: red( up-regulated), green(down-regulated);
miRNA: border color reflects the presence of miR-family.
TF: red (activated) and green (inhibited);
TF activation; TF repression; miRNA repression; 
Figure 4: Selected first neighbors of TF epigenetically modified genes from Figure 3.
From  our  regulatory  map  we  found  that  five  TFs  correspond  to  up-regulated  genes  upon  DAC 
treatment.  The most  up-regulated  transcription  factor  is  CEBPA (with  a  log2  (NR)  = 3.68),  called 
CCAAT/enhancer binding protein alpha. This is a key transcription factor involved in the regulation of 
cellular processes, especially in Hematopoietic system [75]. It was found epigenetically modified and 
post-transcriptionally regulated by miR-124 after DAC and trichostatin treatment in Acute Myeloid 
Leukemia [76]. This mechanism of regulation may be the same also in Breast cancer, in agreement with 
our outcomes (Figure 4). Another important miRNA that regulate CEBPA is miR-138, which was found 
to inhibit adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells [77]. We 
couldn't found any association to Breast cancer and epigenetic status. However, we found also that 
CEBPA together with RUNX2 (runt-related transcription factor 2) activates PTGS2 (prostaglandin-
endoperoxide synthase 2), also known as cyclooxygenase-2(COX-2), which is an inducible enzyme 
responsible  in  the  prostanoid  biosynthesis  and  is  involved  in  inflammation  and  mitogenesis  [78]. 
PTGS2 is a target for development of anticancer therapy, and the use of anti-inflammatory PTGS2 
inhibitors represents a promising strategy in the treatment of solid tumors [79].
Another interesting result is that the up-regulation of Jun TF is connected to the activation of TIMP1 
which is a mettallopeptidase inhibitor and its overexpression contribute to antimetastatic effect in BC 
[80] and to the activation of NQO1 (NADPH quinone oxidoreductase 1), which plays a cytoprotective 
role  and was also found associated  to  increase cell-sensitivity to  anticancer  treatment  in  BC  [81]. 
Another important JUN target is the SERPINB5 (serpin peptidase inhibitor clade B, member 5) found 
also up-regulated upon DAC treatment and known as an important suppressor of the invasion and 
migration  of  cancer  cells  [82].  STAT5B (signal  transducer  and  activator  of  transcription  5B)  is  a 
member of the STAT family of transcription factors, normally activated in response to cytokines and 
growth factors signals.  It  has been shown that  the regulation of STAT1/STAT5 signalling pathway 
mediated by STAT5B is important in the regulation of essential functions in the mammary gland [83]. 
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The TFact tool reported among the up-regulated target of STAT5B the DPAGT1 target, which is an 
enzyme that catalyzes glycoprotein biosynthesis and was found to be targeted also by wnt/β-Catenin 
signalling pathways, mediating a variety of critical developmental processes [84].
4 Discussion
The improved curation of database reporting pathway definitions and regulatory interactions allowed to 
to draw a representative picture of the major gene players and pathway landscape that are regulated in 
DAC  treatment  in  Breast  cancer.  The  dissection  of  the  key  pathways  and  the  knowledge  of  the 
interconnections between its components,  are fundamental to conceive new therapeutic approaches. 
Our results are in agreement with other studies that showed the mechanism underlying the anticancer 
effect of DAC treatment and its involvement in activation ATM-p53 signalling pathways in cancer cell 
lines [61] and oncogenic pathways in MCF-7 brest cancer cells [19]. 
The  identification  of  a  potential  TF-miRNA regulatory  network  contributes  to  shed  light  on  the 
potential  molecular  mechanism  played  by  DAC  treatment  in  MCF-7  breast  cancer.  One  of  this 
molecular mechanism is the activation of an important transcription factor (TF), the CEBPA and its 
post-transcriptional  regulator  miR-124  by  demethylating  agent,  suggested  as  predictors  for 
effectiveness  of  epigenetic  therapy  in  Acute  Myeloid  Leukemia  [76] and  that  could  be  further 
investigated also in breast cancer. 
All these evidences will help to design new therapeutic formulations, and to find the best therapeutic 
combinations  between  the  use  of  demethylating  agent  as  DAC  and  immonotherapy,  e.g  directly 
targeting  the  CT  antigens  the  cancer  antigens  or  other  therapeutic  tools  that  could  improve  the 
anticancer  effect  of  the  demethylating  agent,  obtaining  therefore more  efficient  therapy for  breast 
cancer. Moreover, we are confident that gene expression signatures could give aid to the discovery of 
connections among pathways, molecular mechanisms and drugs and might significantly contribute to 
the improvement of drug for cancer therapy.
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Supplementary materials:
Table 1S: The list with the expression values of up-regulated genes and the corresponding information 
extracted from F-census about Gene type: oncogene or TSG (tumor suppressor gene) extracted from 
both CGC and TSGDB; Cancer type according to the classes provided in COSMIC; mutation 
frequency calculated by the means of six high-throughput mutational screen data of cancer genomes 
(PMID: 18772890, 18772396, 18772397, 18948947, 17932254, 17344846); the number of miRNA 
predicted to regulate the target cancer genes, extracted from prediction tools including TargetScans, 
PicTar, DIANA-microT and MirTarget2. 
Table 2S: Same as Table 1, but the provided list is with the expression value of down-regulated genes.
Table 3S: The list of the most enriched Functional categories and pathways among up-regulated genes 
extracted from different data sources using FatiGO tool. The database ID (identifier) which starts with 
h_ indicates ID from Biocarta database, REACT indicates ID from Reactome database, hsa corresponds 
to KEGG ID, GO indicates Gene Ontology biological process or cellular component ID. 
1To whom correspondence should be addressed. Email: ECapobianco@med.miami.edu
Table 4S: The list of the most enriched Functional categories and pathways among down-regulated 
genes extracted from different data sources using FatiGO tool. The database ID (identifier) which starts 
with hsa corresponds to KEGG ID, GO indicate Gene Ontology biological process or cellular 
component ID. 
Table 5S: The list of terms and pathways resulted from David bioinformatics analysis that involve gene 
significantly up-regulated after DAC treatment.
Table 6S: The list of terms and pathways resulted from David bioinformatics analysis that involve gene 
significantly down-regulated after DAC treatment.
Table 7S: The list of manually curated pathways resulted from ORA tool using as input list the up 
-regulated genes.
Table 8S: The list of pathways resulted from ORA using as input list the  down-regulated genes.
Table 9S: The list of TFs resulted enriched among the epigenetically modified genes.
Table 1S
Gene Symbol Gene type Tumor type mutate percent Source Gene Function
CTAG1 156,39 7,29 cancertestis antigen 1
RAB30 72,71 6,18 rab30 member ras oncogene family
MAGEA1 70,24 6,13
IL8 49,82 5,64
CDA 38,53 5,27 cytidine deaminase
AADAC 38,13 5,25 arylacetamide deacetylase
GNA12 32,89 5,04 0 R-list 
BRDT 31,47 4,98 Gastric, Lung 2/210=0.0095 H-list testis-specific bromodomain protein
LGALS4 25,07 4,65 galectin 4
CTAG2 24,76 4,63 cancertestis antigen 2
POV1 24,74 4,63 0 R-list prostate cancer overexpressed 1
DNM1 22,36 4,48 dynamin 1
TEAD4 21,67 4,44 clone mgc:9014 image:3913870 
PRKRI 21,54 4,43
THRB 20,96 4,39
TRPM1 20,30 4,34 0 1/67=0.0149 melastatin 1
NKTR 20,25 4,34 natural killer-tumor recognition sequence
FLJ20539 19,97 4,32 hypothetical protein flj20539
GNA13 19,10 4,26
HCK 18,69 4,22 0 5/527=0.0095 hemopoietic cell kinase
CYP24 17,50 4,13 cytochrome p450 subfamily xxiv
ABL2 17,22 4,11 Oncogene AML 5/498=0.01 
RAD50 17,02 4,09 rad50 homolog s. cerevisiae
MADH4 16,70 4,06 TSG 15/375=0.04 
PARM1 16,57 4,05 clone mgc:3551 image:3028327 
CCK 16,33 4,03 cholecystokinin 8
CEACAM1 16,31 4,03 0
CRABP1 16,31 4,03 cellular retinoic acid-binding protein 1
TIAM1 15,99 4,00 Colorectal 2/125=0.016 t-cell lymphoma invasion and metastasis 1
CFLAR 15,91 3,99 0 casp8 and fadd-like apoptosis regulator
GNE 15,71 3,97
MCC 15,40 3,95 TSG Breast, Colorectal mutated in colorectal cancers
PTGS2 14,56 3,86 0 prostaglandin-endoperoxide synthase 2
MAGEB2 14,40 3,85 melanoma antigen family b 2
MALT1 14,20 3,83 Oncogene MALT 
HPSE 13,92 3,80 0 R-list heparanase
ZNF43 13,52 3,76 zinc finger protein 43 htf6
FANCE 13,40 3,74 TSG AML, Leukemia fanconi anemia complementation group e
IFNAR2-2 13,17 3,72 interferon receptor ifnar2-2 splice variant 
TU3A 13,04 3,70 downregulated in renal cell carcinoma
LBC 12,95 3,70 0 1/67=0.0149 R-list lymphoid blast crisis oncogene
CEBPA 12,82 3,68 Oncogene ccaatenhancer binding protein cebp alpha
ALPPL2 12,79 3,68 placental-like alkaline phosphatase
CYP3A3 12,75 3,67




DPAGT1 11,95 3,58 Breast 2/125=0.016 H-list 
IGF2 11,84 3,57 0 insulin-like growth factor somatomedin a
ZNF217 11,79 3,56 0 1/125=0.008 zinc finger protein 217
MMP8 11,75 3,56 0 matrix metalloproteinase 8
PRKCE 11,46 3,52 protein kinase c epsilon
STAT5B 11,42 3,51 Leukemia 2/230=0.0087 











guanine nucleotide binding protein g alpha 
12
17 
protein-kinase interferon-inducible double 
stranded rna dependent inhibitor
thyroid hormone receptor beta 
erythroblastic leukemia viral v-erb-a 
oncogene homolog 2 avian
AGCOH 
guanine nucleotide binding protein g alpha 
13
28 R-list, TGDBs 
AGCOH , CGC , 
Reviews , TGDBs 
v-abl abelson murine leukemia viral 
oncogene homolog 2 isoform a
Gastrointestinal, 
Pancreatic 369 
AGCOH , CGC , H-
list, OMIM , TSGDB 
mad mothers against decapentaplegic 
homolog 4 drosophila
AGCOH 
carcinoembryonic antigen-related cell 
adhesion molecule biliary glycoprotein
276 AGCOH , H-list, R-list 
AGCOH 
udp-n-acetylglucosamine-2-epimerasen- 




AGCOH , CGC , 
OMIM , Reviews 
mucosa associated lymphoid tissue 
lymphoma translocation 1
87 AGCOH , CGC 
Myelodysplastic 
syndrome 55 
AGCOH , CGC , 
OMIM 
cytochrome p450 subfamily iiia 
niphedipine oxidase polypeptide 3




killer cell immunoglobulin-like receptor 






285 AGCOH , R-list 
TGDBs 
227 OMIM , R-list 






Renal, T-PLL 325 
AGCOH , CGC , H-
list, OMIM , 
Reviews , TGDBs , 
TSGDB 
ataxia telangiectasia mutated includes 
complementation groups a c and d
Table 1S
PMX1 11,38 3,51 Oncogene AML 
PGF 11,26 3,49
VAV2 11,25 3,49 vav 2 oncogene
C21ORF7 11,17 3,48 chromosome open reading frame 7
LHX1 11,03 3,46 lim homeobox protein 1
XRCC2 10,84 3,44
PPY 10,83 3,44 pancreatic polypeptide
ACATN 10,83 3,44 acetyl-coenzyme a transporter
TNFRSF8 10,82 3,44 0 1/154=0.0065 R-list cd30 antigen ki-1 antigen
FOLR1 10,56 3,40 folate receptor 1
SLC12A2 10,55 3,40
TFF3 10,47 3,39 0 trefoil factor intestinal
LOC51339 10,18 3,35 heptacellular carcinoma novel-3 protein
10,05 3,33
DCC 10,01 3,32 TSG Breast, Colorectal 1/125=0.008 deleted in colorectal carcinoma
CSR1 9,89 3,31 csr1 protein
PPM1D 9,86 3,30 Breast 
PNMA2 9,76 3,29 paraneoplastic antigen ma2
IL13RA2 9,74 3,28 interleukin 13 receptor alpha 2
TNFRSF14 9,44 3,24 0 R-list 
CSF2RA 9,43 3,24 0
RUNX2 9,42 3,24 0 runt-related transcription factor 2
SFTPC 9,42 3,24 surfactant pulmonary-associated protein c
NR0B1 9,41 3,23 adrenal hypoplasia protein
MC2R 9,37 3,23 melanocortin receptor
HUNK 9,30 3,22
FLJ20825 9,17 3,20 hypothetical protein flj20825
FUT8 9,16 3,20
FXYD 9,12 3,19
OVOL1 9,05 3,18 ovo-like binding protein
TNFAIP6 9,00 3,17
WRN 8,93 3,16 TSG 1/125=0.008 werner syndrome wrn. 
SIAT8A 8,92 3,16
AHR 8,92 3,16 aryl hydrocarbon receptor
SSI-1 8,86 3,15 TSG 1/154=0.0065 jak binding protein
CPNE7 8,73 3,13 copine 7
POMC 8,69 3,12
MAGEB3 8,66 3,11 melanoma antigen family b 3
TM4SF2 8,47 3,08 transmembrane superfamily member 2
FVT1 8,45 3,08 Oncogene B-NHL 
C16ORF3 8,44 3,08 chromosome 16 open reading frame 3
CYP4A11 8,22 3,04
MDM2 8,18 3,03 3/317=0.0095 
TNFRSF11A 8,12 3,02
TACC2 8,07 3,01 Breast 3/125=0.024 H-list 
DDX6 7,97 2,99 Oncogene B-NHL 
EIF4EBP3 7,85 2,97
RBBP8 7,83 2,97 Pancreatic retinoblastoma-binding protein 8
SIGLEC5 7,82 2,97 sialic acid binding ig-like lectin 5
TAL1 7,79 2,96 Oncogene t-cell acute lymphocytic leukemia 1
PDGFRL 7,79 2,96 TSG Colorectal, Hepatic 
SERPINC1 7,78 2,96
ABCG2 7,77 2,96
TP73 7,75 2,95 0 1/230=0.0043 tumor protein p73
TOM1 7,72 2,95 target of myb1 chicken homolog
359 CGC , Reviews 
paired mesoderm homeobox isoform pmx-
1a
placental growth factor vascular 
endothelial factor-related protein
x-ray repair cross complementing protein 
2






ig alpha 2=immunoglobulin a heavy chain 
allotype 2 {constant region germ line}
73 
OMIM , TGDBs , 
TSGDB 
132 AGCOH , OMIM 
protein phosphatase 1d magnesium-
dependent delta isoform
tumor necrosis factor receptor superfamily 




stimulating factor receptor alpha-subunit 
gm-csf-ra3 
AGCOH , R-list 
hormonally upregulated neu-associated 
kinase
fucosyltransferase alpha 16 
fucosyltransferase
fxyd domain-containing ion transport 
regulator 3 fxyd3 transcript variant 1. 
tumor necrosis factor alpha-induced 
protein 6
Osteosarcoma , 





Lymphoma, PMBL 102 AGCOH , CGC 
proopiomelanocortin adrenocorticotropin 
beta-lipotropin alpha-melanocyte 
stimulating hormone beta-melanocyte 
beta-endorphin
133 CGC , Reviews 
follicular lymphoma variant translocation 
1




AGCOH , OMIM , 
Reviews , TGDBs 
mouse double minute 2 homolog isoform 
mdm2c
tumor necrosis factor receptor superfamily 
member 11a activator of nfkb tnfrsf11a. 
70 
transforming acidic coiled-coil containing 
protein 2
250 CGC , R-list, Reviews 
deadh asp-glu-ala-asphis box polypeptide 
6
eukaryotic translation initiation factor 4e 
binding protein 3
47 AGCOH , OMIM 
lymphoblastic 
leukemia/biphasic 306 
OMIM , Reviews , 
TGDBs 
68 OMIM , TSGDB 
platelet-derived growth factor receptor-
like protein
serine or cysteine proteinase inhibitor 
clade c antithrombin member 1




LOC151096 7,68 2,94 hypothetical protein xp_087095
CLCA4 7,65 2,93 calcium activated chloride channel 4
LOC51049 7,61 2,93 clone 1900 unknown protein
LOC51213 7,56 2,92 hom-tes-85 tumor antigen
JUN 7,54 2,92 0
SEL1L 7,54 2,91 0 sel-1 suppressor of lin-12-like c. elegans
SDCCAG10 7,46 2,90
SLC2A8 7,43 2,89
AKAP1 7,35 2,88 a kinase prka anchor protein 1
IL8RA 7,33 2,87 interleukin 8 receptor alpha
TFPI2 7,28 2,86 tissue factor pathway inhibitor 2
STATI2 7,27 2,86 0 stat induced inhibitor-2
ARTS-1 7,16 2,84
DF 6,99 2,80 adipsincomplement factor d
RAB7L1 6,88 2,78 rab7 member ras oncogene family-like 1
PTPRU 6,85 2,78 Colorectal 3/125=0.024 H-list 
NR2C2 6,78 2,76
NCP94 6,71 2,75
APAF1 6,67 2,74 0
CIS4 6,66 2,74 stat induced inhibitor-4
SCYB10 6,65 2,73
RSN 6,65 2,73
MRAS 6,63 2,73 muscle ras oncogene homolog
AMPH 6,63 2,73 amphiphysin
MMP14 6,63 2,73 0 R-list matrix metalloproteinase 14
EPO 6,62 2,73 0 erythropoietin
KLK5 6,60 2,72 0 kallikrein 5
ISLR 6,55 2,71
REG1A 6,51 2,70
IFNW1 6,47 2,69 interferon-omega 1
OSR1 6,46 2,69 oxidative-stress responsive 1
ANGPT2 6,46 2,69 angiopoietin 2
RCV1 6,44 2,69 recoverin
XYLB 6,44 2,69 xylulokinase homolog h. influenzae
PTGIS 6,41 2,68 prostaglandin i2 prostacyclin synthase
LIG3 6,37 2,67 clone mgc:16948 image:4184595 
CDR1 6,36 2,67
CACNA1A 6,33 2,66
PTH 6,30 2,65 Breast parathyroid hormone
CHS1 6,27 2,65 beige protein homolog
RAD54L 6,25 2,64 rad54-like s. cerevisiae
CTSO 6,23 2,64 cathepsin o
HCA112 6,23 2,64
PILRALPHA 6,21 2,63
ERG 6,17 2,63 Oncogene 2/230=0.0087 
TNFRSF6 6,13 2,62 TSG apoptosis apo-1 antigen 1
CDH11 6,12 2,61 Oncogene 0 4/230=0.0174 cadherin 11 type 2 isoform 1
SEMA3C 6,04 2,59
EVI5 6,03 2,59 ecotropic viral integration site 5
HTLF 6,00 2,58 t-cell leukemia virus enhancer factor
DLEU1 5,93 2,57 TSG 0 deleted in lymphocytic leukemia 1
XPR1 5,93 2,57
RAF1 5,81 2,54 Lung, Ovarian 3/527=0.0057 
ABCA3 5,78 2,53 Breast 4/212=0.0189 H-list 
MEST 5,77 2,53
C3 5,76 2,53 complement component 3 alpha chain
WNT1 5,73 2,52 0
NCYM 5,66 2,50 dna-binding transcriptional activator
CTSG 5,59 2,48 cathepsin g
PAX8 5,59 2,48 Oncogene Thyroid paired box 8 isoform pax8b
CP 5,54 2,47 ceruloplasmin ferroxidase mature peptide
116 AGCOH , TGDBs 
v-jun avian sarcoma virus 17 oncogene 
homolog
393 AGCOH 
serologically defined colon cancer antigen 
10 sdccag10. 
solute carrier family 2 facilitated glucose 
transporter member 8
109 AGCOH 
type tumor necrosis factor receptor 
shedding aminopeptidase regulator
145 
protein tyrosine phosphatase receptor type 
u
nuclear receptor subfamily group c 
member 2
fer fpsfes related tyrosine kinase 
phosphoprotein ncp94
222 AGCOH 
apoptotic protease activating factor 
isoform b
interferon gamma-induced protein of 10 
kda




immunoglobulin superfamily containing 
leucine-rich repeat
regenerating islet-derived alpha pancreatic 
stone protein thread protein
cerebellar degeneration-related protein 
34kd




Lymphoma 17 OMIM 
hepatocellular carcinoma-associated 
antigen 112
paired immunoglobulin-like receptor alpha
AML, Ewing 
sarcoma, Prostate 
AGCOH , CGC , R-
list, Reviews , TGDBs 
v-ets erythroblastosis virus e26 oncogene 
like avianLymphoma, Oral, 
Testis 161 
CGC , OMIM , R-list, 
TGDBs 
290 CGC 
sema domain immunoglobulin ig short 
basic secreted semaphorin 3c
TSGDB 
xenotropic and polytropic retrovirus 
receptor
124 
AGCOH , H-list, 
Reviews 
v-raf-1 murine leukemia viral oncogene 
homolog 1
80 
atp-binding cassette sub-family a member 
3
mesoderm specific transcript homolog 
mouse
150 R-list, TGDBs 
wingless-type mmtv integration site family 
member 1
210 CGC , Reviews 
Table 1S
RGS4 5,42 2,44 regulator of g-protein signaling 4
RIG 5,39 2,43 0 regulated in glioma rig 
FRAT1 5,37 2,43
HOXA9 5,34 2,42 Oncogene AML homeo box a9
SCGF 5,32 2,41
VPREB1 5,32 2,41 0 R-list immunoglobulin iota chain
SLC29A2 5,32 2,41
GAGE7 5,30 2,41 g antigen 7
HSD17B2 5,30 2,40 hydroxysteroid 17-beta dehydrogenase 2
UGT2A1 5,29 2,40
RIPK3 5,28 2,40
MLLT3 5,26 2,39 Oncogene ALL 
DCC 5,16 2,37 deleted in colorectal carcinoma
PRG2 5,10 2,35 Pancreatic 1/67=0.0149 H-list 
ERCC6 5,09 2,35 Colorectal, Lung 4/125=0.032 
PCDH7 5,07 2,34 protocadherin 7 isoform b
ID2 5,01 2,33 0 R-list 
CD6 4,98 2,32 0 1/67=0.0149 R-list cd6 antigen
POM121L1 4,95 2,31
CD5 4,83 2,27 put. mature peptide aa 1-471




GOLGA3 4,70 2,23 golgi autoantigen golgin subfamily a 3
IL22 4,69 2,23 il-10-related t-cell-derived inducible factor
CTSL2 4,61 2,21 cathepsin l2
POU2AF1 4,61 2,20 Oncogene NHL pou domain class associating factor 1
XPC 4,59 2,20 TSG 
COL1A2 4,55 2,19 0 1/154=0.0065 alpha 2 type i collagen
WNT2B 4,54 2,18
PBX2 4,53 2,18 pre-b-cell leukemia transcription factor 2
FANCC 4,53 2,18 TSG AML, Leukemia fanconi anemia complementation group c
NAGA 4,46 2,16 alpha-n-actylgalactosaminidase
ADAM17 4,43 2,15
OTC 4,43 2,15 ornithine carbamoyltransferase
MGAT5 4,41 2,14
TGFB3 4,41 2,14 transforming growth factor beta 3
TDG 4,38 2,13 thymine-dna glycosylase
LIFR 4,36 2,12 Oncogene Salivary gland 1/212=0.0047 leukemia inhibitory factor receptor
SCYB14 4,35 2,12
DSG3 4,21 2,07 desmoglein 3
LOC63928 4,20 2,07 hepatocellular carcinoma antigen 520
CYP27A1 4,18 2,07
FHL2 4,17 2,06 0 four and a half lim domains 2
ABCC4 4,12 2,04
TYROBP 4,12 2,04
OA1 4,05 2,02 ocular albinism nettleship-falls protein
PUTATIVE 4,05 2,02
TSC1 4,04 2,01 TSG 3/317=0.0095 tsc1 hamartin
PRKCH 4,04 2,01 3/527=0.0057 H-list protein kinase c eta
TGDBs 
frequently rearranged in advanced t-cell 
lymphomas
163 
AGCOH , CGC , R-
list, Reviews 
stem cell growth factor LYMPHOCYTE 
SECRETED C-TYPE LECTIN SCGF. 
solute carrier family 29 nucleoside 
transporters member 2





AGCOH , CGC , 
Reviews 
myeloidlymphoid or mixed-lineage 
leukemia trithorax drosophila homolog
93 
proteoglycan bone marrow natural killer 
cell activator eosinophil granule major 
basic protein
31 
AGCOH , H-list, 
OMIM 
excision repair cross-complementing 
rodent deficiency complementation group 
6
inhibitor of dna binding dominant negative 
helix-loop-helix protein
similar to rat integral membrane 
glycoprotein pom121
22 OMIM 
protein phosphatase formerly 2a regulatory 
subunit a pr 65 beta isoform




tyrosine kinase with immunoglobulin and 
epidermal growth factor homology 
domains
149 
AGCOH , CGC , 
Reviews 
basal cell, Skin 
squamous cell 102 AGCOH , CGC 
xeroderma pigmentosum complementation 
group c
148 AGCOH , Reviews 
wingless-type mmtv integration site family 
member 2b isoform wnt-2b2
241 
AGCOH , CGC , R-
list 
a disintegrin and metalloproteinase 
domain 17 isoform 1
alpha-136-mannosylglycoprotein beta-16-
n-acetyl-glucosaminyltransferase
440 CGC , Reviews 
small inducible cytokine subfamily b cys-
x-cys member 14 brak
cytochrome p450 subfamily xxviia 
polypeptide precursor
AGCOH 
atp-binding cassette sub-family c member 
4
tyro protein tyrosine kinase binding 
protein




matosis, Renal 290 
AGCOH , CGC , 
OMIM ALL, Color ctal, 
Ovarian 116 
Table 2S
Gene_Symbol Breast Cancer ratio Log2 (BC.ratio) gene type tumor type mutate percent micro num source Gene Function
CDKN2B 0,01 -6,43 TSG 0 1/317=0.0032 cyclin-dependent kinase inhibitor 2b isoform 1
CDH6 0,01 -6,41 cadherin 6 type 2
CDH7 0,02 -5,34 Breast 2/125=0.016 H-list cadherin 7 type 2
LOC146359 0,03 -5,32 similar to nadh dehydrogenase ubiquinone 1 alpha subcomplex 5 13kd b13 loc146359. 
FKSG2 0,03 -5,20 apoptosis inhibitor
MMP16 0,04 -4,61 matrix metalloproteinase 16 isoform 2
FGF20 0,04 -4,56 fibroblast growth factor 20
MGB2 0,04 -4,56 mammaglobin 2
PRO1866 0,04 -4,49 hypothetical protein pro1866
LOC158668 0,05 -4,42 similar to telomeric repeat binding factor nima-interacting 1
FCGR2A 0,05 -4,31 igg fc receptor
ANKTM1 0,05 -4,26 ankyrin-like protein 1
CYP1A2 0,06 -3,97 cytochrome p450 subfamily i aromatic compound-inducible polypeptide 2
IMPG1 0,07 -3,86 interphotoreceptor matrix proteoglycan 1
CALCR 0,07 -3,75 Oncogene 0 calcitonin receptor
ACVRL1 0,08 -3,72 activin a receptor type ii-like mature peptide
SERPINB13 0,08 -3,58 serine or cysteine proteinase inhibitor clade b ovalbumin member 13
MYO1A 0,08 -3,58 myosin ia
EBI2 0,08 -3,57 0 R-list ebv-induced g protein-coupled receptor 2
ACTC 0,09 -3,55 actin alpha cardiac muscle actc
P45 0,09 -3,53 0 cd38 antigen p45
LOC147584 0,09 -3,53 similar to smoothened homolog drosophila
TCF2 0,10 -3,36 Renal transcription factor 2 isoform a
CBFA2T2 0,10 -3,35 core-binding factor runt domain alpha subunit 2
CRYBA1 0,10 -3,32 crystallin beta a3
SLC26A4 0,10 -3,29 pendrin
IFNA1 0,11 -3,23 from leukocyte
MAGEB1 0,11 -3,22 melanoma antigen family b 1
TNFRSF7 0,11 -3,21 0 R-list cd27 antigen
VEGF 0,11 -3,19 0 vascular endothelial growth factor
STAG1 0,11 -3,13 0 R-list stromal antigen 1
NY-REN-60 0,12 -3,11 ubiquitin specific protease
PTPRC 0,12 -3,04 0 1/125=0.008 R-list mature lca aa - 1281
SH3BP2 0,12 -3,03 sh3-domain binding protein 2
KLRG1 0,12 -3,02 killer cell lectin-like receptor subfamily g member 1
NDRG2 0,13 -2,97 0 1/125=0.008 kiaa1248
PSG3 0,13 -2,96 pregnancy-specific beta-1 glycoprotein
RORB 0,13 -2,91 rar-related orphan receptor b
IL2RA 0,13 -2,90 0 interleukin-2 receptor
NOL4 0,13 -2,90 nucleolar protein 4
TNFSF8 0,14 -2,84 tumor necrosis factor ligand superfamily member 8
CD8B1 0,14 -2,84 cd8 antigen beta polypeptide p37
IL2 0,14 -2,82 Oncogene Intestinal T-cell lymphoma interleukin 2
SERPINA2 0,15 -2,76 serine or cysteine proteinase inhibitor clade a alpha-1 antiproteinase antitrypsin member 2
NR2E1 0,15 -2,73 nuclear receptor subfamily group e member 1
TNFRSF18 0,15 -2,72 tumor necrosis factor receptor superfamily member 18
ITOR A 0,15 -2,71 rab3a member ras oncogene family
CDK8 0,15 -2,70 Colorectal, Lung 2/527=0.0038 H-list cyclin-dependent kinase 8
ENPP1 0,16 -2,67 ectonucleotide pyrophosphatasephosphodiesterase 1
SULT4A1 0,16 -2,66 sulfotransferase family 4a member 1
BRAF 0,16 -2,66 Oncogene 12/585=0.0205 v-raf murine sarcoma viral oncogene homolog b1
PTPN13 0,16 -2,64 TSG 0 protein tyrosine phosphatase non-receptor type 13 isoform 1
BMPR1B 0,16 -2,63 Gastric, Melanoma 4/527=0.0076 H-list bone morphogenetic protein receptor type ib
ZNF125 0,16 -2,62 znf125=zinc finger {clone hzf-3 tandem repeats}
FGF12 0,16 -2,62 fibroblast growth factor 12
GIPR 0,16 -2,61 gastric inhibitory polypeptide receptor
TRG 0,16 -2,61 0 t-cell receptor active beta-chain v2-d-j-c clone pl6.21
CYP21A2 0,17 -2,57 cytochrome p450 subfamily xxia polypeptide 2
IGFBP1 0,17 -2,57 insulin-like growth factor binding protein 1
MMP2 0,17 -2,56 Colorectal 3/212=0.0142 matrix metalloproteinase 2
JM27 0,17 -2,54 jm27 protein
XRCC3 0,17 -2,53 Breast, Melanoma x-ray repair cross complementing protein 3
PSG1 0,17 -2,52 pregnancy specific beta-1-glycoprotein 1
STS 0,18 -2,50 steroid sulfatase
PSG7 0,18 -2,46 pregnancy specific beta-1-glycoprotein 7
DYRK1 0,18 -2,46 dual-specificity tyrosine-y-phosphorylation regulated kinase 1
STAR 0,18 -2,45 steroidogenic acute regulatory protein
EVI2A 0,18 -2,45 0 1/125=0.008 ecotropic viral integration site 2a
ST5 0,19 -2,42 TSG 0 suppression of tumorigenicity 5
LOC51176 0,19 -2,39 lymphoid enhancer binding factor-1
SLC26A2 0,19 -2,39 sulfate anion transporter 1
TFRC 0,19 -2,38 Oncogene NHL transferrin receptor p90 cd71
IL26 0,19 -2,38 ak155 protein ak155
HHGF 0,19 -2,37 hepatocyte growth factor hhgf 
HHCM 0,19 -2,37 mahlavu hepatocellular carcinoma
RAB27B 0,19 -2,37 rab27b member ras oncogene family
BY55 0,20 -2,36 natural killer cell receptor immunoglobulin superfamily member
PAH 0,20 -2,36 phenylalanine hydroxylase
BRD1 0,20 -2,33 bromodomain-containing protein 1
SDCCAG43 0,20 -2,32 serologically defined colon cancer antigen 43
LOC91227 0,21 -2,28 similar to gamma-glutamyltransferase 1
NR1D1 0,21 -2,25 nuclear receptor subfamily group d member 1
IGSF4 0,21 -2,23 TSG 0 immunoglobulin superfamily member 4
CTDP1 0,22 -2,22 ctd carboxy-terminal domain rna polymerase ii polypeptide a phosphatase subunit isoform fcp1b
THRSP 0,22 -2,20 thyroid hormone responsive spot14 homolog rat
MSH5 0,22 -2,18 muts e. coli homolog 5
ETV1 0,22 -2,17 Oncogene Ewing sarcoma, Prostate ets variant 1
CA9 0,22 -2,17 carbonic anhydrase ix
DNTT 0,22 -2,17 deoxynucleotidyltransferase terminal
GML 0,22 -2,16 Glioblastoma 1/154=0.0065 H-list gpi anchored molecule like protein
TSC2 0,22 -2,16 TSG 6/317=0.0189 tuberous sclerosis 2 isoform 1
CTSF 0,23 -2,14 cathepsin f
HOXA5 0,23 -2,12 homeobox protein hox-1.3
PP32R2 0,23 -2,10 TSG 0 pp32 related 2
DLK1 0,23 -2,09 delta-like homolog drosophila
RECK 0,24 -2,09 TSG 0 reck protein
RXRA 0,24 -2,09 retinoid x receptor alpha
HLF 0,24 -2,08 Oncogene ALL hepatic leukemia factor
DEFA3 0,24 -2,08 defensin alpha 3
IFNA8 0,24 -2,07 interferon alpha 8
TM4-B 0,24 -2,07 tetraspanin tm4-b
FES 0,24 -2,05 0 2/440=0.0045 v-fes feline sarcoma viralv-fps fujinami avian viral oncogene homolog
CD1D 0,24 -2,05 cd1d antigen d polypeptide
APOA1 0,24 -2,05 apolipoprotein a-i
SKIL 0,24 -2,04 0 ski-like
EPHA3 0,24 -2,04 Colorectal, Lung 18/585=0.0308 H-list epha3
ALK 0,24 -2,04 Oncogene 9/585=0.0154 anaplastic lymphoma kinase ki-1
CHEK2 0,24 -2,03 TSG chk2 checkpoint homolog s. pombe
PMS2 0,25 -2,02 TSG 1/154=0.0065 pms2
TERF1 0,25 -2,01 0 telomeric repeat binding factor isoform 1
THBS2 0,25 -2,01 0 thrombospondin 2
TMSF 0,25 -2,01 similar to transmembrane superfamily member clone mgc:14656 image:4101110 
DACH 0,25 -2,00 dachshund homolog isoform b









28 CGC , Reviews , TGDBs 
46 
Cholangiocarcinoma, Colorectal, Lung, 
Melanoma, NSCLC, Ovarian, Papillary 
thyroid, Pilocytic astrocytoma 5 
AGCOH , CGC , H-list, OMIM , 
Reviews 
79 AGCOH , TSGDB 
18 
AGCOH 
AGCOH , H-list, TGDBs 
82 AGCOH , OMIM 
TGDBs 
80 TSGDB 
265 AGCOH , CGC , R-list 
234 TSGDB 
380 CGC , Reviews 
14 
Hamartoma, 
Lymphangioleiomyomatosis, Renal 2 AGCOH , CGC , OMIM 
TSGDB 
233 TSGDB 




ALCL, Colorectal, Neuroblastoma, 
NSCLC 18 
AGCOH , CGC , H-list, Reviews , 
TGDBs 
Breast, Colorectal, Li-Fraumeni 
syndrome, Osteosarcoma , Prostate 73 AGCOH , CGC , OMIM 
Colorectal, Endometrial, Glioma, 
Medulloblastoma, Mismatch repair 
cancer syndrome, Ovarian, Turcot 
syndrome 18 CGC , OMIM 
41 Reviews 
230 AGCOH 
Chondrosarcoma, Multiple Exostoses 
Type 1, Osteosarcoma 288 AGCOH , CGC , OMIM 
Table 3S
Terms Database ID ID number ID name p_value adj_pvalue
DNA Repair REACT_216 8 ATM,ERCC6,FANCC,FANCE,LIG3,RAD50,TDG,XPC 1.41798E-5 9.35868E-4
Signalling by NGF REACT_11061 8 ADAM17,DNM1,MDM2,PPP2R1B,PRKCE,RAF1,TIAM1,VAV2 1.16451E-3 2.12684E-2
Biological oxidations REACT_13433 6 CEBPA,CYP27A1,CYP4A11,PTGIS,PTGS2,UGT2A1 1.28899E-3 2.12684E-2
Hormone biosynthesis REACT_15314 4 CEBPA,POMC,PTGIS,PTGS2 1.77374E-3 2.34134E-2
Phase 1 functionalization REACT_649 3 CYP4A11,PTGIS,PTGS2 4.17871E-4 1.37898E-2
Cytokine-cytokine receptor interaction hsa04060 13 3.27529E-6 6.35406E-4
Pathways in cancer hsa05200 12 7.05519E-5 6.84353E-3
Jak-STAT signaling pathway hsa04630 8 CEBPA,CSF2RA,EPO,IFNW1,IL13RA2,IL22,LIFR,STAT5B 1.07385E-4 6.94425E-3
Chemokine signaling pathway hsa04062 8 CEBPA,HCK,IL8,IL8RA,RAF1,STAT5B,TIAM1,VAV2 4.03182E-4 1.33351E-2
Fc gamma R-mediated phagocytosis hsa04666 6 AMPH,DNM1,HCK,PRKCE,RAF1,VAV2 2.33193E-4 1.13099E-2
Vascular smooth muscle contraction hsa04270 6 CYP4A11,GNA12,GNA13,PRKCE,PRKCH,RAF1 1.09286E-3 1.86123E-2
Long-term depression hsa04730 5 CACNA1A,GNA12,GNA13,PPP2R1B,RAF1 4.81164E-4 1.33351E-2
B cell receptor signaling pathway hsa04662 5 DAPP1,JUN,MALT1,RAF1,VAV2 6.64031E-4 1.43135E-2
p53 signaling pathway hsa04115 5 APAF1,ATM,MDM2,PPM1D,TP73 4.19802E-4 1.33351E-2
Bladder cancer hsa05219 4 IL8,MDM2,PGF,RAF1 6.40163E-4 1.43135E-2
ABC transporters hsa02010 4 ABCA3,ABCC4,ABCG2,TAP1 1.15127E-3 1.86123E-2
N-Glycan biosynthesis hsa00510 4 CEBPA,DPAGT1,FUT8,MGAT5 8.33634E-4 1.61725E-2
Homologous recombination hsa03440 3 RAD50,RAD54L,XRCC2 2.24988E-3 3.35751E-2
ATM Signaling Pathway h_atmPathway 6 ATM,JUN,MDM2,RAD50,RBBP8,TP73 1.0822E-8 2.94358E-6
Keratinocyte Differentiation h_keratinocytePathway 5 CEBPA,JUN,PRKCE,PRKCH,RAF1 4.47217E-5 4.39363E-3
h_atrbrcaPathway 4 ATM,FANCC,FANCE,RAD50 4.84592E-5 4.39363E-3
p53 Signaling Pathway h_p53Pathway 3 APAF1,ATM,MDM2 2.17902E-4 1.48173E-2
EPO Signaling Pathway h_epoPathway 3 EPO,JUN,RAF1 3.41883E-4 1.85985E-2
regulation of cell proliferation GO:0042127 24 9.69017E-7 1.28945E-3
regulation of programmed cell death GO:0043067 23 5.60524E-6 1.36706E-3
regulation of apoptosis GO:0042981 23 4.70948E-6 1.36706E-3
positive regulation of metabolic process GO:0009893 22 2.34601E-5 3.96115E-3
cell cycle GO:0007049 22 1.012E-4 8.54359E-3
defense response GO:0006952 22 6.26994E-5 6.66269E-3
protein amino acid phosphorylation GO:0006468 22 3.8506E-5 5.28255E-3
cellular response to stimulus GO:0051716 21 8.0147E-5 7.64881E-3
extracellular space GO:0005615 21 6.97936E-6 1.61921E-3
organ morphogenesis GO:0009887 20 7.18825E-5 7.17192E-3
transcription from RNA polymerase II promoter GO:0006366 20 2.82614E-4 1.55084E-2
response to organic substance GO:0010033 19 2.20892E-4 1.33309E-2
regulation of signal transduction GO:0009966 19 1.03411E-3 3.84724E-2
DNA metabolic process GO:0006259 18 4.41969E-5 5.70659E-3
positive regulation of cellular biosynthetic GO:0031328 17 3.70639E-4 1.93703E-2
regulation of protein metabolic process GO:0051246 16 3.10331E-5 4.78827E-3
positive regulation of transcription GO:0045941 16 9.0781E-5 7.97058E-3
positive regulation of programmed cell death GO:0043068 16 2.76528E-6 1.28945E-3
positive regulation of apoptosis GO:0043065 16 2.52427E-6 1.28945E-3
positive regulation of cell death GO:0010942 16 2.93724E-6 1.28945E-3
positive regulation of gene expression GO:0010628 16 1.30357E-4 9.85146E-3
embryonic development GO:0009790 16 2.38712E-4 1.37887E-2
regulation of phosphorylation GO:0042325 15 4.90929E-5 5.9866E-3
cell cycle process GO:0022402 15 1.28265E-3 4.28688E-2
positive regulation of cell proliferation GO:0008284 15 1.61485E-5 3.38726E-3
skeletal system development GO:0001501 15 5.2753E-6 1.36706E-3
response to hormone stimulus GO:0009725 14 1.77066E-5 3.38726E-3
small GTPase mediated signal transduction GO:0007264 14 1.27564E-3 4.28688E-2
protein kinase cascade GO:0007243 14 8.70178E-4 3.49032E-2
enzyme linked receptor protein signaling GO:0007167 14 6.37432E-5 6.66269E-3
















































































cell motility GO:0048870 13 7.01827E-4 3.02159E-2
cellular response to DNA damage stimulus GO:0034984 13 8.57406E-5 7.84169E-3
cell migration GO:0016477 13 1.28018E-4 9.85146E-3
response to biotic stimulus GO:0009607 13 7.42845E-4 3.13566E-2
response to DNA damage stimulus GO:0006974 13 2.24713E-4 1.33309E-2
DNA repair GO:0006281 13 1.85181E-5 3.38726E-3
response to other organism GO:0051707 12 5.25281E-5 6.06838E-3
GO:0048646 12 3.40655E-4 1.82375E-2
chordate embryonic development GO:0043009 12 1.33288E-4 9.85146E-3
GO:0009792 12 1.48051E-4 1.04829E-2
bone development GO:0060348 11 3.53196E-6 1.29211E-3
negative regulation of apoptosis GO:0043066 11 1.57488E-3 4.93837E-2
Ras protein signal transduction GO:0007265 11 2.11672E-4 1.32749E-2
induction of apoptosis GO:0006917 11 2.00405E-4 1.29379E-2
ossification GO:0001503 11 2.51185E-6 1.28945E-3
regulation of cell cycle GO:0051726 10 ADAM17,ATM,ID2,IGF2,JUN,MDM2,PTGS2,RBBP8,STAT5B,XPC 9.83905E-4 3.72357E-2
response to bacterium GO:0009617 10 3.27216E-5 4.78827E-3
response to drug GO:0042493 9 ABCA3,ABCG2,ADAM17,JUN,PGF,PTGS2,RAD54L,SEMA3C,SLC2A8 8.69219E-4 3.49032E-2
neuron apoptosis GO:0051402 7 APAF1,ATM,CACNA1A,JUN,TGFB3,TP73,XRCC2 1.34644E-4 9.85146E-3
response to peptide hormone stimulus GO:0043434 7 CEBPA,IGF2,NR0B1,SLC2A8,STAT5B,TFF3,TSC1 1.15552E-3 4.09093E-2
forebrain development GO:0030900 7 APAF1,LHX1,NR0B1,TACC2,TP73,TSC1,WNT1 6.98781E-4 3.02159E-2
Rho protein signal transduction GO:0007266 7 COL1A2,GNA12,GNA13,PTH,TIAM1,TSC1,VAV2 2.80257E-4 1.55084E-2
DNA recombination GO:0006310 7 ATM,CEBPA,LIG3,RAD50,RAD54L,WRN,XRCC2 1.82795E-4 1.21605E-2
response to hypoxia GO:0001666 7 ADAM17,EPO,MMP14,PGF,SLC2A8,STAT5B,TGFB3 5.31946E-4 2.65368E-2
meiotic cell cycle GO:0051321 6 ATM,LIG3,OVOL1,RAD50,RAD54L,XRCC2 6.69946E-4 3.02159E-2
homeostasis of number of cells GO:0048872 6 ADAM17,EPO,FANCC,ID2,STAT5B,TAL1 1.28899E-3 4.28688E-2
regulation of neuron apoptosis GO:0043523 6 ATM,CACNA1A,JUN,TGFB3,TP73,XRCC2 5.80401E-4 2.83107E-2
female pregnancy GO:0007565 6 EPO,PGF,PTGS2,STAT5B,TEAD4,TGFB3 7.02055E-4 3.02159E-2
meiosis GO:0007126 6 ATM,LIG3,OVOL1,RAD50,RAD54L,XRCC2 6.09147E-4 2.90669E-2
response to molecule of bacterial origin GO:0002237 6 ADAM17,CEBPA,JUN,MALT1,PTGS2,STAT5B 1.82822E-4 1.21605E-2
regulation of inflammatory response GO:0050727 5 C3,CEBPA,PTGS2,SERPINC1,STAT5B 8.94522E-4 3.49032E-2
positive regulation of cell cycle GO:0045787 5 ADAM17,ID2,IGF2,MDM2,STAT5B 6.23872E-4 2.91362E-2
response to lipopolysaccharide GO:0032496 5 ADAM17,CEBPA,JUN,PTGS2,STAT5B 8.94522E-4 3.49032E-2
GO:0007179 5 ADAM17,COL1A2,FUT8,JUN,TGFB3 1.52751E-3 4.91585E-2
negative regulation of neuron apoptosis GO:0043524 4 CACNA1A,TGFB3,TP73,XRCC2 1.5453E-3 4.91585E-2
meiosis I GO:0007127 4 ATM,LIG3,OVOL1,RAD50 9.06371E-4 3.49032E-2
metanephros development GO:0001656 4 LHX1,OSR1,PAX8,PGF 1.06505E-3 3.89631E-2
positive regulation of ossification GO:0045778 3 RUNX2,TGFB3,THRB 1.42895E-3 4.68141E-2
release of cytochrome c from mitochondria GO:0001836 3 CCK,JUN,TP73 1.10238E-3 3.96676E-2





































transforming growth factor beta receptor signaling 
pathway
Table 4S
Terms Database ID ID number ID name p_value adj_pvalue
Cytokine-cytokine receptor interaction hsa04060 9 1,17E-05 2,27E-03
Jak-STAT signaling pathway hsa04630 5 IFNA1,IFNA8,IL2,IL26,IL2RA 9,70E-04 4,15E-02
TGF-beta signaling pathway hsa04350 4 ACVRL1,BMPR1B,CDKN2B,THBS2 1,00E-03 4,15E-02
Hematopoietic cell lineage hsa04640 4 CD1D,DNTT,IL2RA,TFRC 1,18E-03 4,15E-02
Pathways in cancer hsa05200 7 BRAF,CDKN2B,FGF12,FGF20,HOXA5,MMP2,RXRA 1,19E-03 4,15E-02
Natural killer cell mediated cytotoxicity hsa04650 5 BRAF,HOXA5,IFNA1,IFNA8,SH3BP2 1,28E-03 4,15E-02
Non-homologous end-joining hsa03450 2 DNTT,HOXA5 1,78E-03 4,95E-02
defense response GO:0006952 17 2,41E-06 5,30E-03
response to peptide hormone stimulus GO:0043434 7 ENPP1,HOXA5,IGFBP1,RXRA,STAR,STS,TSC2 2,07E-05 1,16E-02
DNA recombination GO:0006310 6 HOXA5,IL2,MSH5,PMS2,PTPRC,XRCC3 3,05E-05 1,16E-02
cellular response to insulin stimulus GO:0032869 5 ENPP1,IGFBP1,RXRA,STAR,TSC2 4,32E-05 1,16E-02
ossification GO:0001503 7 BMPR1B,CALCR,ENPP1,EXT1,HOXA5,MMP2,SLC26A2 4,82E-05 1,16E-02
response to nutrient GO:0007584 7 CDKN2B,GIPR,HOXA5,MSH5,RXRA,STAR,TFRC 4,82E-05 1,16E-02
enzyme linked receptor protein signaling pathway GO:0007167 10 4,98E-05 1,16E-02
acute-phase response GO:0006953 4 EPHA3,HOXA5,TFRC,TSC2 5,26E-05 1,16E-02
cellular response to hormone stimulus GO:0032870 6 ENPP1,HOXA5,IGFBP1,RXRA,STAR,TSC2 5,62E-05 1,16E-02
bone development GO:0060348 7 BMPR1B,CALCR,ENPP1,EXT1,HOXA5,MMP2,SLC26A2 6,03E-05 1,16E-02
sulfate transport GO:0008272 3 HOXA5,SLC26A2,SLC26A4 6,09E-05 1,16E-02
negative regulation of phosphorylation GO:0042326 4 CDKN2B,ENPP1,IL2,PTPRC 6,33E-05 1,16E-02
response to hormone stimulus GO:0009725 9 CA9,CALCR,ENPP1,HOXA5,IGFBP1,RXRA,STAR,STS,TSC2 1,13E-04 1,91E-02
response to organic substance GO:0010033 13 1,39E-04 2,19E-02
positive regulation of cell differentiation GO:0045597 7 BMPR1B,CDKN2B,HOXA5,IL2,IL2RA,PTPRC,STAR 1,60E-04 2,34E-02
regulation of cell size GO:0008361 7 ACVRL1,ENPP1,FGF20,HOXA5,IGFBP1,IL2,TSC2 1,91E-04 2,53E-02
steroid metabolic process GO:0008202 7 APOA1,CYP21A2,HOXA5,RXRA,STAR,STS,SULT4A1 1,96E-04 2,53E-02
female pregnancy GO:0007565 5 PSG1,PSG3,PSG7,RXRA,STS 2,36E-04 2,82E-02
response to insulin stimulus GO:0032868 5 ENPP1,IGFBP1,RXRA,STAR,TSC2 2,46E-04 2,82E-02
response to nutrient levels GO:0031667 7 CDKN2B,GIPR,HOXA5,MSH5,RXRA,STAR,TFRC 2,57E-04 2,82E-02
cellular response to stimulus GO:0051716 13 2,99E-04 3,13E-02
negative regulation of cytokine-mediated signaling pathway GO:0001960 2 HOXA5,PTPRC 3,51E-04 3,50E-02
transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 7 ALK,ENPP1,EPHA3,FGF20,HOXA5,IGFBP1,TSC2 3,96E-04 3,57E-02
response to virus GO:0009615 5 DEFA3,HOXA5,IFNA1,IFNA8,PTPRC 4,05E-04 3,57E-02
protein amino acid phosphorylation GO:0006468 13 4,06E-04 3,57E-02
response to extracellular stimulus GO:0009991 7 CDKN2B,GIPR,HOXA5,MSH5,RXRA,STAR,TFRC 4,32E-04 3,65E-02
response to organic cyclic substance GO:0014070 5 CDKN2B,HOXA5,RXRA,STAR,STS 5,54E-04 4,37E-02
regulation of ossification GO:0030278 4 BMPR1B,CALCR,ENPP1,HOXA5 5,58E-04 4,37E-02
negative regulation of cell proliferation GO:0008285 8 ACVRL1,CDKN2B,GML,HOXA5,IL2,IL2RA,RXRA,TSC2 5,98E-04 4,53E-02
regulation of focal adhesion formation GO:0051893 2 ACVRL1,TSC2 6,51E-04 4,63E-02
skeletal system development GO:0001501 8 BMPR1B,CALCR,DLK1,ENPP1,EXT1,HOXA5,MMP2,SLC26A2 6,73E-04 4,63E-02
cell cycle checkpoint GO:0000075 4 CDKN2B,CHEK2,GML,HOXA5 6,75E-04 4,63E-02
inflammatory response GO:0006954 9 BMPR1B,EPHA3,HOXA5,IL2,IL2RA,KLRG1,RXRA,TFRC,TSC2 7,70E-04 4,92E-02
somatic cell DNA recombination GO:0016444 3 IL2,PMS2,PTPRC 7,84E-04 4,92E-02
somatic diversification of immunoglobulins GO:0016445 3 IL2,PMS2,PTPRC 7,84E-04 4,92E-02
extracellular space GO:0005615 13 6,63E-05 1,54E-02
steroid binding GO:0005496 7 APOA1,CYP21A2,HOXA5,NR1D1,NR2E1,RXRA,STAR 1.23751E-5 4.06317E-3
double-stranded DNA binding GO:0003690 6 HLF,HOXA5,MSH5,PMS2,RXRA,TERF1 1.10125E-5 4.06317E-3
structure-specific DNA binding GO:0043566 6 HLF,HOXA5,MSH5,PMS2,RXRA,TERF1 1.07831E-4 2.12427E-2
steroid hormone receptor activity GO:0003707 5 HOXA5,NR1D1,NR2E1,RORB,RXRA 1.12832E-5 4.06317E-3













APOA1, DEFA3, DLK1, ENPP1, FGF12, HOXA5, IFNA1, IFNA8, 
IGFBP1, IL2, IL26, MMP2, TNFSF8
Table 5S
Data source Term Count Genes PValue Benjamini
BIOCARTA h_atmPathway:ATM Signaling Pathway 6 JUN, MDM2, ATM, RAD50, TP73, RBBP8 1,01E-04 1,28E-02
BIOCARTA h_atrbrcaPathway:Role of BRCA1,  BRCA2 and ATR in Cancer Susceptibility 4 FANCE, ATM, RAD50, FANCC 1,95E-02 7,17E-01
BIOCARTA h_bArrestin-srcPathway:Roles of ???-arrestin-dependent Recruitment of Src Kinases in GPCR Signaling 3 HCK, RAF1, DNM1 7,62E-02 9,21E-01
BIOCARTA h_epoPathway:EPO Signaling Pathway 3 JUN, RAF1, EPO 7,62E-02 9,21E-01
BIOCARTA h_p53Pathway:p53 Signaling Pathway 3 MDM2, APAF1, ATM 6,88E-02 9,52E-01
COG_ONTOLOGY Secondary metabolites biosynthesis, transport, and catabolism 3 CYP4A11, PTGIS, CYP27A1 5,82E-02 2,59E-01
GOTERM_BP_FAT GO:0007166~cell surface receptor linked signal transduction 31 1,86E-02 2,75E-01
GOTERM_BP_FAT GO:0051252~regulation of RNA metabolic process 30 2,35E-02 3,09E-01
GOTERM_BP_FAT GO:0006355~regulation of transcription, DNA-dependent 30 1,79E-02 2,78E-01
GOTERM_BP_FAT GO:0007242~intracellular signaling cascade 26 2,58E-03 9,88E-02
GOTERM_BP_FAT GO:0010941~regulation of cell death 25 9,10E-06 3,84E-03
GOTERM_BP_FAT GO:0043067~regulation of programmed cell death 25 8,56E-06 4,82E-03
GOTERM_BP_FAT GO:0042981~regulation of apoptosis 25 7,24E-06 6,11E-03
GOTERM_BP_FAT GO:0010604~positive regulation of macromolecule metabolic process 23 1,72E-04 2,05E-02
GOTERM_BP_FAT GO:0042127~regulation of cell proliferation 23 4,95E-05 9,26E-03
GOTERM_BP_FAT GO:0006357~regulation of transcription from RNA polymerase II promoter 20 3,96E-04 3,00E-02
GOTERM_BP_FAT GO:0009891~positive regulation of biosynthetic process 18 1,67E-03 7,36E-02
GOTERM_BP_FAT GO:0031328~positive regulation of cellular biosynthetic process 18 1,43E-03 6,51E-02
GOTERM_BP_FAT GO:0010557~positive regulation of macromolecule biosynthetic process 18 8,64E-04 4,61E-02
GOTERM_BP_FAT GO:0051173~positive regulation of nitrogen compound metabolic process 18 7,28E-04 4,46E-02
GOTERM_BP_FAT GO:0045935~positive regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 18 5,11E-04 3,40E-02
GOTERM_BP_FAT GO:0006952~defense response 18 4,33E-04 3,01E-02
GOTERM_BP_FAT GO:0042592~homeostatic process 17 8,58E-03 1,83E-01
GOTERM_BP_FAT GO:0010033~response to organic substance 17 5,89E-03 1,51E-01
GOTERM_BP_FAT GO:0051254~positive regulation of RNA metabolic process 17 8,01E-05 1,12E-02
GOTERM_BP_FAT GO:0010942~positive regulation of cell death 17 2,41E-05 5,80E-03
GOTERM_BP_FAT GO:0043068~positive regulation of programmed cell death 17 2,28E-05 6,40E-03
GOTERM_BP_FAT GO:0043065~positive regulation of apoptosis 17 2,09E-05 7,05E-03
GOTERM_BP_FAT GO:0007049~cell cycle 16 2,40E-02 3,10E-01
GOTERM_BP_FAT GO:0016265~death 16 1,37E-02 2,45E-01
GOTERM_BP_FAT GO:0008219~cell death 16 1,29E-02 2,36E-01
GOTERM_BP_FAT GO:0010628~positive regulation of gene expression 16 1,87E-03 7,81E-02
GOTERM_BP_FAT GO:0045941~positive regulation of transcription 16 1,40E-03 6,55E-02
GOTERM_BP_FAT GO:0051174~regulation of phosphorus metabolic process 16 2,97E-04 2,61E-02
GOTERM_BP_FAT GO:0019220~regulation of phosphate metabolic process 16 2,97E-04 2,61E-02
GOTERM_BP_FAT GO:0045893~positive regulation of transcription, DNA-dependent 16 2,49E-04 2,31E-02
GOTERM_BP_FAT GO:0032268~regulation of cellular protein metabolic process 16 2,33E-04 2,29E-02
GOTERM_BP_FAT GO:0042325~regulation of phosphorylation 16 1,94E-04 2,16E-02
GOTERM_BP_FAT GO:0010605~negative regulation of macromolecule metabolic process 14 6,15E-02 4,97E-01
GOTERM_BP_FAT GO:0022610~biological adhesion 14 4,57E-02 4,32E-01
GOTERM_BP_FAT GO:0007155~cell adhesion 14 4,53E-02 4,33E-01
GOTERM_BP_FAT GO:0012501~programmed cell death 14 1,74E-02 2,74E-01
GOTERM_BP_FAT GO:0006915~apoptosis 14 1,56E-02 2,63E-01
GOTERM_BP_FAT GO:0033554~cellular response to stress 14 9,72E-03 1,98E-01
GOTERM_BP_FAT GO:0022402~cell cycle process 14 9,59E-03 1,98E-01
GOTERM_BP_FAT GO:0009611~response to wounding 14 5,74E-03 1,52E-01
GOTERM_BP_FAT GO:0006259~DNA metabolic process 14 3,91E-03 1,18E-01
GOTERM_BP_FAT GO:0008284~positive regulation of cell proliferation 14 6,60E-04 4,21E-02
GOTERM_BP_FAT GO:0044093~positive regulation of molecular function 13 2,85E-02 3,35E-01
GOTERM_BP_FAT GO:0009890~negative regulation of biosynthetic process 13 2,45E-02 3,13E-01
GOTERM_BP_FAT GO:0031327~negative regulation of cellular biosynthetic process 13 2,12E-02 2,99E-01
GOTERM_BP_FAT GO:0043085~positive regulation of catalytic activity 13 1,24E-02 2,32E-01
GOTERM_BP_FAT GO:0009719~response to endogenous stimulus 13 1,74E-03 7,47E-02
GOTERM_BP_FAT GO:0006974~response to DNA damage stimulus 13 8,64E-04 4,76E-02
GOTERM_BP_FAT GO:0007167~enzyme linked receptor protein signaling pathway 13 4,01E-04 2,91E-02
GOTERM_BP_FAT GO:0009792~embryonic development ending in birth or egg hatching 13 3,24E-04 2,58E-02
GOTERM_BP_FAT GO:0043009~chordate embryonic development 13 2,99E-04 2,49E-02
GOTERM_BP_FAT GO:0001501~skeletal system development 13 2,13E-04 2,23E-02
GOTERM_BP_FAT GO:0031399~regulation of protein modification process 13 1,03E-04 1,33E-02
GOTERM_BP_FAT GO:0006281~DNA repair 13 7,15E-05 1,09E-02
GNA13, CCK, FUT8, C3, GNA12, STAT5B, TGFB3, POMC, SLC2A8, 
WNT1, TIAM1, PTH, FRAT1, CDA, CEACAM1, SLC12A2, IL8, LIFR, RAF1, 
MALT1, TNFRSF14, IGF2, PTPRU, WNT2B, XPR1, JUN, MC2R, COL1A2, 
ADAM17, CACNA1A, SEL1L
THRB, STAT5B, TGFB3, FHL2, NR2C2, TAL1, WNT1, ERCC6, LHX1, 
PAX8, OVOL1, TEAD4, PTH, HOXA9, RUNX2, MLLT3, EPO, ZNF43, 
CEBPA, ERG, IGF2, NR0B1, IL22, TP73, AHR, RBBP8, ID2, JUN, MDM2, 
PBX2
THRB, STAT5B, TGFB3, FHL2, NR2C2, TAL1, WNT1, ERCC6, LHX1, 
PAX8, OVOL1, TEAD4, PTH, HOXA9, RUNX2, MLLT3, EPO, ZNF43, 
CEBPA, ERG, IGF2, NR0B1, IL22, TP73, AHR, RBBP8, ID2, JUN, MDM2, 
PBX2
GNA13, MRAS, GNA12, STAT5B, TGFB3, FHL2, ERCC6, TIAM1, PTH, 
TYROBP, IL8, RAF1, PRKCH, IGF2, MALT1, RAB7L1, PRKCE, VAV2, 
ATM, TP73, XPC, RAB30, RGS4, MC2R, RIPK3, COL1A2
DCC, XRCC2, CCK, PTGS2, STAT5B, TGFB3, TNFRSF8, PTGIS, ERCC6, 
TIAM1, PTH, CD5, CFLAR, IGF2, MALT1, WRN, PRKCE, VAV2, ATM, 
TP73, JUN, RIPK3, ADAM17, APAF1, CACNA1A
DCC, XRCC2, CCK, PTGS2, STAT5B, TGFB3, TNFRSF8, PTGIS, ERCC6, 
TIAM1, PTH, CD5, CFLAR, IGF2, MALT1, WRN, PRKCE, VAV2, ATM, 
TP73, JUN, RIPK3, ADAM17, APAF1, CACNA1A
DCC, XRCC2, CCK, PTGS2, STAT5B, TGFB3, TNFRSF8, PTGIS, ERCC6, 
TIAM1, PTH, CD5, CFLAR, IGF2, MALT1, WRN, PRKCE, VAV2, ATM, 
TP73, JUN, RIPK3, ADAM17, APAF1, CACNA1A
CEBPA, CCK, THRB, STAT5B, TGFB3, FHL2, TNFRSF8, TNFRSF14, 
IGF2, IL22, AHR, TP73, WNT1, ERCC6, JUN, PAX8, TEAD4, PTH, MDM2, 
ADAM17, RUNX2, PBX2, EPO
CEBPA, IL8, PTGS2, PGF, STAT5B, TGFB3, LIFR, TNFRSF8, IGF2, 
TNFRSF14, PTPRU, PPM1D, TNFRSF11A, REG1A, TSC1, ID2, LHX1, 
JUN, MDM2, ADAM17, CD5, RUNX2, EPO
CEBPA, THRB, STAT5B, TGFB3, FHL2, NR0B1, IL22, AHR, RBBP8, 
TAL1, ID2, JUN, PAX8, OVOL1, TEAD4, PTH, MDM2, RUNX2, PBX2, EPO
CEBPA, THRB, STAT5B, TGFB3, FHL2, TNFRSF8, IGF2, IL22, AHR, 
TP73, WNT1, JUN, PAX8, PTH, TEAD4, RUNX2, PBX2, EPO
CEBPA, THRB, STAT5B, TGFB3, FHL2, TNFRSF8, IGF2, IL22, AHR, 
TP73, WNT1, JUN, PAX8, PTH, TEAD4, RUNX2, PBX2, EPO
CEBPA, THRB, STAT5B, TGFB3, FHL2, TNFRSF8, IGF2, IL22, AHR, 
TP73, WNT1, JUN, PAX8, PTH, TEAD4, RUNX2, PBX2, EPO
CEBPA, THRB, STAT5B, TGFB3, FHL2, IGF2, IL22, AHR, TP73, WNT1, 
ERCC6, JUN, PAX8, PTH, TEAD4, RUNX2, PBX2, EPO
CEBPA, THRB, STAT5B, TGFB3, FHL2, IGF2, IL22, AHR, TP73, WNT1, 
ERCC6, JUN, PAX8, PTH, TEAD4, RUNX2, PBX2, EPO
CCK, IL8, C3, HCK, STAT5B, PRG2, IFNW1, MALT1, IGF2, IL22, TP73, 
TNFAIP6, GAGE7, TAP1, TFF3, APAF1, CTSG, TYROBP
GNA13, CCK, SLC12A2, OTC, STAT5B, IGF2, WRN, RAD50, TAL1, 
TSC1, ID2, JUN, PTH, CP, CACNA1A, FANCC, EPO
PTGS2, PGF, STAT5B, TGFB3, LIFR, FHL2, MALT1, IGF2, PTPRU, 
MMP14, NR0B1, SLC2A8, TSC1, ID2, JUN, ADAM17, TFF3
CEBPA, THRB, STAT5B, TGFB3, FHL2, IL22, AHR, TP73, WNT1, ERCC6, 
JUN, PAX8, PTH, TEAD4, RUNX2, PBX2, EPO
DCC, CFLAR, CCK, PTGS2, TGFB3, TNFRSF8, VAV2, PRKCE, TP73, 
ATM, ERCC6, PTGIS, TIAM1, JUN, PTH, RIPK3, CD5
DCC, CFLAR, CCK, PTGS2, TGFB3, TNFRSF8, VAV2, PRKCE, TP73, 
ATM, ERCC6, PTGIS, TIAM1, JUN, PTH, RIPK3, CD5
DCC, CFLAR, CCK, PTGS2, TGFB3, TNFRSF8, VAV2, PRKCE, TP73, 
ATM, ERCC6, PTGIS, TIAM1, JUN, PTH, RIPK3, CD5
XRCC2, IL8, LIG3, IFNW1, RAD54L, AHR, TP73, ATM, RAD50, RBBP8, 
TACC2, PPM1D, EVI5, OVOL1, ADAM17, MDM2
DCC, CFLAR, CCK, RAF1, TNFRSF14, IGF2, VAV2, AHR, TP73, ATM, 
TIAM1, JUN, RIPK3, APAF1, CACNA1A, EPO
DCC, CFLAR, CCK, RAF1, TNFRSF14, IGF2, VAV2, AHR, TP73, ATM, 
TIAM1, JUN, RIPK3, APAF1, CACNA1A, EPO
CEBPA, THRB, STAT5B, TGFB3, FHL2, IL22, AHR, TP73, WNT1, JUN, 
PAX8, PTH, TEAD4, RUNX2, PBX2, EPO
CEBPA, THRB, STAT5B, TGFB3, FHL2, IL22, AHR, TP73, WNT1, JUN, 
PAX8, PTH, TEAD4, RUNX2, PBX2, EPO
CCK, TGFB3, MALT1, TNFRSF14, IGF2, VAV2, PRKCE, IL22, TP73, 
ERCC6, TSC1, RGS4, JUN, ADAM17, CD6, EPO
CCK, TGFB3, MALT1, TNFRSF14, IGF2, VAV2, PRKCE, IL22, TP73, 
ERCC6, TSC1, RGS4, JUN, ADAM17, CD6, EPO
CEBPA, THRB, STAT5B, TGFB3, FHL2, IL22, AHR, TP73, WNT1, JUN, 
PAX8, PTH, TEAD4, RUNX2, PBX2, EPO
CCK, TGFB3, TNFRSF14, IGF2, PRKCE, IL22, TP73, EIF4EBP3, ERCC6, 
TSC1, SERPINA5, JUN, ADAM17, MDM2, CD6, EPO
CCK, TGFB3, MALT1, TNFRSF14, IGF2, VAV2, PRKCE, IL22, TP73, 
ERCC6, TSC1, RGS4, JUN, ADAM17, CD6, EPO
CEBPA, THRB, TGFB3, IGF2, PTPRU, NR0B1, EIF4EBP3, TSC1, ID2, 
JUN, SERPINA5, OVOL1, MDM2, RUNX2
GNE, LGALS4, PTPRU, PCDH7, ISLR, TNFAIP6, TSC1, SIGLEC5, DSG3, 
ADAM17, CD6, ABL2, CEACAM1, CDH11
GNE, LGALS4, PTPRU, PCDH7, ISLR, TNFAIP6, TSC1, SIGLEC5, DSG3, 
ADAM17, CD6, ABL2, CEACAM1, CDH11
DCC, CFLAR, CCK, RAF1, TNFRSF14, VAV2, TP73, ATM, AHR, TIAM1, 
JUN, RIPK3, APAF1, EPO
DCC, CFLAR, CCK, RAF1, TNFRSF14, VAV2, TP73, ATM, AHR, TIAM1, 
JUN, RIPK3, APAF1, EPO
XRCC2, LIG3, WRN, RAD54L, TP73, ATM, RAD50, RBBP8, ERCC6, XPC, 
JUN, TDG, FANCE, FANCC
XRCC2, IL8, LIG3, IFNW1, RAD54L, TP73, ATM, RAD50, RBBP8, TACC2, 
PPM1D, OVOL1, ADAM17, MDM2
GNA13, IL8, C3, GNA12, STAT5B, TGFB3, IGF2, IL22, TP73, TNFAIP6, 
SERPINC1, ADAM17, TFPI2, EPO
XRCC2, LIG3, WRN, RAD54L, TP73, ATM, RAD50, RBBP8, ERCC6, XPC, 
TDG, FANCE, APAF1, FANCC
PTGS2, PGF, STAT5B, LIFR, IGF2, TNFRSF11A, REG1A, ID2, LHX1, 
JUN, ADAM17, MDM2, RUNX2, EPO
GNA13, CCK, TGFB3, IGF2, MALT1, WRN, VAV2, ERCC6, TSC1, PTH, 
ADAM17, APAF1, ABL2
CEBPA, THRB, TGFB3, IGF2, PTPRU, NR0B1, EIF4EBP3, TSC1, ID2, 
OVOL1, MDM2, RUNX2, CACNA1A
CEBPA, THRB, TGFB3, IGF2, PTPRU, NR0B1, EIF4EBP3, TSC1, ID2, 
OVOL1, MDM2, RUNX2, CACNA1A
GNA13, CCK, TGFB3, IGF2, MALT1, WRN, VAV2, ERCC6, TSC1, PTH, 
ADAM17, APAF1, ABL2
PTGS2, PGF, STAT5B, TGFB3, FHL2, IGF2, PTPRU, MMP14, NR0B1, 
SLC2A8, TSC1, ADAM17, TFF3
XRCC2, LIG3, WRN, RAD54L, TP73, ATM, RAD50, RBBP8, XPC, ERCC6, 
TDG, FANCE, FANCC
FUT8, STAT5B, TGFB3, LIFR, RAF1, IGF2, PTPRU, SLC2A8, TIAM1, 
JUN, COL1A2, ADAM17, CACNA1A
GNA13, CEBPA, XRCC2, FUT8, GNA12, TGFB3, ATM, RBBP8, WNT1, 
TSC1, TEAD4, HOXA9, APAF1
GNA13, CEBPA, XRCC2, FUT8, GNA12, TGFB3, ATM, RBBP8, WNT1, 
TSC1, TEAD4, HOXA9, APAF1
PTGS2, MMP8, TGFB3, FHL2, IGF2, MMP14, TNFRSF11A, PTH, TEAD4, 
COL1A2, HOXA9, RUNX2, CDH11
CCK, TGFB3, TNFRSF14, IGF2, PRKCE, IL22, TP73, ERCC6, TSC1, JUN, 
ADAM17, CD6, EPO
XRCC2, LIG3, WRN, RAD54L, TP73, ATM, RAD50, RBBP8, XPC, ERCC6, 
TDG, FANCE, FANCC
Table 5S
GOTERM_BP_FAT GO:0006928~cell motion 12 1,60E-02 2,64E-01
GOTERM_BP_FAT GO:0045944~positive regulation of transcription from RNA polymerase II promoter 12 2,69E-03 1,00E-01
GOTERM_BP_FAT GO:0009725~response to hormone stimulus 12 2,47E-03 9,70E-02
GOTERM_BP_FAT GO:0012502~induction of programmed cell death 12 8,51E-04 4,85E-02
GOTERM_BP_FAT GO:0006917~induction of apoptosis 12 8,30E-04 4,89E-02
GOTERM_BP_FAT GO:0001932~regulation of protein amino acid phosphorylation 12 3,27E-06 5,51E-03
GOTERM_BP_FAT GO:0010558~negative regulation of macromolecule biosynthetic process 11 8,02E-02 5,69E-01
GOTERM_BP_FAT GO:0032504~multicellular organism reproduction 11 4,30E-02 4,23E-01
GOTERM_BP_FAT GO:0048609~reproductive process in a multicellular organism 11 4,30E-02 4,23E-01
GOTERM_BP_FAT GO:0008283~cell proliferation 11 2,25E-02 3,02E-01
GOTERM_BP_FAT GO:0022403~cell cycle phase 11 1,63E-02 2,66E-01
GOTERM_BP_FAT GO:0051338~regulation of transferase activity 10 ERCC6, CCK, TSC1, RGS4, TGFB3, ADAM17, MALT1, IGF2, VAV2, TP73 2,20E-02 3,01E-01
GOTERM_BP_FAT GO:0009628~response to abiotic stimulus 10 2,07E-02 2,95E-01
GOTERM_BP_FAT GO:0008285~negative regulation of cell proliferation 10 1,85E-02 2,78E-01
GOTERM_BP_FAT GO:0060548~negative regulation of cell death 10 1,82E-02 2,77E-01
GOTERM_BP_FAT GO:0043069~negative regulation of programmed cell death 10 1,79E-02 2,75E-01
GOTERM_BP_FAT GO:0043549~regulation of kinase activity 10 ERCC6, CCK, TSC1, RGS4, TGFB3, ADAM17, MALT1, IGF2, VAV2, TP73 1,73E-02 2,75E-01
GOTERM_BP_FAT GO:0043066~negative regulation of apoptosis 10 1,65E-02 2,66E-01
GOTERM_BP_FAT GO:0051726~regulation of cell cycle 10 XPC, ID2, PTGS2, JUN, STAT5B, ADAM17, MDM2, IGF2, ATM, RBBP8 1,11E-02 2,12E-01
GOTERM_BP_FAT GO:0051674~localization of cell 10 6,94E-03 1,61E-01
GOTERM_BP_FAT GO:0048870~cell motility 10 6,94E-03 1,61E-01
GOTERM_BP_FAT GO:0007264~small GTPase mediated signal transduction 10 6,66E-03 1,60E-01
GOTERM_BP_FAT GO:0051094~positive regulation of developmental process 10 TAL1, XRCC2, ID2, THRB, TIAM1, JUN, STAT5B, TGFB3, IGF2, RUNX2 3,67E-03 1,13E-01
GOTERM_BP_FAT GO:0002520~immune system development 10 3,50E-03 1,16E-01
GOTERM_BP_FAT GO:0016477~cell migration 10 3,50E-03 1,16E-01
GOTERM_BP_FAT GO:0045597~positive regulation of cell differentiation 10 TAL1, XRCC2, ID2, THRB, TIAM1, JUN, STAT5B, TGFB3, IGF2, RUNX2 9,79E-04 4,90E-02
GOTERM_BP_FAT GO:0007243~protein kinase cascade 9 GNA13, ERCC6, RGS4, STAT5B, GNA12, RIPK3, TGFB3, MALT1, IGF2 5,22E-02 4,63E-01
GOTERM_BP_FAT GO:0045859~regulation of protein kinase activity 9 ERCC6, CCK, TSC1, RGS4, TGFB3, ADAM17, MALT1, IGF2, TP73 3,71E-02 3,91E-01
GOTERM_BP_FAT GO:0010647~positive regulation of cell communication 9 CFLAR, PTGS2, KLK5, PTH, TGFB3, ADAM17, MALT1, IGF2, EPO 2,92E-02 3,40E-01
GOTERM_BP_FAT GO:0048534~hemopoietic or lymphoid organ development 9 8,13E-03 1,79E-01
GOTERM_BP_FAT GO:0001944~vasculature development 9 GNA13, IL8, PGF, JUN, COL1A2, SEMA3C, MMP14, ANGPT2, CEACAM1 6,63E-03 1,61E-01
GOTERM_BP_FAT GO:0001568~blood vessel development 9 GNA13, IL8, PGF, JUN, COL1A2, SEMA3C, MMP14, ANGPT2, CEACAM1 5,76E-03 1,50E-01
GOTERM_BP_FAT GO:0042493~response to drug 9 2,70E-03 9,87E-02
GOTERM_BP_FAT GO:0009617~response to bacterium 9 PPM1D, PTGS2, JUN, HCK, PRG2, STAT5B, ADAM17, MALT1, CTSG 1,33E-03 6,42E-02
GOTERM_BP_FAT GO:0060348~bone development 9 6,35E-05 1,07E-02
GOTERM_BP_FAT GO:0001503~ossification 9 3,93E-05 8,27E-03
GOTERM_BP_FAT GO:0048598~embryonic morphogenesis 8 WNT1, TSC1, LHX1, GNA12, TGFB3, HOXA9, APAF1, PBX2 5,34E-02 4,64E-01
GOTERM_BP_FAT GO:0009967~positive regulation of signal transduction 8 CFLAR, KLK5, PTH, TGFB3, ADAM17, MALT1, IGF2, EPO 4,48E-02 4,32E-01
GOTERM_BP_FAT GO:0007389~pattern specification process 8 GNA13, WNT1, LHX1, FRAT1, HOXA9, PBX2, ATM, MLLT3 2,84E-02 3,36E-01
GOTERM_BP_FAT GO:0003006~reproductive developmental process 8 PTGS2, OSR1, STAT5B, TGFB3, MMP14, NR0B1, NR2C2, FANCC 2,60E-02 3,23E-01
GOTERM_BP_FAT GO:0030097~hemopoiesis 8 CEBPA, TAL1, ID2, STAT5B, ADAM17, HOXA9, MALT1, EPO 1,56E-02 2,61E-01
GOTERM_BP_FAT GO:0035295~tube development 8 GNA13, CEBPA, TSC1, PGF, LHX1, TGFB3, APAF1, MMP14 1,10E-02 2,15E-01
GOTERM_BP_FAT GO:0048514~blood vessel morphogenesis 8 GNA13, IL8, PGF, JUN, SEMA3C, MMP14, ANGPT2, CEACAM1 8,85E-03 1,86E-01
GOTERM_BP_FAT GO:0001701~in utero embryonic development 8 GNA13, CEBPA, XRCC2, FUT8, TEAD4, GNA12, TGFB3, RBBP8 3,34E-03 1,14E-01
GOTERM_BP_FAT GO:0032101~regulation of response to external stimulus 8 CCK, PTGS2, IL8, C3, STAT5B, SERPINC1, ADAM17, IGF2 1,89E-03 7,70E-02
GOTERM_BP_FAT GO:0001775~cell activation 7 GNA13, KIR3DS1, IL8, STAT5B, ADAM17, MALT1, IGF2 9,77E-02 6,28E-01
GOTERM_BP_FAT GO:0032535~regulation of cellular component size 7 TSC1, TGFB3, ADAM17, CDA, IGF2, CACNA1A, TP73 7,92E-02 5,67E-01
GOTERM_BP_FAT GO:0010627~regulation of protein kinase cascade 7 CFLAR, ERCC6, MALT1, IGF2, IL22, TP73, EPO 5,74E-02 4,80E-01
GOTERM_BP_FAT GO:0051247~positive regulation of protein metabolic process 7 CCK, TGFB3, ADAM17, MDM2, TNFRSF14, IGF2, EPO 5,22E-02 4,60E-01
GOTERM_BP_FAT GO:0051347~positive regulation of transferase activity 7 ERCC6, CCK, TGFB3, ADAM17, MALT1, IGF2, VAV2 4,97E-02 4,53E-01
GOTERM_BP_FAT GO:0032270~positive regulation of cellular protein metabolic process 7 CCK, TGFB3, ADAM17, MDM2, TNFRSF14, IGF2, EPO 4,41E-02 4,30E-01
GOTERM_BP_FAT GO:0033674~positive regulation of kinase activity 7 ERCC6, CCK, TGFB3, ADAM17, MALT1, IGF2, VAV2 4,26E-02 4,26E-01
GOTERM_BP_FAT GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway 7 SLC2A8, TIAM1, STAT5B, ADAM17, RAF1, IGF2, CACNA1A 3,76E-02 3,91E-01
GOTERM_BP_FAT GO:0005996~monosaccharide metabolic process 7 SLC2A8, FUT8, GNE, DPAGT1, IGF2, CACNA1A, XYLB 3,62E-02 3,86E-01
GOTERM_BP_FAT GO:0009991~response to extracellular stimulus 7 CCK, HSD17B2, PTGS2, JUN, SERPINC1, CP, MEST 3,49E-02 3,82E-01
GOTERM_BP_FAT GO:0008361~regulation of cell size 7 TSC1, TGFB3, ADAM17, CDA, IGF2, CACNA1A, TP73 2,65E-02 3,26E-01
GOTERM_BP_FAT GO:0009314~response to radiation 7 PPM1D, XRCC2, ERCC6, XPC, WRN, RAD54L, ATM 2,33E-02 3,09E-01
GOTERM_BP_FAT GO:0031667~response to nutrient levels 7 CCK, HSD17B2, PTGS2, JUN, SERPINC1, CP, MEST 2,19E-02 3,02E-01
GOTERM_BP_FAT GO:0042060~wound healing 7 GNA13, GNA12, TGFB3, SERPINC1, ADAM17, IGF2, TFPI2 1,91E-02 2,78E-01
GOTERM_BP_FAT GO:0051130~positive regulation of cellular component organization 7 CCK, TSC1, C3, TIAM1, TGFB3, IGF2, AHR 1,50E-02 2,58E-01
GOTERM_BP_FAT GO:0030900~forebrain development 7 WNT1, TSC1, LHX1, APAF1, NR0B1, TP73, TACC2 6,71E-03 1,59E-01
GOTERM_BP_FAT GO:0001525~angiogenesis 7 GNA13, IL8, PGF, JUN, MMP14, ANGPT2, CEACAM1 5,91E-03 1,49E-01
GOTERM_BP_FAT GO:0070482~response to oxygen levels 7 SLC2A8, PGF, STAT5B, TGFB3, ADAM17, MMP14, EPO 4,68E-03 1,32E-01
GOTERM_BP_FAT GO:0001666~response to hypoxia 7 SLC2A8, PGF, STAT5B, TGFB3, ADAM17, MMP14, EPO 3,65E-03 1,14E-01
GOTERM_BP_FAT GO:0003002~regionalization 6 WNT1, LHX1, HOXA9, PBX2, ATM, MLLT3 6,68E-02 5,21E-01
GOTERM_BP_FAT GO:0031401~positive regulation of protein modification process 6 CCK, TGFB3, ADAM17, TNFRSF14, IGF2, EPO 5,59E-02 4,75E-01
GOTERM_BP_FAT GO:0006979~response to oxidative stress 6 ERCC6, PTGS2, JUN, WRN, MMP14, FANCC 3,49E-02 3,80E-01
GOTERM_BP_FAT GO:0043434~response to peptide hormone stimulus 6 SLC2A8, TSC1, STAT5B, TFF3, IGF2, NR0B1 2,78E-02 3,37E-01
GOTERM_BP_FAT GO:0008624~induction of apoptosis by extracellular signals 6 CFLAR, TIAM1, PTH, RIPK3, VAV2, CD5 7,92E-03 1,77E-01
GOTERM_BP_FAT GO:0007565~female pregnancy 6 PTGS2, PGF, TEAD4, STAT5B, TGFB3, EPO 7,35E-03 1,68E-01
GOTERM_BP_FAT GO:0006310~DNA recombination 6 XRCC2, LIG3, WRN, RAD54L, ATM, RAD50 6,06E-03 1,51E-01
GOTERM_BP_FAT GO:0007265~Ras protein signal transduction 6 GNA13, MRAS, PTH, GNA12, COL1A2, RAF1 6,06E-03 1,51E-01
GOTERM_BP_FAT GO:0021700~developmental maturation 6 CEBPA, WNT1, PTGS2, RUNX2, CACNA1A, EPO 5,15E-03 1,40E-01
GOTERM_BP_FAT GO:0010562~positive regulation of phosphorus metabolic process 6 CCK, TGFB3, ADAM17, TNFRSF14, IGF2, EPO 4,93E-03 1,37E-01
GOTERM_BP_FAT GO:0051321~meiotic cell cycle 6 XRCC2, OVOL1, LIG3, RAD54L, ATM, RAD50 4,93E-03 1,37E-01
GOTERM_BP_FAT GO:0045937~positive regulation of phosphate metabolic process 6 CCK, TGFB3, ADAM17, TNFRSF14, IGF2, EPO 4,93E-03 1,37E-01
GOTERM_BP_FAT GO:0007126~meiosis 6 XRCC2, OVOL1, LIG3, RAD54L, ATM, RAD50 4,53E-03 1,30E-01
GOTERM_BP_FAT GO:0051327~M phase of meiotic cell cycle 6 XRCC2, OVOL1, LIG3, RAD54L, ATM, RAD50 4,53E-03 1,30E-01
GOTERM_BP_FAT GO:0042327~positive regulation of phosphorylation 6 CCK, TGFB3, ADAM17, TNFRSF14, IGF2, EPO 4,34E-03 1,27E-01
GOTERM_BP_FAT GO:0043523~regulation of neuron apoptosis 6 XRCC2, JUN, TGFB3, ATM, CACNA1A, TP73 3,14E-03 1,09E-01
GOTERM_BP_FAT GO:0001934~positive regulation of protein amino acid phosphorylation 6 CCK, TGFB3, ADAM17, TNFRSF14, IGF2, EPO 3,00E-03 1,07E-01
GOTERM_BP_FAT GO:0050730~regulation of peptidyl-tyrosine phosphorylation 6 CCK, TNFRSF14, IGF2, PRKCE, IL22, EPO 9,04E-04 4,67E-02
GOTERM_BP_FAT GO:0044087~regulation of cellular component biogenesis 5 CCK, TSC1, TGFB3, MMP14, AHR 7,19E-02 5,37E-01
GOTERM_BP_FAT GO:0050878~regulation of body fluid levels 5 GNA13, GNA12, SERPINC1, TFPI2, TP73 7,04E-02 5,33E-01
GOTERM_BP_FAT GO:0007584~response to nutrient 5 HSD17B2, PTGS2, SERPINC1, CP, MEST 6,90E-02 5,28E-01
GOTERM_BP_FAT GO:0009952~anterior/posterior pattern formation 5 WNT1, LHX1, HOXA9, ATM, MLLT3 6,90E-02 5,28E-01
GOTERM_BP_FAT GO:0048732~gland development 5 PAX8, STAT5B, TGFB3, HOXA9, NR0B1 6,20E-02 4,98E-01
GOTERM_BP_FAT GO:0032583~regulation of gene-specific transcription 5 CEBPA, TAL1, TGFB3, IGF2, EPO 6,07E-02 4,95E-01
GOTERM_BP_FAT GO:0022604~regulation of cell morphogenesis 5 GNA13, TIAM1, GNA12, TGFB3, CACNA1A 5,68E-02 4,78E-01
GOTERM_BP_FAT GO:0035239~tube morphogenesis 5 GNA13, TSC1, PGF, APAF1, MMP14 5,17E-02 4,62E-01
GOTERM_BP_FAT GO:0051052~regulation of DNA metabolic process 5 JUN, TGFB3, IGF2, RAD50, EPO 3,72E-02 3,89E-01
GOTERM_BP_FAT GO:0001655~urogenital system development 5 OSR1, TSC1, PGF, LHX1, PAX8 3,33E-02 3,72E-01
GOTERM_BP_FAT GO:0048872~homeostasis of number of cells 5 TAL1, ID2, STAT5B, EPO, FANCC 2,46E-02 3,11E-01
GOTERM_BP_FAT GO:0001822~kidney development 5 OSR1, TSC1, PGF, LHX1, PAX8 2,15E-02 3,00E-01
GOTERM_BP_FAT GO:0002237~response to molecule of bacterial origin 5 PTGS2, JUN, STAT5B, ADAM17, MALT1 1,50E-02 2,59E-01
GOTERM_BP_FAT GO:0050727~regulation of inflammatory response 5 PTGS2, C3, STAT5B, SERPINC1, IGF2 9,82E-03 1,97E-01
GNA13, DCC, WNT1, CCK, PTGS2, FUT8, IL8, ADAM17, SEMA3C, 
MMP14, VAV2, CEACAM1
CEBPA, THRB, JUN, PAX8, TEAD4, STAT5B, PTH, TGFB3, IL22, PBX2, 
RUNX2, AHR
SLC2A8, PTGS2, TSC1, PGF, STAT5B, TGFB3, FHL2, TFF3, IGF2, 
PTPRU, MMP14, NR0B1
DCC, CFLAR, ERCC6, TIAM1, PTH, RIPK3, TGFB3, VAV2, PRKCE, CD5, 
ATM, TP73
DCC, CFLAR, ERCC6, TIAM1, PTH, RIPK3, TGFB3, VAV2, PRKCE, CD5, 
ATM, TP73
ERCC6, CCK, JUN, TGFB3, ADAM17, TNFRSF14, IGF2, CD6, PRKCE, 
IL22, TP73, EPO
EIF4EBP3, CEBPA, ID2, TSC1, THRB, OVOL1, TGFB3, MDM2, PTPRU, 
NR0B1, RUNX2
PTGS2, SERPINA5, OVOL1, STAT5B, LIG3, TGFB3, MMP14, NR0B1, 
ATM, NR2C2, FANCC
PTGS2, SERPINA5, OVOL1, STAT5B, LIG3, TGFB3, MMP14, NR0B1, 
ATM, NR2C2, FANCC
TAL1, ERG, SLC29A2, EVI5, PGF, RAF1, MALT1, MMP14, CD5, NR2C2, 
TACC2
PPM1D, XRCC2, OVOL1, LIG3, ADAM17, MDM2, RAD54L, ATM, RAD50, 
RBBP8, TACC2
PPM1D, XRCC2, ERCC6, XPC, SLC12A2, JUN, WRN, MMP14, RAD54L, 
ATM
CEBPA, PPM1D, PTGS2, TSC1, IL8, JUN, TGFB3, TNFRSF8, TNFRSF14, 
PTPRU
CFLAR, XRCC2, STAT5B, TGFB3, ADAM17, MALT1, IGF2, ATM, 
CACNA1A, TP73
CFLAR, XRCC2, STAT5B, TGFB3, ADAM17, MALT1, IGF2, ATM, 
CACNA1A, TP73
CFLAR, XRCC2, STAT5B, TGFB3, ADAM17, MALT1, IGF2, ATM, 
CACNA1A, TP73
DCC, WNT1, CCK, FUT8, IL8, ADAM17, SEMA3C, MMP14, VAV2, 
CEACAM1
DCC, WNT1, CCK, FUT8, IL8, ADAM17, SEMA3C, MMP14, VAV2, 
CEACAM1
GNA13, RAB30, TIAM1, MRAS, PTH, GNA12, COL1A2, RAF1, RAB7L1, 
VAV2
CEBPA, TAL1, TNFRSF11A, ID2, STAT5B, LIG3, ADAM17, HOXA9, 
MALT1, EPO
DCC, WNT1, CCK, FUT8, IL8, ADAM17, SEMA3C, MMP14, VAV2, 
CEACAM1
CEBPA, TAL1, TNFRSF11A, ID2, STAT5B, ADAM17, HOXA9, MALT1, 
EPO
SLC2A8, PTGS2, PGF, JUN, ADAM17, SEMA3C, RAD54L, ABCA3, 
ABCG2
TNFRSF11A, PTGS2, MMP8, TGFB3, FHL2, IGF2, MMP14, RUNX2, 
CDH11
TNFRSF11A, PTGS2, MMP8, TGFB3, FHL2, IGF2, MMP14, RUNX2, 
CDH11
Table 5S
GOTERM_BP_FAT GO:0045787~positive regulation of cell cycle 5 ID2, STAT5B, ADAM17, MDM2, IGF2 3,55E-03 1,13E-01
GOTERM_BP_FAT GO:0002526~acute inflammatory response 4 C3, STAT5B, IGF2, IL22 9,38E-02 6,16E-01
GOTERM_BP_FAT GO:0030099~myeloid cell differentiation 4 CEBPA, TAL1, ID2, EPO 8,32E-02 5,79E-01
GOTERM_BP_FAT GO:0042770~DNA damage response, signal transduction 4 ERCC6, XPC, ATM, TP73 5,83E-02 4,83E-01
GOTERM_BP_FAT GO:0032496~response to lipopolysaccharide 4 PTGS2, JUN, STAT5B, ADAM17 5,31E-02 4,64E-01
GOTERM_BP_FAT GO:0007498~mesoderm development 4 OSR1, HCK, OVOL1, MEST 4,82E-02 4,47E-01
GOTERM_BP_FAT GO:0045637~regulation of myeloid cell differentiation 4 TAL1, ID2, JUN, STAT5B 4,20E-02 4,23E-01
GOTERM_BP_FAT GO:0032103~positive regulation of response to external stimulus 4 IL8, C3, STAT5B, ADAM17 3,35E-02 3,72E-01
GOTERM_BP_FAT GO:0006275~regulation of DNA replication 4 JUN, TGFB3, IGF2, EPO 3,09E-02 3,53E-01
GOTERM_BP_FAT GO:0010212~response to ionizing radiation 4 XRCC2, ERCC6, RAD54L, ATM 2,84E-02 3,41E-01
GOTERM_BP_FAT GO:0007179~transforming growth factor beta receptor signaling pathway 4 FUT8, JUN, COL1A2, TGFB3 2,84E-02 3,41E-01
GOTERM_BP_FAT GO:0048771~tissue remodeling 4 PTH, TGFB3, SEMA3C, MMP14 2,37E-02 3,09E-01
GOTERM_BP_FAT GO:0051054~positive regulation of DNA metabolic process 4 JUN, TGFB3, IGF2, EPO 2,37E-02 3,09E-01
GOTERM_BP_FAT GO:0043524~negative regulation of neuron apoptosis 4 XRCC2, TGFB3, CACNA1A, TP73 1,85E-02 2,76E-01
GOTERM_BP_FAT GO:0050731~positive regulation of peptidyl-tyrosine phosphorylation 4 CCK, TNFRSF14, IGF2, EPO 1,49E-02 2,61E-01
GOTERM_BP_FAT GO:0001656~metanephros development 4 OSR1, PGF, LHX1, PAX8 1,25E-02 2,31E-01
GOTERM_BP_FAT GO:0007127~meiosis I 4 OVOL1, LIG3, ATM, RAD50 1,10E-02 2,13E-01
GOTERM_BP_FAT GO:0007266~Rho protein signal transduction 4 GNA13, PTH, GNA12, COL1A2 8,33E-03 1,81E-01
GOTERM_BP_FAT GO:0045740~positive regulation of DNA replication 4 JUN, TGFB3, IGF2, EPO 3,51E-03 1,14E-01
GOTERM_BP_FAT GO:0045793~positive regulation of cell size 3 ADAM17, IGF2, TP73 9,79E-02 6,27E-01
GOTERM_BP_FAT GO:0051302~regulation of cell division 3 PGF, TGFB3, IGF2 9,45E-02 6,17E-01
GOTERM_BP_FAT GO:0048660~regulation of smooth muscle cell proliferation 3 PTGS2, JUN, STAT5B 9,11E-02 6,07E-01
GOTERM_BP_FAT GO:0021543~pallium development 3 TSC1, TP73, TACC2 9,11E-02 6,07E-01
GOTERM_BP_FAT GO:0002699~positive regulation of immune effector process 3 C3, STAT5B, MALT1 8,45E-02 5,82E-01
GOTERM_BP_FAT GO:0006487~protein amino acid N-linked glycosylation 3 FUT8, DPAGT1, MGAT5 8,45E-02 5,82E-01
GOTERM_BP_FAT GO:0051899~membrane depolarization 3 CCK, JUN, CACNA1A 8,12E-02 5,72E-01
GOTERM_BP_FAT GO:0030218~erythrocyte differentiation 3 TAL1, ID2, EPO 8,12E-02 5,72E-01
GOTERM_BP_FAT GO:0001649~osteoblast differentiation 3 FHL2, IGF2, RUNX2 7,80E-02 5,63E-01
GOTERM_BP_FAT GO:0006953~acute-phase response 3 STAT5B, IGF2, IL22 7,16E-02 5,38E-01
GOTERM_BP_FAT GO:0051781~positive regulation of cell division 3 PGF, TGFB3, IGF2 6,85E-02 5,28E-01
GOTERM_BP_FAT GO:0002705~positive regulation of leukocyte mediated immunity 3 C3, STAT5B, MALT1 5,37E-02 4,64E-01
GOTERM_BP_FAT GO:0002708~positive regulation of lymphocyte mediated immunity 3 C3, STAT5B, MALT1 5,37E-02 4,64E-01
GOTERM_BP_FAT GO:0008630~DNA damage response, signal transduction resulting in induction of apoptosis 3 ERCC6, ATM, TP73 5,09E-02 4,59E-01
GOTERM_BP_FAT GO:0045639~positive regulation of myeloid cell differentiation 3 TAL1, ID2, JUN 5,09E-02 4,59E-01
GOTERM_BP_FAT GO:0021761~limbic system development 3 TSC1, NR0B1, TP73 4,82E-02 4,45E-01
GOTERM_BP_FAT GO:0008637~apoptotic mitochondrial changes 3 CCK, JUN, TP73 4,55E-02 4,33E-01
GOTERM_BP_FAT GO:0048661~positive regulation of smooth muscle cell proliferation 3 PTGS2, JUN, STAT5B 4,55E-02 4,33E-01
GOTERM_BP_FAT GO:0007566~embryo implantation 3 PTGS2, TEAD4, EPO 4,29E-02 4,25E-01
GOTERM_BP_FAT GO:0006284~base-excision repair 3 ERCC6, TDG, WRN 3,53E-02 3,81E-01
GOTERM_BP_FAT GO:0007131~reciprocal meiotic recombination 3 LIG3, ATM, RAD50 2,84E-02 3,38E-01
GOTERM_BP_FAT GO:0045778~positive regulation of ossification 3 THRB, TGFB3, RUNX2 2,84E-02 3,38E-01
GOTERM_BP_FAT GO:0001836~release of cytochrome c from mitochondria 3 CCK, JUN, TP73 2,21E-02 3,00E-01
GOTERM_BP_FAT GO:0032332~positive regulation of chondrocyte differentiation 2 THRB, RUNX2 8,48E-02 5,82E-01
GOTERM_BP_FAT GO:0051893~regulation of focal adhesion formation 2 TSC1, MMP14 8,48E-02 5,82E-01
GOTERM_BP_FAT GO:0010224~response to UV-B 2 ERCC6, XPC 8,48E-02 5,82E-01
GOTERM_BP_FAT GO:0021702~cerebellar Purkinje cell differentiation 2 LHX1, CACNA1A 8,48E-02 5,82E-01
GOTERM_BP_FAT GO:0021692~cerebellar Purkinje cell layer morphogenesis 2 LHX1, CACNA1A 8,48E-02 5,82E-01
GOTERM_BP_FAT GO:0007184~SMAD protein nuclear translocation 2 JUN, TGFB3 8,48E-02 5,82E-01
GOTERM_BP_FAT GO:0021694~cerebellar Purkinje cell layer formation 2 LHX1, CACNA1A 8,48E-02 5,82E-01
GOTERM_BP_FAT GO:0031952~regulation of protein amino acid autophosphorylation 2 JUN, IGF2 7,46E-02 5,49E-01
GOTERM_BP_FAT GO:0006047~UDP-N-acetylglucosamine metabolic process 2 GNE, DPAGT1 6,43E-02 5,09E-01
GOTERM_CC_FAT GO:0005886~plasma membrane 50 8,41E-02 8,48E-01
GOTERM_CC_FAT GO:0005576~extracellular region 38 6,54E-04 4,12E-02
GOTERM_CC_FAT GO:0044459~plasma membrane part 32 7,31E-02 9,13E-01
GOTERM_CC_FAT GO:0044421~extracellular region part 24 2,62E-04 2,49E-02
GOTERM_CC_FAT GO:0031226~intrinsic to plasma membrane 22 2,20E-02 6,59E-01
GOTERM_CC_FAT GO:0005887~integral to plasma membrane 21 3,23E-02 7,18E-01
GOTERM_CC_FAT GO:0005615~extracellular space 20 1,53E-04 2,92E-02
GOTERM_CC_FAT GO:0005654~nucleoplasm 15 9,86E-02 7,86E-01
GOTERM_CC_FAT GO:0044432~endoplasmic reticulum part 8 AADAC, CYP4A11, PTGIS, HSD17B2, PTGS2, TAP1, DPAGT1, IGF2 8,45E-02 8,18E-01
GOTERM_CC_FAT GO:0031012~extracellular matrix 8 WNT1, MMP8, COL1A2, TGFB3, TFF3, MMP14, TFPI2, WNT2B 8,25E-02 8,75E-01
GOTERM_CC_FAT GO:0031225~anchored to membrane 6 GNA13, ALPPL2, FOLR1, HCK, GNA12, CP 9,21E-02 7,88E-01
GOTERM_CC_FAT GO:0005667~transcription factor complex 6 CEBPA, JUN, TEAD4, HOXA9, PBX2, RUNX2 7,91E-02 8,97E-01
GOTERM_CC_FAT GO:0005903~brush border 3 GNA13, FOLR1, GNA12 8,92E-02 8,06E-01
GOTERM_MF_FAT GO:0017076~purine nucleotide binding 29 5,13E-02 6,68E-01
GOTERM_MF_FAT GO:0032553~ribonucleotide binding 29 3,17E-02 7,04E-01
GOTERM_MF_FAT GO:0032555~purine ribonucleotide binding 29 3,17E-02 7,04E-01
GOTERM_MF_FAT GO:0030528~transcription regulator activity 25 3,08E-02 7,31E-01
GOTERM_MF_FAT GO:0001882~nucleoside binding 24 9,11E-02 6,87E-01
GOTERM_MF_FAT GO:0032559~adenyl ribonucleotide binding 23 7,63E-02 6,70E-01
GOTERM_MF_FAT GO:0005524~ATP binding 23 6,81E-02 6,55E-01
GOTERM_MF_FAT GO:0003700~transcription factor activity 17 5,72E-02 6,89E-01
GOTERM_MF_FAT GO:0042802~identical protein binding 13 4,18E-02 7,10E-01
GOTERM_MF_FAT GO:0043565~sequence-specific DNA binding 12 6,11E-02 6,78E-01
GOTERM_MF_FAT GO:0008134~transcription factor binding 11 4,88E-02 6,92E-01
GOTERM_MF_FAT GO:0016563~transcription activator activity 10 3,21E-02 6,74E-01
GOTERM_MF_FAT GO:0030246~carbohydrate binding 10 1,39E-02 8,27E-01
GOTERM_MF_FAT GO:0004175~endopeptidase activity 9 CFLAR, CTSL2, CTSO, KLK5, MMP8, ADAM17, MALT1, MMP14, CTSG 4,85E-02 7,13E-01
GOTERM_MF_FAT GO:0003712~transcription cofactor activity 8 DCC, POU2AF1, THRB, RIPK3, BRDT, FHL2, NR0B1, NR2C2 9,51E-02 6,81E-01
GOTERM_MF_FAT GO:0016887~ATPase activity 8 XRCC2, ERCC6, TAP1, ABCC4, WRN, ABCA3, ABCG2, DDX6 6,77E-02 6,67E-01
GOTERM_MF_FAT GO:0042623~ATPase activity, coupled 8 XRCC2, ERCC6, TAP1, ABCC4, WRN, ABCA3, ABCG2, DDX6 2,70E-02 7,72E-01
GNA13, ALPPL2, PTGS2, GNA12, TGFB3, SLC2A8, TIAM1, CSF2RA, 
CEACAM1, CLCA4, LIFR, PRKCH, TNFRSF14, PTPRU, PCDH7, MMP14, 
PRKCE, TRPM1, XPR1, MC2R, COL1A2, MDM2, ADAM17, CTSG, 
KIR3DS1, MRAS, MAGEA1, FHL2, TNFRSF8, ABCA3, AMPH, SLC29A2, 
FOLR1, TAP1, SERPINC1, CD6, CD5, TYROBP, SLC12A2, LGALS4, 
RAF1, RAB7L1, VAV2, ABCG2, RAB30, DSG3, ABCC4, CP, CACNA1A, 
CDH11
PPY, CCK, C3, PGF, VPREB1, MMP8, TGFB3, IFNW1, POMC, ISLR, 
WNT1, FOLR1, HPSE, SERPINA5, PTH, SERPINC1, TFF3, CDA, SFTPC, 
SEMA3C, TFPI2, ANGPT2, CSF2RA, CEACAM1, EPO, IL13RA2, IL8, 
CLCA4, PRG2, KLK5, LIFR, IGF2, MMP14, IL22, WNT2B, PDGFRL, 
COL1A2, CP
GNA13, KIR3DS1, PTGS2, MRAS, TGFB3, FHL2, AMPH, SLC2A8, 
SLC29A2, FOLR1, TAP1, CD6, CD5, CSF2RA, CEACAM1, TYROBP, 
SLC12A2, CLCA4, LIFR, TNFRSF14, PTPRU, PCDH7, RAB7L1, MMP14, 
TRPM1, RAB30, XPR1, DSG3, MC2R, ADAM17, CP, CACNA1A
CCK, IL8, PGF, C3, MMP8, KLK5, TGFB3, IFNW1, IGF2, MMP14, IL22, 
WNT2B, WNT1, PTH, COL1A2, SERPINC1, TFF3, SFTPC, SEMA3C, CP, 
TFPI2, ANGPT2, EPO, IL13RA2
KIR3DS1, CLCA4, SLC12A2, LIFR, TNFRSF14, PTPRU, PCDH7, MMP14, 
TRPM1, SLC2A8, SLC29A2, XPR1, FOLR1, TAP1, MC2R, ADAM17, CP, 
CD6, CD5, CSF2RA, CEACAM1, TYROBP
KIR3DS1, CLCA4, SLC12A2, LIFR, TNFRSF14, PTPRU, PCDH7, MMP14, 
TRPM1, SLC2A8, SLC29A2, XPR1, FOLR1, TAP1, MC2R, ADAM17, CD6, 
CD5, CSF2RA, CEACAM1, TYROBP
CCK, IL8, PGF, C3, MMP8, KLK5, TGFB3, IFNW1, IGF2, IL22, WNT2B, 
PTH, COL1A2, SERPINC1, SFTPC, SEMA3C, CP, ANGPT2, EPO, 
IL13RA2
CEBPA, LIG3, WRN, ATM, TAL1, ERCC6, XPC, JUN, PAX8, TEAD4, TDG, 
MDM2, HOXA9, RUNX2, PBX2
GNA13, XRCC2, GNE, MRAS, GNA12, ABCA3, ERCC6, TAP1, RUNX2, 
HCK, LIG3, RAF1, PRKCH, WRN, PRKCE, RAB7L1, RAD54L, ATM, 
RAD50, ABCG2, DDX6, HUNK, RAB30, RIPK3, ABCC4, APAF1, ABL2, 
DNM1, XYLB
GNA13, XRCC2, GNE, MRAS, GNA12, ABCA3, ERCC6, TAP1, RUNX2, 
HCK, LIG3, RAF1, PRKCH, WRN, PRKCE, RAB7L1, RAD54L, ATM, 
RAD50, ABCG2, DDX6, HUNK, RAB30, RIPK3, ABCC4, APAF1, ABL2, 
DNM1, XYLB
GNA13, XRCC2, GNE, MRAS, GNA12, ABCA3, ERCC6, TAP1, RUNX2, 
HCK, LIG3, RAF1, PRKCH, WRN, PRKCE, RAB7L1, RAD54L, ATM, 
RAD50, ABCG2, DDX6, HUNK, RAB30, RIPK3, ABCC4, APAF1, ABL2, 
DNM1, XYLB
DCC, THRB, STAT5B, FHL2, NR2C2, TAL1, ERCC6, LHX1, TEAD4, 
PAX8, HOXA9, RUNX2, CEBPA, POU2AF1, ERG, NR0B1, TP73, AHR, 
ZNF217, ID2, JUN, RIPK3, BRDT, MDM2, PBX2
XRCC2, GNE, HCK, LIG3, PRKCH, RAF1, WRN, PRKCE, RAD54L, 
ABCA3, RAD50, ATM, ABCG2, DDX6, HUNK, ERCC6, TAP1, RIPK3, 
ABCC4, CDA, APAF1, ABL2, RUNX2, XYLB
XRCC2, GNE, HCK, LIG3, PRKCH, RAF1, WRN, PRKCE, RAD54L, 
ABCA3, RAD50, ATM, ABCG2, DDX6, HUNK, ERCC6, TAP1, RIPK3, 
ABCC4, APAF1, ABL2, RUNX2, XYLB
XRCC2, GNE, HCK, LIG3, PRKCH, RAF1, WRN, PRKCE, RAD54L, 
ABCA3, RAD50, ATM, ABCG2, DDX6, HUNK, ERCC6, TAP1, RIPK3, 
ABCC4, APAF1, ABL2, RUNX2, XYLB
CEBPA, ERG, THRB, STAT5B, NR0B1, AHR, TP73, NR2C2, TAL1, 
ZNF217, LHX1, JUN, PAX8, TEAD4, HOXA9, RUNX2, PBX2
DCC, CEBPA, PGF, TGFB3, FHL2, WRN, NR0B1, ABCG2, TAP1, 
COL1A2, CDA, MDM2, APAF1
CEBPA, TAL1, ERG, THRB, LHX1, JUN, PAX8, STAT5B, HOXA9, NR0B1, 
PBX2, NR2C2
CEBPA, DCC, POU2AF1, THRB, JUN, RIPK3, BRDT, FHL2, NR0B1, AHR, 
NR2C2
DCC, POU2AF1, PAX8, TEAD4, RIPK3, BRDT, FHL2, HOXA9, RUNX2, 
NR2C2
SLC2A8, TNFAIP6, REG1A, PGF, LGALS4, SIGLEC5, SERPINA5, PRG2, 
GALNT4, SERPINC1
Table 5S
GOTERM_MF_FAT GO:0043566~structure-specific DNA binding 7 XPC, THRB, JUN, STAT5B, TDG, WRN, NR0B1 4,66E-03 8,28E-01
GOTERM_MF_FAT GO:0003713~transcription coactivator activity 6 DCC, POU2AF1, RIPK3, BRDT, FHL2, NR2C2 8,00E-02 6,62E-01
GOTERM_MF_FAT GO:0003924~GTPase activity 6 GNA13, RAB30, MRAS, GNA12, RAB7L1, DNM1 7,64E-02 6,57E-01
GOTERM_MF_FAT GO:0005529~sugar binding 6 SLC2A8, REG1A, LGALS4, SIGLEC5, PRG2, GALNT4 5,85E-02 6,79E-01
GOTERM_MF_FAT GO:0005179~hormone activity 6 PPY, CCK, PTH, IGF2, POMC, EPO 6,05E-03 6,81E-01
GOTERM_MF_FAT GO:0030247~polysaccharide binding 5 TNFAIP6, PGF, SERPINA5, PRG2, SERPINC1 8,35E-02 6,66E-01
GOTERM_MF_FAT GO:0001871~pattern binding 5 TNFAIP6, PGF, SERPINA5, PRG2, SERPINC1 8,35E-02 6,66E-01
GOTERM_MF_FAT GO:0005539~glycosaminoglycan binding 5 TNFAIP6, PGF, SERPINA5, PRG2, SERPINC1 6,35E-02 6,59E-01
GOTERM_MF_FAT GO:0019955~cytokine binding 5 LIFR, TGFB3, TNFRSF14, CSF2RA, IL13RA2 2,95E-02 7,57E-01
GOTERM_MF_FAT GO:0003690~double-stranded DNA binding 5 THRB, JUN, STAT5B, TDG, NR0B1 2,03E-02 8,55E-01
GOTERM_MF_FAT GO:0008201~heparin binding 4 PGF, SERPINA5, PRG2, SERPINC1 9,84E-02 6,72E-01
GOTERM_MF_FAT GO:0051427~hormone receptor binding 4 STAT5B, FHL2, NR0B1, TACC2 6,84E-02 6,42E-01
GOTERM_MF_FAT GO:0035257~nuclear hormone receptor binding 4 STAT5B, FHL2, NR0B1, TACC2 4,95E-02 6,76E-01
GOTERM_MF_FAT GO:0004197~cysteine-type endopeptidase activity 4 CFLAR, CTSL2, CTSO, MALT1 4,19E-02 6,85E-01
GOTERM_MF_FAT GO:0019992~diacylglycerol binding 4 RAF1, PRKCH, VAV2, PRKCE 3,63E-02 6,87E-01
GOTERM_MF_FAT GO:0004879~ligand-dependent nuclear receptor activity 4 THRB, NR0B1, AHR, NR2C2 2,42E-02 7,85E-01
GOTERM_MF_FAT GO:0003707~steroid hormone receptor activity 3 THRB, NR0B1, NR2C2 9,67E-02 6,76E-01
GOTERM_MF_FAT GO:0035258~steroid hormone receptor binding 3 STAT5B, FHL2, NR0B1 6,23E-02 6,68E-01
GOTERM_MF_FAT GO:0050780~dopamine receptor binding 2 GNA13, GNA12 9,24E-02 6,81E-01
GOTERM_MF_FAT GO:0000217~DNA secondary structure binding 2 WRN, NR0B1 9,24E-02 6,81E-01
GOTERM_MF_FAT GO:0017163~basal transcription repressor activity 2 MDM2, NR0B1 2,13E-02 8,03E-01
INTERPRO IPR013783:Immunoglobulin-like fold 10 9,63E-02 9,09E-01
INTERPRO IPR003599:Immunoglobulin subtype 8 4,51E-02 9,39E-01
INTERPRO IPR000980:SH2 motif 5 DAPP1, HCK, STAT5B, VAV2, ABL2 2,41E-02 9,25E-01
INTERPRO IPR014001:DEAD-like helicase, N-terminal 4 ERCC6, WRN, RAD54L, DDX6 9,27E-02 9,12E-01
INTERPRO IPR014021:Helicase, superfamily 1 and 2, ATP-binding 4 ERCC6, WRN, RAD54L, DDX6 8,89E-02 9,16E-01
INTERPRO IPR001650:DNA/RNA helicase, C-terminal 4 ERCC6, WRN, RAD54L, DDX6 8,89E-02 9,16E-01
INTERPRO IPR002219:Protein kinase C-like, phorbol ester/diacylglycerol binding 4 RAF1, PRKCH, VAV2, PRKCE 2,84E-02 9,13E-01
INTERPRO IPR017871:ABC transporter, conserved site 4 TAP1, ABCC4, ABCA3, ABCG2 1,86E-02 9,81E-01
INTERPRO IPR003439:ABC transporter-like 4 TAP1, ABCC4, ABCA3, ABCG2 1,17E-02 9,93E-01
INTERPRO IPR008946:Nuclear hormone receptor, ligand-binding 3 THRB, NR0B1, NR2C2 8,10E-02 9,23E-01
INTERPRO IPR000536:Nuclear hormone receptor, ligand-binding, core 3 THRB, NR0B1, NR2C2 8,10E-02 9,23E-01
INTERPRO IPR001723:Steroid hormone receptor 3 THRB, NR0B1, NR2C2 7,81E-02 9,30E-01
INTERPRO IPR001818:Peptidase M10A and M12B, matrixin and adamalysin 3 MMP8, ADAM17, MMP14 6,69E-02 9,31E-01
INTERPRO IPR002190:MAGE protein 3 MAGEA1, MAGEB2, MAGEB3 4,64E-02 9,20E-01
INTERPRO IPR001368:TNFR/CD27/30/40/95 cysteine-rich region 3 TNFRSF11A, TNFRSF8, TNFRSF14 4,17E-02 9,51E-01
INTERPRO IPR015745:Protein kinase C 2 PRKCH, PRKCE 8,52E-02 9,20E-01
INTERPRO IPR003116:Raf-like Ras-binding 2 TIAM1, RAF1 6,69E-02 9,14E-01
INTERPRO IPR012346:p53 and RUNT-type transcription factor, DNA-binding 2 RUNX2, TP73 5,76E-02 9,20E-01
INTERPRO IPR003532:Short hematopoietin receptor, family 2, conserved site 2 CSF2RA, IL13RA2 4,83E-02 9,03E-01
INTERPRO IPR000469:G-protein alpha subunit, group 12 2 GNA13, GNA12 1,96E-02 9,39E-01
KEGG_PATHWAY hsa05200:Pathways in cancer 14 8,14E-03 6,13E-01
KEGG_PATHWAY hsa04060:Cytokine-cytokine receptor interaction 10 5,78E-02 5,78E-01
KEGG_PATHWAY hsa04630:Jak-STAT signaling pathway 7 STAT5B, LIFR, IFNW1, IL22, CSF2RA, EPO, IL13RA2 7,17E-02 5,78E-01
KEGG_PATHWAY hsa04270:Vascular smooth muscle contraction 6 GNA13, CYP4A11, GNA12, RAF1, PRKCH, PRKCE 5,97E-02 5,47E-01
KEGG_PATHWAY hsa04666:Fc gamma R-mediated phagocytosis 6 HCK, RAF1, VAV2, PRKCE, DNM1, AMPH 3,30E-02 8,57E-01
KEGG_PATHWAY hsa04662:B cell receptor signaling pathway 5 DAPP1, JUN, RAF1, MALT1, VAV2 5,25E-02 5,91E-01
KEGG_PATHWAY hsa04730:Long-term depression 5 GNA13, PPP2R1B, GNA12, RAF1, CACNA1A 4,06E-02 6,99E-01
KEGG_PATHWAY hsa04115:p53 signaling pathway 5 PPM1D, MDM2, APAF1, ATM, TP73 3,88E-02 7,83E-01
KEGG_PATHWAY hsa02010:ABC transporters 4 TAP1, ABCC4, ABCA3, ABCG2 4,95E-02 6,25E-01
KEGG_PATHWAY hsa05219:Bladder cancer 4 IL8, PGF, RAF1, MDM2 4,41E-02 6,48E-01
KEGG_PATHWAY hsa03440:Homologous recombination 3 XRCC2, RAD54L, RAD50 9,72E-02 6,60E-01
OMIM_DISEASE Colorectal cancer 3 DCC, PDGFRL, MCC 1,51E-02 8,32E-01
OMIM_DISEASE Lung cancer 2 PPP2R1B, ERCC6 9,27E-02 9,77E-01
OMIM_DISEASE Pulmonary alveolar proteinosis 2 SFTPC, CSF2RA 4,75E-02 9,42E-01
SMART SM00252:SH2 5 DAPP1, HCK, STAT5B, VAV2, ABL2 4,56E-02 9,91E-01
SMART SM00109:C1 4 RAF1, PRKCH, VAV2, PRKCE 4,74E-02 9,14E-01
SMART SM00208:TNFR 3 TNFRSF11A, TNFRSF8, TNFRSF14 6,02E-02 8,76E-01
SMART SM00455:RBD 2 TIAM1, RAF1 8,18E-02 8,84E-01
SP_PIR_KEYWORDS polymorphism 129 3,15E-05 1,56E-03
SP_PIR_KEYWORDS phosphoprotein 85 1,53E-03 3,44E-02
SP_PIR_KEYWORDS glycoprotein 67 1,30E-06 9,68E-05
SP_PIR_KEYWORDS signal 61 6,19E-09 1,84E-06
SP_PIR_KEYWORDS disulfide bond 52 8,55E-07 1,27E-04
SP_PIR_KEYWORDS disease mutation 34 3,64E-06 2,16E-04
SP_PIR_KEYWORDS Secreted 33 3,27E-05 1,39E-03
SP_PIR_KEYWORDS nucleotide-binding 27 3,97E-03 8,09E-02
SP_PIR_KEYWORDS dna-binding 24 6,79E-02 4,07E-01
DCC, ISLR, KIR3DS1, SIGLEC5, PDGFRL, VPREB1, SEMA3C, MALT1, 
PTPRU, CEACAM1
DCC, KIR3DS1, SIGLEC5, PDGFRL, SEMA3C, MALT1, PTPRU, 
CEACAM1
DCC, CEBPA, IL8, PTGS2, PGF, STAT5B, TGFB3, RAF1, WNT2B, WNT1, 
JUN, PAX8, MDM2, CSF2RA
TNFRSF11A, IL8, LIFR, TGFB3, TNFRSF8, IFNW1, TNFRSF14, IL22, 
CSF2RA, EPO
GNA13, ALPPL2, XRCC2, PNMA2, THRB, PTGS2, B3GALT5, STAT5B, 
MMP8, GNA12, TGFB3, SLC2A8, EIF4EBP3, PTGIS, TIAM1, TFPI2, 
ZNF43, POU2AF1, CLCA4, LIG3, LIFR, DPAGT1, TNFRSF14, PTPRU, 
IL22, AHR, NKTR, TACC2, AADAC, TNFAIP6, JUN, MC2R, COL1A2, 
RIPK3, AKAP1, PPY, KIR3DS1, MAGEA1, POMC, ABCA3, SLC29A2, 
FOLR1, TEAD4, SFTPC, CDA, RUNX2, C16ORF3, TYROBP, CFLAR, 
LGALS4, CPNE7, MAGEB2, MALT1, MAGEB3, WRN, VAV2, RAD54L, 
ATM, ABCG2, ZNF217, TSC1, DSG3, RGS4, TDG, ABL2, CACNA1A, 
SEL1L, TNFRSF11A, EVI5, HPSE, SERPINA5, PAX8, SEMA3C, FANCE, 
ANGPT2, CEACAM1, GOLGA3, IL13RA2, FANCC, PPP2R1B, PARM1, 
OTC, PRG2, PRKCH, PRKCE, MMP14, RAD50, TRPM1, RBBP8, HUNK, 
XPC, CYP27A1, SIGLEC5, XPR1, BRDT, ADAM17, TOM1, MCC, CTSG, 
XYLB, DCC, CCK, FUT8, HSD17B2, C3, GALNT4, VPREB1, IFNW1, 
TNFRSF8, AMPH, ISLR, CTAG2, ERCC6, TAP1, SERPINC1, UGT2A1, 
CD6, CD5, EPO, HCK, KLK5, RAF1, IGF2, CYP4A11, C21ORF7, ABCC4, 
CP, DNM1, CDH11
GNA13, ALPPL2, XRCC2, CRABP1, PTGS2, GNA12, STAT5B, EIF4EBP3, 
TNFRSF11A, EVI5, TIAM1, PAX8, FRAT1, FANCE, GOLGA3, LIG3, LIFR, 
PRKCH, TNFRSF14, PCDH7, PTPRU, PRKCE, RAD50, NKTR, TACC2, 
TRPM1, RBBP8, TNFAIP6, PPM1D, XPC, XPR1, GAGE7, JUN, MC2R, 
RIPK3, TOM1, ADAM17, MDM2, MCC, AKAP1, DCC, HSD17B2, GNE, C3, 
TNFRSF8, FHL2, POMC, ABCA3, NR2C2, AMPH, TAL1, SLC29A2, 
ERCC6, DAPP1, NAGA, SERPINC1, SFTPC, CD6, RUNX2, CD5, MLLT3, 
TYROBP, ERG, SLC12A2, HCK, RAF1, MAGEB2, MALT1, WRN, VAV2, 
TP73, ATM, DDX6, ZNF217, RAB30, TSC1, RGS4, ABCC4, APAF1, CP, 
ABL2, PBX2, CACNA1A, DNM1, CDH11
ALPPL2, PTGS2, PGF, B3GALT5, MMP8, TGFB3, SLC2A8, WNT1, 
TNFRSF11A, HPSE, SERPINA5, SEMA3C, ANGPT2, TFPI2, CEACAM1, 
CSF2RA, IL13RA2, PARM1, CLCA4, PRG2, LIFR, DPAGT1, TNFRSF14, 
PCDH7, PTPRU, MMP14, IL22, AADAC, TNFAIP6, SIGLEC5, CTSO, 
PDGFRL, MC2R, COL1A2, ADAM17, MGAT5, CTSG, DCC, CTSL2, 
KIR3DS1, C3, GALNT4, IFNW1, TNFRSF8, POMC, ISLR, SLC29A2, 
REG1A, FOLR1, NAGA, SERPINC1, UGT2A1, CD6, CD5, MEST, EPO, 
SLC12A2, KLK5, IGF2, WNT2B, ABCG2, DSG3, ABCC4, CP, CACNA1A, 
CDH11, SEL1L
ALPPL2, PTGS2, PGF, MMP8, TGFB3, WNT1, TNFRSF11A, HPSE, 
SERPINA5, SEMA3C, ANGPT2, TFPI2, CSF2RA, CEACAM1, IL13RA2, 
PARM1, CLCA4, PRG2, LIFR, TNFRSF14, PCDH7, PTPRU, MMP14, IL22, 
TNFAIP6, SIGLEC5, CTSO, PDGFRL, COL1A2, ADAM17, CTSG, DCC, 
CTSL2, PPY, CCK, KIR3DS1, C3, VPREB1, IFNW1, TNFRSF8, POMC, 
ISLR, REG1A, FOLR1, PTH, NAGA, SERPINC1, UGT2A1, TFF3, CD6, 
CD5, TYROBP, EPO, IL8, KLK5, IGF2, WNT2B, DSG3, CP, CDH11, 
SEL1L
ALPPL2, PTGS2, PGF, MMP8, TGFB3, TNFRSF11A, SEMA3C, ANGPT2, 
TFPI2, CSF2RA, CEACAM1, IL13RA2, PRG2, LIFR, TNFRSF14, PTPRU, 
MMP14, IL22, AADAC, TNFAIP6, SIGLEC5, CTSO, PDGFRL, ADAM17, 
CTSG, DCC, CTSL2, KIR3DS1, C3, VPREB1, GALNT4, IFNW1, 
TNFRSF8, POMC, ISLR, REG1A, FOLR1, NAGA, SERPINC1, TFF3, CD6, 
CD5, EPO, TYROBP, IL8, KLK5, MALT1, IGF2, ABCG2, CP, CACNA1A, 
SEL1L
DCC, THRB, C3, GNE, STAT5B, ABCA3, ERCC6, TNFRSF11A, PAX8, 
PTH, NAGA, SERPINC1, FANCE, SFTPC, RUNX2, CSF2RA, FANCC, 
OTC, LIFR, DPAGT1, RAF1, IGF2, WRN, NR0B1, RAD54L, ATM, XPC, 
CYP27A1, TSC1, MC2R, PDGFRL, COL1A2, MCC, CACNA1A
PPY, CCK, C3, PGF, MMP8, TGFB3, IFNW1, ISLR, WNT1, HPSE, FOLR1, 
SERPINA5, PTH, SERPINC1, TFF3, SFTPC, SEMA3C, TFPI2, ANGPT2, 
CEACAM1, CSF2RA, EPO, IL8, CLCA4, PRG2, KLK5, LIFR, IGF2, IL22, 
WNT2B, PDGFRL, COL1A2, CP
GNA13, GNE, MRAS, GNA12, ABCA3, ERCC6, TAP1, HCK, LIG3, RAF1, 
PRKCH, WRN, RAB7L1, PRKCE, RAD54L, ATM, RAD50, ABCG2, DDX6, 
HUNK, RAB30, RIPK3, ABCC4, APAF1, ABL2, DNM1, XYLB
ZNF43, CEBPA, ERG, XRCC2, THRB, STAT5B, WRN, RAD54L, AHR, 
TP73, NR2C2, ATM, TAL1, ERCC6, XPC, ZNF217, LHX1, JUN, PAX8, 
OVOL1, TEAD4, HOXA9, PBX2, RUNX2
Table 5S
SP_PIR_KEYWORDS hydrolase 24 1,09E-02 1,83E-01
SP_PIR_KEYWORDS atp-binding 21 1,42E-02 2,10E-01
SP_PIR_KEYWORDS lipoprotein 13 1,24E-02 1,95E-01
SP_PIR_KEYWORDS Proto-oncogene 13 1,06E-06 1,05E-04
SP_PIR_KEYWORDS transmembrane protein 12 2,87E-02 2,74E-01
SP_PIR_KEYWORDS cleavage on pair of basic residues 11 1,61E-04 4,76E-03
SP_PIR_KEYWORDS ubl conjugation 10 DCC, HUNK, TAL1, POU2AF1, EVI5, TDG, MDM2, NKTR, TP73, RBBP8 7,98E-02 4,53E-01
SP_PIR_KEYWORDS Immunoglobulin domain 10 2,49E-02 2,59E-01
SP_PIR_KEYWORDS chromosomal rearrangement 10 8,99E-04 2,40E-02
SP_PIR_KEYWORDS DNA damage 10 9,36E-05 3,08E-03
SP_PIR_KEYWORDS dna repair 10 5,41E-05 2,01E-03
SP_PIR_KEYWORDS cell adhesion 8 TNFAIP6, SIGLEC5, DSG3, PCDH7, PTPRU, CD6, ABL2, CDH11 8,32E-02 4,59E-01
SP_PIR_KEYWORDS DNA binding 7 ZNF43, TAL1, THRB, JUN, PAX8, HOXA9, PBX2 8,45E-02 4,57E-01
SP_PIR_KEYWORDS duplication 6 PRKCH, CP, PRKCE, TFPI2, CD5, CDH11 5,32E-02 3,63E-01
SP_PIR_KEYWORDS glycosyltransferase 6 FUT8, B3GALT5, GALNT4, UGT2A1, DPAGT1, MGAT5 4,25E-02 3,32E-01
SP_PIR_KEYWORDS palmitate 6 GNA13, HCK, RGS4, GNA12, MC2R, SFTPC 4,12E-02 3,32E-01
SP_PIR_KEYWORDS zymogen 6 CTSL2, CTSO, MMP8, ADAM17, MMP14, CTSG 3,71E-02 3,12E-01
SP_PIR_KEYWORDS hormone 6 PPY, CCK, PTH, IGF2, POMC, EPO 1,08E-03 2,63E-02
SP_PIR_KEYWORDS Lectin 5 REG1A, LGALS4, SIGLEC5, PRG2, GALNT4 5,37E-02 3,58E-01
SP_PIR_KEYWORDS tumor suppressor 5 DCC, TSC1, MCC, ATM, TP73 3,41E-02 2,99E-01
SP_PIR_KEYWORDS P-loop 5 RAB30, TAP1, ABCA3, DNM1, DDX6 2,00E-02 2,39E-01
SP_PIR_KEYWORDS SH2 domain 5 DAPP1, HCK, STAT5B, VAV2, ABL2 1,73E-02 2,19E-01
SP_PIR_KEYWORDS nucleotide binding 5 RAB30, TAP1, ABCA3, DNM1, DDX6 1,53E-02 2,15E-01
SP_PIR_KEYWORDS metalloprotein 4 CYP4A11, ALPPL2, PTGS2, CYP27A1 9,87E-02 4,89E-01
SP_PIR_KEYWORDS wnt signaling pathway 4 WNT1, FRAT1, MCC, WNT2B 9,51E-02 4,83E-01
SP_PIR_KEYWORDS heme 4 CYP4A11, PTGIS, PTGS2, CYP27A1 9,33E-02 4,84E-01
SP_PIR_KEYWORDS plasma 4 C3, PTH, SERPINC1, CP 5,01E-02 3,54E-01
SP_PIR_KEYWORDS angiogenesis 4 PGF, IGF2, VAV2, ANGPT2 2,10E-02 2,31E-01
SP_PIR_KEYWORDS tumor antigen 4 PNMA2, MAGEA1, MAGEB2, MAGEB3 4,63E-03 8,79E-02
SP_PIR_KEYWORDS amidation 3 PPY, CCK, POMC 5,83E-02 3,75E-01
SP_PIR_KEYWORDS pharmaceutical 3 PPY, IGF2, EPO 5,83E-02 3,75E-01
SP_PIR_KEYWORDS mitogen 3 PGF, TGFB3, IGF2 4,70E-02 3,43E-01
SP_PIR_KEYWORDS dwarfism 3 ERCC6, COL1A2, IGF2 4,48E-02 3,38E-01
SP_PIR_KEYWORDS monomer 3 SERPINA5, PRG2, IGF2 3,09E-02 2,83E-01
SP_PIR_KEYWORDS acute phase 3 C3, SERPINC1, CP 2,73E-02 2,71E-01
SP_PIR_KEYWORDS inflammation 3 IL8, C3, PRG2 2,06E-02 2,36E-01
SP_PIR_KEYWORDS serine proteinase inhibitor 3 SERPINA5, SERPINC1, TFPI2 1,62E-02 2,15E-01
SP_PIR_KEYWORDS phorbol ester binding 2 PRKCH, PRKCE 6,06E-02 3,79E-01
SP_PIR_KEYWORDS prostaglandin biosynthesis 2 PTGIS, PTGS2 6,06E-02 3,79E-01
UP_SEQ_FEATURE sequence variant 135 7,72E-06 1,38E-03
UP_SEQ_FEATURE glycosylation site:N-linked (GlcNAc...) 64 3,56E-06 1,28E-03
UP_SEQ_FEATURE signal peptide 61 7,90E-09 5,67E-06
UP_SEQ_FEATURE disulfide bond 49 4,85E-06 1,16E-03
UP_SEQ_FEATURE mutagenesis site 33 1,17E-03 1,55E-01
UP_SEQ_FEATURE nucleotide phosphate-binding region:ATP 16 2,60E-02 8,49E-01
UP_SEQ_FEATURE domain:Ig-like C2-type 2 6 DCC, KIR3DS1, SIGLEC5, PDGFRL, MALT1, CEACAM1 2,87E-02 8,00E-01
UP_SEQ_FEATURE domain:Ig-like C2-type 1 6 DCC, KIR3DS1, SIGLEC5, PDGFRL, MALT1, CEACAM1 2,82E-02 8,19E-01
UP_SEQ_FEATURE lipid moiety-binding region:S-palmitoyl cysteine 5 GNA13, RGS4, GNA12, MC2R, SFTPC 7,97E-02 9,17E-01
UP_SEQ_FEATURE domain:SH2 5 DAPP1, HCK, STAT5B, VAV2, ABL2 1,09E-02 6,74E-01
UP_SEQ_FEATURE propeptide:Activation peptide 5 CTSL2, CTSO, MMP8, MMP14, CTSG 4,17E-03 3,93E-01
UP_SEQ_FEATURE compositionally biased region:Asp/Glu-rich (acidic) 4 ERCC6, XPC, MDM2, TP73 8,26E-02 9,16E-01
UP_SEQ_FEATURE domain:Helicase ATP-binding 4 ERCC6, WRN, RAD54L, DDX6 7,60E-02 9,24E-01
UP_SEQ_FEATURE domain:Helicase C-terminal 4 ERCC6, WRN, RAD54L, DDX6 6,82E-02 9,11E-01
UP_SEQ_FEATURE metal ion-binding site:Iron (heme axial ligand) 4 CYP4A11, PTGIS, PTGS2, CYP27A1 5,78E-02 8,95E-01
UP_SEQ_FEATURE domain:Fibronectin type-III 3 4 DCC, LIFR, PTPRU, IL13RA2 3,84E-02 8,47E-01
UP_SEQ_FEATURE site:Reactive bond 3 SERPINA5, SERPINC1, TFPI2 6,13E-02 8,97E-01
UP_SEQ_FEATURE short sequence motif:Cysteine switch 3 MMP8, ADAM17, MMP14 5,66E-02 9,02E-01
UP_SEQ_FEATURE compositionally biased region:Arg/Lys-rich (basic) 3 XPC, SEMA3C, NKTR 4,53E-02 8,59E-01
UP_SEQ_FEATURE domain:MAGE 3 MAGEA1, MAGEB2, MAGEB3 3,31E-02 8,22E-01
UP_SEQ_FEATURE short sequence motif:WSXWS motif 3 LIFR, CSF2RA, IL13RA2 2,76E-02 8,39E-01
UP_SEQ_FEATURE repeat:TNFR-Cys 1 3 TNFRSF11A, TNFRSF8, TNFRSF14 2,09E-02 8,14E-01
UP_SEQ_FEATURE repeat:TNFR-Cys 2 3 TNFRSF11A, TNFRSF8, TNFRSF14 2,09E-02 8,14E-01
UP_SEQ_FEATURE repeat:TNFR-Cys 3 3 TNFRSF11A, TNFRSF8, TNFRSF14 1,78E-02 8,00E-01
CTSL2, ALPPL2, C3, MMP8, KLK5, MALT1, WRN, PTPRU, MMP14, 
RAD54L, RAD50, DDX6, AADAC, PPM1D, ERCC6, HPSE, CTSO, NAGA, 
TDG, CDA, ADAM17, CTSG, DNM1, MEST
GNE, HCK, LIG3, RAF1, PRKCH, WRN, PRKCE, RAD54L, ABCA3, 
RAD50, ATM, DDX6, ABCG2, HUNK, ERCC6, TAP1, RIPK3, ABCC4, 
APAF1, ABL2, XYLB
GNA13, ALPPL2, HCK, MRAS, GNA12, RAB7L1, RAB30, TIAM1, FOLR1, 
RGS4, MC2R, SFTPC, ABL2
POU2AF1, ERG, THRB, RAF1, RAD54L, DDX6, TAL1, WNT1, JUN, 
FRAT1, MDM2, HOXA9, MLLT3
DCC, WNT1, CYP4A11, HSD17B2, CYP27A1, MC2R, TNFRSF8, MGAT5, 
CD5, ABCA3, CSF2RA, CEACAM1
PPY, CCK, C3, DSG3, PTH, TGFB3, ADAM17, IGF2, MMP14, POMC, 
CDH11
DCC, ISLR, KIR3DS1, SIGLEC5, PDGFRL, VPREB1, SEMA3C, MALT1, 
PTPRU, CEACAM1
TAL1, ERG, POU2AF1, EVI5, COL1A2, LIFR, HOXA9, MALT1, MLLT3, 
DDX6
XRCC2, ERCC6, XPC, TDG, LIG3, FANCE, RAD54L, ATM, RAD50, 
FANCC
XRCC2, ERCC6, XPC, TDG, LIG3, FANCE, RAD54L, ATM, RAD50, 
FANCC
GNA13, ALPPL2, XRCC2, PNMA2, THRB, PTGS2, B3GALT5, STAT5B, 
MMP8, GNA12, TGFB3, SLC2A8, EIF4EBP3, PTGIS, TIAM1, TFPI2, 
ZNF43, POU2AF1, CLCA4, LIG3, LIFR, DPAGT1, TNFRSF14, PTPRU, 
NR0B1, IL22, AHR, NKTR, TACC2, AADAC, TNFAIP6, JUN, MC2R, 
PDGFRL, COL1A2, RIPK3, AKAP1, PPY, KIR3DS1, GNE, MAGEA1, 
POMC, ABCA3, SLC29A2, FOLR1, TEAD4, NAGA, SFTPC, CDA, RUNX2, 
C16ORF3, TYROBP, CFLAR, LGALS4, CPNE7, MAGEB2, MALT1, WRN, 
MAGEB3, VAV2, RAD54L, ATM, ABCG2, ZNF217, TSC1, DSG3, RGS4, 
TDG, ABL2, CACNA1A, SEL1L, TNFRSF11A, EVI5, HPSE, SERPINA5, 
PAX8, SEMA3C, FANCE, ANGPT2, CEACAM1, CSF2RA, GOLGA3, 
IL13RA2, FANCC, PPP2R1B, PARM1, OTC, PRG2, PRKCH, PRKCE, 
MMP14, RAD50, TRPM1, RBBP8, HUNK, XPC, CYP27A1, SIGLEC5, 
XPR1, BRDT, ADAM17, TOM1, MCC, CTSG, XYLB, DCC, CCK, FUT8, 
HSD17B2, C3, GALNT4, VPREB1, IFNW1, TNFRSF8, AMPH, ISLR, 
ERCC6, CTAG2, PTH, TAP1, SERPINC1, UGT2A1, CD6, CD5, EPO, HCK, 
KLK5, RAF1, IGF2, CYP4A11, C21ORF7, ABCC4, CP, DNM1, CDH11
ALPPL2, PTGS2, PGF, B3GALT5, MMP8, TGFB3, SLC2A8, WNT1, 
TNFRSF11A, HPSE, SERPINA5, SEMA3C, ANGPT2, TFPI2, CSF2RA, 
CEACAM1, IL13RA2, PARM1, CLCA4, PRG2, LIFR, DPAGT1, TNFRSF14, 
PCDH7, PTPRU, IL22, AADAC, TNFAIP6, SIGLEC5, CTSO, PDGFRL, 
MC2R, COL1A2, ADAM17, MGAT5, CTSG, DCC, CTSL2, KIR3DS1, C3, 
GALNT4, IFNW1, TNFRSF8, POMC, ISLR, SLC29A2, FOLR1, NAGA, 
SERPINC1, UGT2A1, CD6, CD5, MEST, EPO, SLC12A2, KLK5, WNT2B, 
ABCG2, DSG3, ABCC4, CP, CACNA1A, CDH11, SEL1L
ALPPL2, PTGS2, PGF, MMP8, TGFB3, WNT1, TNFRSF11A, HPSE, 
SERPINA5, SEMA3C, ANGPT2, TFPI2, CSF2RA, CEACAM1, IL13RA2, 
PARM1, CLCA4, PRG2, LIFR, TNFRSF14, PCDH7, PTPRU, MMP14, IL22, 
TNFAIP6, SIGLEC5, CTSO, PDGFRL, COL1A2, ADAM17, CTSG, DCC, 
CTSL2, PPY, CCK, KIR3DS1, C3, VPREB1, IFNW1, TNFRSF8, POMC, 
ISLR, REG1A, FOLR1, PTH, NAGA, SERPINC1, UGT2A1, TFF3, CD6, 
CD5, TYROBP, EPO, IL8, KLK5, IGF2, WNT2B, DSG3, CP, CDH11, 
SEL1L
ALPPL2, PTGS2, PGF, MMP8, TGFB3, TNFRSF11A, SEMA3C, TFPI2, 
ANGPT2, CSF2RA, CEACAM1, IL13RA2, PRG2, LIFR, TNFRSF14, 
PTPRU, MMP14, IL22, AADAC, TNFAIP6, SIGLEC5, CTSO, PDGFRL, 
ADAM17, CTSG, DCC, CTSL2, KIR3DS1, C3, VPREB1, GALNT4, 
TNFRSF8, IFNW1, POMC, ISLR, REG1A, NAGA, SERPINC1, TFF3, CD6, 
CD5, EPO, IL8, KLK5, MALT1, IGF2, ABCG2, CP, SEL1L
GNA13, CCK, FUT8, C3, GALNT4, MAGEA1, EIF4EBP3, DAPP1, HPSE, 
PTH, NAGA, SERPINC1, GOLGA3, CFLAR, RAF1, MALT1, PTPRU, 
NR0B1, PRKCE, RAD54L, RAD50, ATM, AHR, TP73, ABCG2, RBBP8, 
CYP4A11, PPM1D, RIPK3, TDG, MDM2, APAF1, DNM1
GNE, HCK, RAF1, PRKCH, WRN, PRKCE, RAD54L, RAD50, DDX6, 
ABCG2, HUNK, ERCC6, TAP1, RIPK3, APAF1, ABL2
Table 5S
UP_SEQ_FEATURE domain:SRCR 3 2 CD6, CD5 9,42E-02 9,35E-01
UP_SEQ_FEATURE short sequence motif:DEGH box 2 ERCC6, RAD54L 7,77E-02 9,20E-01
UP_SEQ_FEATURE domain:RBD 2 TIAM1, RAF1 4,39E-02 8,67E-01
Table 6S
Data source Term Count Genes PValue Benjamini
COG_ONTOLOGY Secondary metabolites biosynthesis, transport, and catabolism 2 CYP21A2, CYP1A2 9,68E-002 1,84E-001
GOTERM_BP_FAT GO:0006952~defense response 15 5,06E-006 5,72E-003
GOTERM_BP_FAT GO:0006793~phosphorus metabolic process 12 1,62E-002 5,53E-001
GOTERM_BP_FAT GO:0006796~phosphate metabolic process 12 1,62E-002 5,53E-001
GOTERM_BP_FAT GO:0010033~response to organic substance 11 CALCR, STS, CA9, CDKN2B, STAR, TFRC, ENPP1, MSH5, RXRA, IGFBP1, EPHA3 5,68E-003 5,12E-001
GOTERM_BP_FAT GO:0042592~homeostatic process 11 CALCR, SLC26A4, PTPRC, APOA1, IL2RA, TFRC, ENPP1, GIPR, TERF1, IL2, EPHA3 7,51E-003 5,09E-001
GOTERM_BP_FAT GO:0042127~regulation of cell proliferation 10 PTPRC, STS, ACVRL1, IL2RA, CDKN2B, RXRA, TSC2, GML, NR2E1, IL2 2,73E-002 5,17E-001
GOTERM_BP_FAT GO:0042981~regulation of apoptosis 10 PTPRC, IL2RA, BRAF, RXRA, TNFRSF18, CHEK2, NR2E1, TERF1, TNFSF8, IL2 3,07E-002 5,29E-001
GOTERM_BP_FAT GO:0043067~regulation of programmed cell death 10 PTPRC, IL2RA, BRAF, RXRA, TNFRSF18, CHEK2, NR2E1, TERF1, TNFSF8, IL2 3,24E-002 5,26E-001
GOTERM_BP_FAT GO:0010941~regulation of cell death 10 PTPRC, IL2RA, BRAF, RXRA, TNFRSF18, CHEK2, NR2E1, TERF1, TNFSF8, IL2 3,31E-002 5,20E-001
GOTERM_BP_FAT GO:0009611~response to wounding 9 ACVRL1, IL2RA, KLRG1, TFRC, RXRA, TSC2, IGFBP1, BMPR1B, EPHA3 8,20E-003 5,12E-001
GOTERM_BP_FAT GO:0006468~protein amino acid phosphorylation 9 PTPRC, ACVRL1, BRAF, CDK8, CHEK2, ALK, FES, BMPR1B, EPHA3 2,88E-002 5,21E-001
GOTERM_BP_FAT GO:0016310~phosphorylation 9 PTPRC, ACVRL1, BRAF, CDK8, CHEK2, ALK, FES, BMPR1B, EPHA3 7,01E-002 6,33E-001
GOTERM_BP_FAT GO:0048878~chemical homeostasis 8 CALCR, SLC26A4, PTPRC, APOA1, TFRC, ENPP1, GIPR, IL2 2,16E-002 5,28E-001
GOTERM_BP_FAT GO:0006954~inflammatory response 7 IL2RA, KLRG1, TFRC, RXRA, TSC2, BMPR1B, EPHA3 8,65E-003 4,81E-001
GOTERM_BP_FAT GO:0007167~enzyme linked receptor protein signaling pathway 7 ACVRL1, TSC2, IGFBP1, ALK, FGF20, BMPR1B, EPHA3 1,10E-002 5,20E-001
GOTERM_BP_FAT GO:0008285~negative regulation of cell proliferation 7 ACVRL1, IL2RA, CDKN2B, RXRA, TSC2, GML, IL2 1,40E-002 5,50E-001
GOTERM_BP_FAT GO:0009725~response to hormone stimulus 7 CALCR, STS, CA9, STAR, ENPP1, RXRA, IGFBP1 1,51E-002 5,59E-001
GOTERM_BP_FAT GO:0009719~response to endogenous stimulus 7 CALCR, STS, CA9, STAR, ENPP1, RXRA, IGFBP1 2,33E-002 5,04E-001
GOTERM_BP_FAT GO:0050801~ion homeostasis 7 CALCR, SLC26A4, PTPRC, TFRC, ENPP1, GIPR, IL2 2,43E-002 5,10E-001
GOTERM_BP_FAT GO:0043085~positive regulation of catalytic activity 7 CALCR, PTPRC, APOA1, GIPR, TSC2, TERF1, IL2 6,47E-002 6,31E-001
GOTERM_BP_FAT GO:0007584~response to nutrient 6 CDKN2B, STAR, TFRC, MSH5, RXRA, GIPR 1,00E-003 4,34E-001
GOTERM_BP_FAT GO:0031667~response to nutrient levels 6 CDKN2B, STAR, TFRC, MSH5, RXRA, GIPR 4,45E-003 5,69E-001
GOTERM_BP_FAT GO:0008202~steroid metabolic process 6 SULT4A1, STS, APOA1, STAR, CYP21A2, RXRA 4,95E-003 5,52E-001
GOTERM_BP_FAT GO:0008361~regulation of cell size 6 ACVRL1, ENPP1, TSC2, IGFBP1, FGF20, IL2 5,37E-003 5,33E-001
GOTERM_BP_FAT GO:0009991~response to extracellular stimulus 6 CDKN2B, STAR, TFRC, MSH5, RXRA, GIPR 7,06E-003 5,18E-001
GOTERM_BP_FAT GO:0045597~positive regulation of cell differentiation 6 PTPRC, IL2RA, CDKN2B, STAR, BMPR1B, IL2 8,32E-003 4,91E-001
GOTERM_BP_FAT GO:0032535~regulation of cellular component size 6 ACVRL1, ENPP1, TSC2, IGFBP1, FGF20, IL2 1,63E-002 5,40E-001
GOTERM_BP_FAT GO:0051094~positive regulation of developmental process 6 PTPRC, IL2RA, CDKN2B, STAR, BMPR1B, IL2 1,80E-002 5,21E-001
GOTERM_BP_FAT GO:0055080~cation homeostasis 6 CALCR, SLC26A4, PTPRC, TFRC, GIPR, IL2 2,01E-002 5,35E-001
GOTERM_BP_FAT GO:0001501~skeletal system development 6 HOXA5, DLK1, EXT1, BMPR1B, SLC26A2, MMP2 3,04E-002 5,32E-001
GOTERM_BP_FAT GO:0051726~regulation of cell cycle 6 PTPRC, CDKN2B, TSC2, CHEK2, GML, TERF1 3,48E-002 5,24E-001
GOTERM_BP_FAT GO:0051338~regulation of transferase activity 6 PTPRC, APOA1, CDKN2B, TSC2, TERF1, IL2 5,28E-002 5,84E-001
GOTERM_BP_FAT GO:0006873~cellular ion homeostasis 6 CALCR, PTPRC, TFRC, ENPP1, GIPR, IL2 5,38E-002 5,81E-001
GOTERM_BP_FAT GO:0055082~cellular chemical homeostasis 6 CALCR, PTPRC, TFRC, ENPP1, GIPR, IL2 5,69E-002 5,97E-001
GOTERM_BP_FAT GO:0043065~positive regulation of apoptosis 6 PTPRC, IL2RA, RXRA, CHEK2, TERF1, TNFSF8 8,62E-002 6,74E-001
GOTERM_BP_FAT GO:0043068~positive regulation of programmed cell death 6 PTPRC, IL2RA, RXRA, CHEK2, TERF1, TNFSF8 8,81E-002 6,75E-001
GOTERM_BP_FAT GO:0010942~positive regulation of cell death 6 PTPRC, IL2RA, RXRA, CHEK2, TERF1, TNFSF8 8,95E-002 6,73E-001
GOTERM_BP_FAT GO:0008283~cell proliferation 6 PTPRC, APOA1, IL2RA, RXRA, FES, TNFSF8 9,01E-002 6,68E-001
GOTERM_BP_FAT GO:0007565~female pregnancy 5 STS, PSG7, RXRA, PSG3, PSG1 3,08E-003 5,02E-001
GOTERM_BP_FAT GO:0043434~response to peptide hormone stimulus 5 STS, STAR, ENPP1, RXRA, IGFBP1 1,00E-002 5,10E-001
GOTERM_BP_FAT GO:0040007~growth 5 HOXA5, RXRA, IGFBP1, FGF20, BMPR1B 1,79E-002 5,31E-001
GOTERM_BP_FAT GO:0007169~transmembrane receptor protein tyrosine kinase signaling pathway 5 TSC2, IGFBP1, ALK, FGF20, EPHA3 3,42E-002 5,25E-001
GOTERM_BP_FAT GO:0030005~cellular di-, tri-valent inorganic cation homeostasis 5 CALCR, PTPRC, TFRC, GIPR, IL2 3,57E-002 5,14E-001
GOTERM_BP_FAT GO:0007423~sensory organ development 5 RORB, FGF20, BMPR1B, CRYBA1, NR2E1 3,67E-002 5,06E-001
GOTERM_BP_FAT GO:0055066~di-, tri-valent inorganic cation homeostasis 5 CALCR, PTPRC, TFRC, GIPR, IL2 4,19E-002 5,36E-001
GOTERM_BP_FAT GO:0030003~cellular cation homeostasis 5 CALCR, PTPRC, TFRC, GIPR, IL2 5,03E-002 5,72E-001
GOTERM_BP_FAT GO:0002520~immune system development 5 CALCR, PTPRC, PMS2, CD1D, IL2 6,44E-002 6,34E-001
GOTERM_BP_FAT GO:0042326~negative regulation of phosphorylation 4 PTPRC, CDKN2B, ENPP1, IL2 1,89E-003 5,11E-001
GOTERM_BP_FAT GO:0010563~negative regulation of phosphorus metabolic process 4 PTPRC, CDKN2B, ENPP1, IL2 2,28E-003 4,76E-001
GOTERM_BP_FAT GO:0045936~negative regulation of phosphate metabolic process 4 PTPRC, CDKN2B, ENPP1, IL2 2,28E-003 4,76E-001
GOTERM_BP_FAT GO:0032869~cellular response to insulin stimulus 4 STAR, ENPP1, RXRA, IGFBP1 6,10E-003 5,00E-001
GOTERM_BP_FAT GO:0000075~cell cycle checkpoint 4 CDKN2B, CHEK2, GML, TERF1 1,35E-002 5,56E-001
GOTERM_BP_FAT GO:0032868~response to insulin stimulus 4 STAR, ENPP1, RXRA, IGFBP1 1,74E-002 5,35E-001
GOTERM_BP_FAT GO:0048585~negative regulation of response to stimulus 4 PTPRC, IL2RA, ENPP1, IL2 1,74E-002 5,35E-001
GOTERM_BP_FAT GO:0009615~response to virus 4 PTPRC, IFNA1, DEFA3, IFNA8 2,18E-002 5,10E-001
GOTERM_BP_FAT GO:0007204~elevation of cytosolic calcium ion concentration 4 CALCR, PTPRC, GIPR, IL2 2,23E-002 5,09E-001
GOTERM_BP_FAT GO:0032844~regulation of homeostatic process 4 PTPRC, IL2RA, TERF1, IL2 2,45E-002 5,05E-001
GOTERM_BP_FAT GO:0051480~cytosolic calcium ion homeostasis 4 CALCR, PTPRC, GIPR, IL2 2,68E-002 5,28E-001
GOTERM_BP_FAT GO:0014070~response to organic cyclic substance 4 STS, CDKN2B, STAR, RXRA 2,86E-002 5,26E-001
GOTERM_BP_FAT GO:0002521~leukocyte differentiation 4 CALCR, PTPRC, CD1D, IL2 3,50E-002 5,20E-001
GOTERM_BP_FAT GO:0001654~eye development 4 RORB, BMPR1B, CRYBA1, NR2E1 3,56E-002 5,20E-001
GOTERM_BP_FAT GO:0032870~cellular response to hormone stimulus 4 STAR, ENPP1, RXRA, IGFBP1 3,63E-002 5,15E-001
GOTERM_BP_FAT GO:0001932~regulation of protein amino acid phosphorylation 4 PTPRC, APOA1, ENPP1, IL2 6,90E-002 6,37E-001
GOTERM_BP_FAT GO:0051259~protein oligomerization 4 BRAF, TSC2, SKIL, TERF1 7,00E-002 6,37E-001
GOTERM_BP_FAT GO:0048729~tissue morphogenesis 4 CA9, HOXA5, RXRA, TSC2 7,57E-002 6,50E-001
GOTERM_BP_FAT GO:0006874~cellular calcium ion homeostasis 4 CALCR, PTPRC, GIPR, IL2 7,87E-002 6,56E-001
GOTERM_BP_FAT GO:0055074~calcium ion homeostasis 4 CALCR, PTPRC, GIPR, IL2 8,38E-002 6,68E-001
GOTERM_BP_FAT GO:0048545~response to steroid hormone stimulus 4 CALCR, STS, CA9, RXRA 8,79E-002 6,78E-001
GOTERM_BP_FAT GO:0001558~regulation of cell growth 4 ACVRL1, ENPP1, IGFBP1, IL2 9,01E-002 6,72E-001
GOTERM_BP_FAT GO:0006875~cellular metal ion homeostasis 4 CALCR, PTPRC, GIPR, IL2 9,22E-002 6,69E-001
GOTERM_BP_FAT GO:0001933~negative regulation of protein amino acid phosphorylation 3 PTPRC, ENPP1, IL2 1,32E-002 5,66E-001
GOTERM_BP_FAT GO:0045582~positive regulation of T cell differentiation 3 PTPRC, IL2RA, IL2 1,32E-002 5,66E-001
GOTERM_BP_FAT GO:0045621~positive regulation of lymphocyte differentiation 3 PTPRC, IL2RA, IL2 1,56E-002 5,56E-001
GOTERM_BP_FAT GO:0042102~positive regulation of T cell proliferation 3 PTPRC, IL2RA, IL2 1,92E-002 5,31E-001
GOTERM_BP_FAT GO:0006953~acute-phase response 3 TFRC, TSC2, EPHA3 2,01E-002 5,25E-001
GOTERM_BP_FAT GO:0002700~regulation of production of molecular mediator of immune response 3 PTPRC, APOA1, IL2 2,11E-002 5,30E-001
GOTERM_BP_FAT GO:0007093~mitotic cell cycle checkpoint 3 CDKN2B, GML, TERF1 2,31E-002 5,11E-001
GOTERM_BP_FAT GO:0045580~regulation of T cell differentiation 3 PTPRC, IL2RA, IL2 3,17E-002 5,32E-001
GOTERM_BP_FAT GO:0051291~protein heterooligomerization 3 BRAF, TSC2, SKIL 3,28E-002 5,24E-001
GOTERM_BP_FAT GO:0050671~positive regulation of lymphocyte proliferation 3 PTPRC, IL2RA, IL2 3,64E-002 5,09E-001
GOTERM_BP_FAT GO:0070665~positive regulation of leukocyte proliferation 3 PTPRC, IL2RA, IL2 3,76E-002 5,09E-001
GOTERM_BP_FAT GO:0032946~positive regulation of mononuclear cell proliferation 3 PTPRC, IL2RA, IL2 3,76E-002 5,09E-001
GOTERM_BP_FAT GO:0042129~regulation of T cell proliferation 3 PTPRC, IL2RA, IL2 4,52E-002 5,54E-001
GOTERM_BP_FAT GO:0045619~regulation of lymphocyte differentiation 3 PTPRC, IL2RA, IL2 4,65E-002 5,59E-001
GOTERM_BP_FAT GO:0030217~T cell differentiation 3 PTPRC, CD1D, IL2 4,92E-002 5,69E-001
GOTERM_BP_FAT GO:0050870~positive regulation of T cell activation 3 PTPRC, IL2RA, IL2 6,49E-002 6,28E-001
GOTERM_BP_FAT GO:0030278~regulation of ossification 3 CALCR, ENPP1, BMPR1B 6,79E-002 6,40E-001
GOTERM_BP_FAT GO:0002683~negative regulation of immune system process 3 PTPRC, IL2RA, IL2 7,57E-002 6,54E-001
GOTERM_BP_FAT GO:0050670~regulation of lymphocyte proliferation 3 PTPRC, IL2RA, IL2 7,57E-002 6,54E-001
GOTERM_BP_FAT GO:0070663~regulation of leukocyte proliferation 3 PTPRC, IL2RA, IL2 7,73E-002 6,53E-001
GOTERM_BP_FAT GO:0032944~regulation of mononuclear cell proliferation 3 PTPRC, IL2RA, IL2 7,73E-002 6,53E-001
GOTERM_BP_FAT GO:0006694~steroid biosynthetic process 3 APOA1, STAR, CYP21A2 7,88E-002 6,53E-001
GOTERM_BP_FAT GO:0015698~inorganic anion transport 3 SLC26A4, ENPP1, SLC26A2 9,19E-002 6,72E-001
GOTERM_BP_FAT GO:0051260~protein homooligomerization 3 TSC2, SKIL, TERF1 9,53E-002 6,75E-001
GOTERM_BP_FAT GO:0051348~negative regulation of transferase activity 3 PTPRC, TSC2, TERF1 9,70E-002 6,78E-001
GOTERM_BP_FAT GO:0051251~positive regulation of lymphocyte activation 3 PTPRC, IL2RA, IL2 9,87E-002 6,81E-001
GOTERM_BP_FAT GO:0046013~regulation of T cell homeostatic proliferation 2 IL2RA, IL2 1,63E-002 5,26E-001
GOTERM_BP_FAT GO:0001955~blood vessel maturation 2 RECK, MMP2 2,17E-002 5,19E-001
GOTERM_BP_FAT GO:0031953~negative regulation of protein amino acid autophosphorylation 2 PTPRC, ENPP1 2,71E-002 5,23E-001
GOTERM_BP_FAT GO:0048304~positive regulation of isotype switching to IgG isotypes 2 PTPRC, IL2 3,24E-002 5,33E-001
GOTERM_BP_FAT GO:0031952~regulation of protein amino acid autophosphorylation 2 PTPRC, ENPP1 3,77E-002 5,04E-001
GOTERM_BP_FAT GO:0048302~regulation of isotype switching to IgG isotypes 2 PTPRC, IL2 4,29E-002 5,40E-001
GOTERM_BP_FAT GO:0051893~regulation of focal adhesion formation 2 ACVRL1, TSC2 4,29E-002 5,40E-001
GOTERM_BP_FAT GO:0042104~positive regulation of activated T cell proliferation 2 IL2RA, IL2 4,82E-002 5,66E-001
GOTERM_BP_FAT GO:0045830~positive regulation of isotype switching 2 PTPRC, IL2 4,82E-002 5,66E-001
GOTERM_BP_FAT GO:0045911~positive regulation of DNA recombination 2 PTPRC, IL2 4,82E-002 5,66E-001
GOTERM_BP_FAT GO:0008211~glucocorticoid metabolic process 2 APOA1, STAR 5,34E-002 5,83E-001
GOTERM_BP_FAT GO:0046006~regulation of activated T cell proliferation 2 IL2RA, IL2 6,37E-002 6,35E-001
GOTERM_BP_FAT GO:0045191~regulation of isotype switching 2 PTPRC, IL2 6,89E-002 6,41E-001
GOTERM_BP_FAT GO:0030279~negative regulation of ossification 2 CALCR, ENPP1 7,40E-002 6,50E-001
GOTERM_BP_FAT GO:0008272~sulfate transport 2 SLC26A4, SLC26A2 7,90E-002 6,49E-001
GOTERM_BP_FAT GO:0031575~G1/S transition checkpoint 2 CDKN2B, GML 8,91E-002 6,75E-001
GOTERM_BP_FAT GO:0019915~lipid storage 2 APOA1, ENPP1 9,41E-002 6,74E-001
GOTERM_BP_FAT GO:0046626~regulation of insulin receptor signaling pathway 2 ENPP1, TSC2 9,90E-002 6,79E-001
PTPRC, IL2RA, RXRA, MSH5, PSG3, CD1D, EPHA3, IFNA1, KLRG1, TFRC, PSG7, TSC2, 
DEFA3, IFNA8, BMPR1B
PTPRC, ACVRL1, BRAF, ENPP1, CDK8, PTPN13, CHEK2, ALK, FES, BMPR1B, CTDP1, 
EPHA3
PTPRC, ACVRL1, BRAF, ENPP1, CDK8, PTPN13, CHEK2, ALK, FES, BMPR1B, CTDP1, 
EPHA3
Table 6S
GOTERM_BP_FAT GO:0045058~T cell selection 2 PTPRC, CD1D 9,90E-002 6,79E-001
GOTERM_CC_FAT GO:0005886~plasma membrane 28 2,09E-002 5,75E-001
GOTERM_CC_FAT GO:0005576~extracellular region 22 5,27E-004 8,18E-002
GOTERM_CC_FAT GO:0044459~plasma membrane part 17 7,37E-002 8,30E-001
GOTERM_CC_FAT GO:0044421~extracellular region part 14 8,02E-004 4,24E-002
GOTERM_CC_FAT GO:0005615~extracellular space 12 IFNA1, APOA1, ENPP1, DEFA3, IL26, IFNA8, DLK1, FGF12, IGFBP1, MMP2, TNFSF8, IL2 5,33E-004 4,23E-002
GOTERM_CC_FAT GO:0005887~integral to plasma membrane 11 CALCR, PTPRC, ACVRL1, TFRC, MMP16, ALK, BMPR1B, SLC26A2, TNFSF8, CD1D, EPHA3 7,00E-002 8,59E-001
GOTERM_CC_FAT GO:0031226~intrinsic to plasma membrane 11 CALCR, PTPRC, ACVRL1, TFRC, MMP16, ALK, BMPR1B, SLC26A2, TNFSF8, CD1D, EPHA3 7,88E-002 8,10E-001
GOTERM_CC_FAT GO:0000267~cell fraction 10 RECK, STS, CYP21A2, TSC2, IL26, DLK1, CYP1A2, FGF20, CRYBA1, SLC26A2 8,93E-002 7,80E-001
GOTERM_CC_FAT GO:0009986~cell surface 5 PTPRC, ACVRL1, IL2RA, ENPP1, MMP16 9,64E-002 7,75E-001
GOTERM_CC_FAT GO:0030141~secretory granule 4 CALCR, APOA1, RAB27B, THBS2 6,13E-002 8,71E-001
GOTERM_CC_FAT GO:0016323~basolateral plasma membrane 4 PTPRC, MYO1A, CA9, ENPP1 8,14E-002 7,83E-001
GOTERM_MF_FAT GO:0008289~lipid binding 8 APOA1, BRAF, STAR, CYP21A2, RXRA, NR2E1, CD1D, IL2 1,13E-002 3,69E-001
GOTERM_MF_FAT GO:0046983~protein dimerization activity 8 HLF, BRAF, ENPP1, TSC2, PAH, EXT1, CRYBA1, TERF1 2,82E-002 5,39E-001
GOTERM_MF_FAT GO:0004672~protein kinase activity 8 ACVRL1, BRAF, CDK8, CHEK2, ALK, FES, BMPR1B, EPHA3 4,72E-002 6,24E-001
GOTERM_MF_FAT GO:0043565~sequence-specific DNA binding 8 HLF, NR1D1, HOXA5, RXRA, ETV1, RORB, NR2E1, TERF1 4,75E-002 5,97E-001
GOTERM_MF_FAT GO:0042803~protein homodimerization activity 6 ENPP1, TSC2, PAH, EXT1, CRYBA1, TERF1 3,58E-002 5,53E-001
GOTERM_MF_FAT GO:0005496~steroid binding 5 APOA1, STAR, CYP21A2, RXRA, NR2E1 4,07E-004 9,43E-002
GOTERM_MF_FAT GO:0003690~double-stranded DNA binding 5 HLF, MSH5, RXRA, PMS2, TERF1 1,94E-003 2,10E-001
GOTERM_MF_FAT GO:0043566~structure-specific DNA binding 5 HLF, MSH5, RXRA, PMS2, TERF1 8,13E-003 3,28E-001
GOTERM_MF_FAT GO:0005125~cytokine activity 5 IFNA1, IL26, IFNA8, TNFSF8, IL2 2,20E-002 5,37E-001
GOTERM_MF_FAT GO:0004857~enzyme inhibitor activity 5 RECK, CDKN2B, SERPINA2, SERPINB13, TERF1 6,03E-002 6,35E-001
GOTERM_MF_FAT GO:0003707~steroid hormone receptor activity 4 NR1D1, RXRA, RORB, NR2E1 2,41E-003 1,78E-001
GOTERM_MF_FAT GO:0004879~ligand-dependent nuclear receptor activity 4 NR1D1, RXRA, RORB, NR2E1 3,90E-003 2,11E-001
GOTERM_MF_FAT GO:0032403~protein complex binding 4 ACVRL1, ENPP1, PMS2, FCGR2A 9,21E-002 6,91E-001
GOTERM_MF_FAT GO:0046332~SMAD binding 3 ACVRL1, SKIL, BMPR1B 2,61E-002 5,53E-001
GOTERM_MF_FAT GO:0004867~serine-type endopeptidase inhibitor activity 3 RECK, SERPINA2, SERPINB13 9,02E-002 7,01E-001
GOTERM_MF_FAT GO:0005025~transforming growth factor beta receptor activity, type I 2 ACVRL1, BMPR1B 3,24E-002 5,51E-001
GOTERM_MF_FAT GO:0008271~secondary active sulfate transmembrane transporter activity 2 SLC26A4, SLC26A2 5,34E-002 6,14E-001
GOTERM_MF_FAT GO:0015116~sulfate transmembrane transporter activity 2 SLC26A4, SLC26A2 6,37E-002 6,32E-001
GOTERM_MF_FAT GO:0017127~cholesterol transporter activity 2 APOA1, STAR 6,37E-002 6,32E-001
GOTERM_MF_FAT GO:0015248~sterol transporter activity 2 APOA1, STAR 7,39E-002 6,66E-001
GOTERM_MF_FAT GO:0015485~cholesterol binding 2 APOA1, STAR 8,91E-002 7,16E-001
GOTERM_MF_FAT GO:0005024~transforming growth factor beta receptor activity 2 ACVRL1, BMPR1B 9,41E-002 6,81E-001
GOTERM_MF_FAT GO:0004675~transmembrane receptor protein serine/threonine kinase activity 2 ACVRL1, BMPR1B 9,41E-002 6,81E-001
GOTERM_MF_FAT GO:0030983~mismatched DNA binding 2 MSH5, PMS2 9,90E-002 6,84E-001
GOTERM_MF_FAT GO:0032934~sterol binding 2 APOA1, STAR 9,90E-002 6,84E-001
INTERPRO IPR017441:Protein kinase, ATP binding site 8 ACVRL1, BRAF, CDK8, CHEK2, ALK, FES, BMPR1B, EPHA3 7,08E-003 3,52E-001
INTERPRO IPR000719:Protein kinase, core 8 ACVRL1, BRAF, CDK8, CHEK2, ALK, FES, BMPR1B, EPHA3 8,96E-003 3,55E-001
INTERPRO IPR008271:Serine/threonine protein kinase, active site 5 ACVRL1, BRAF, CDK8, CHEK2, BMPR1B 9,71E-002 7,69E-001
INTERPRO IPR012351:Four-helical cytokine, core 4 IFNA1, IL26, IFNA8, IL2 1,50E-003 3,06E-001
INTERPRO IPR001628:Zinc finger, nuclear hormone receptor-type 4 NR1D1, RXRA, RORB, NR2E1 1,50E-003 3,06E-001
INTERPRO IPR001723:Steroid hormone receptor 4 NR1D1, RXRA, RORB, NR2E1 1,59E-003 1,77E-001
INTERPRO IPR000536:Nuclear hormone receptor, ligand-binding, core 4 NR1D1, RXRA, RORB, NR2E1 1,69E-003 1,29E-001
INTERPRO IPR008946:Nuclear hormone receptor, ligand-binding 4 NR1D1, RXRA, RORB, NR2E1 1,69E-003 1,29E-001
INTERPRO IPR013151:Immunoglobulin 4 PSG7, PSG3, FCGR2A, PSG1 7,77E-002 8,07E-001
INTERPRO IPR013088:Zinc finger, NHR/GATA-type 3 NR1D1, RORB, NR2E1 2,61E-002 6,59E-001
INTERPRO IPR008266:Tyrosine protein kinase, active site 3 ALK, FES, EPHA3 8,26E-002 7,77E-001
INTERPRO IPR000333:Activin type II receptor 2 ACVRL1, BMPR1B 2,92E-002 6,44E-001
INTERPRO IPR001902:Sulphate anion transporter 2 SLC26A4, SLC26A2 3,40E-002 6,51E-001
INTERPRO IPR003605:TGF beta receptor, GS motif 2 ACVRL1, BMPR1B 3,40E-002 6,51E-001
INTERPRO IPR018045:Sulphate anion transporter, conserved site 2 SLC26A4, SLC26A2 4,82E-002 7,38E-001
INTERPRO IPR000003:Retinoid X receptor 2 RXRA, NR2E1 4,82E-002 7,38E-001
INTERPRO IPR011547:Sulphate transporter 2 SLC26A4, SLC26A2 5,28E-002 7,34E-001
INTERPRO IPR000472:TGF-beta receptor/activin receptor, type I/II 2 ACVRL1, BMPR1B 5,28E-002 7,34E-001
INTERPRO IPR002645:Sulphate transporter/antisigma-factor antagonist STAS 2 SLC26A4, SLC26A2 5,28E-002 7,34E-001
INTERPRO IPR015589:Interferon alpha 2 IFNA1, IFNA8 6,22E-002 7,59E-001
INTERPRO IPR000471:Interferon alpha/beta/delta 2 IFNA1, IFNA8 8,05E-002 7,93E-001
INTERPRO IPR000233:Cadherin cytoplasmic region 2 CDH7, CDH6 8,95E-002 7,83E-001
INTERPRO IPR002209:Heparin-binding growth factor/Fibroblast growth factor 2 FGF12, FGF20 8,95E-002 7,83E-001
INTERPRO IPR002477:Peptidoglycan binding-like 2 MMP16, MMP2 9,40E-002 7,78E-001
KEGG_PATHWAY hsa04060:Cytokine-cytokine receptor interaction 9 IFNA1, ACVRL1, IL2RA, TNFRSF18, IL26, IFNA8, BMPR1B, TNFSF8, IL2 8,13E-004 6,15E-002
KEGG_PATHWAY hsa04630:Jak-STAT signaling pathway 5 IFNA1, IL2RA, IL26, IFNA8, IL2 3,24E-002 4,74E-001
KEGG_PATHWAY hsa04640:Hematopoietic cell lineage 4 IL2RA, DNTT, TFRC, CD1D 2,94E-002 6,88E-001
KEGG_PATHWAY hsa04350:TGF-beta signaling pathway 4 ACVRL1, CDKN2B, BMPR1B, THBS2 3,03E-002 5,51E-001
KEGG_PATHWAY hsa04650:Natural killer cell mediated cytotoxicity 4 IFNA1, BRAF, IFNA8, SH3BP2 8,58E-002 6,88E-001
KEGG_PATHWAY hsa05320:Autoimmune thyroid disease 3 IFNA1, IFNA8, IL2 6,04E-002 6,22E-001
OMIM_DISEASE Breast cancer, susceptibility to 2 XRCC3, CHEK2 5,77E-002 9,95E-001
PIR_SUPERFAMILY PIRSF005448:sulfate transport protein 2 SLC26A4, SLC26A2 5,18E-002 9,72E-001
PIR_SUPERFAMILY PIRSF002534:retinoic X receptor-like nuclear receptor 2 RXRA, NR2E1 7,32E-002 9,22E-001
PIR_SUPERFAMILY PIRSF005503:G protein-coupled receptor, peptide hormone receptor type 2 CALCR, GIPR 8,72E-002 8,70E-001
SMART SM00399:ZnF_C4 4 NR1D1, RXRA, RORB, NR2E1 3,74E-003 2,42E-001
SMART SM00430:HOLI 4 NR1D1, RXRA, RORB, NR2E1 4,22E-003 1,45E-001
SMART SM00467:GS 2 ACVRL1, BMPR1B 4,68E-002 6,94E-001
SP_PIR_KEYWORDS polymorphism 59 5,59E-002 4,50E-001
SP_PIR_KEYWORDS phosphoprotein 41 4,09E-002 4,50E-001
SP_PIR_KEYWORDS glycoprotein 36 6,26E-005 2,86E-003
SP_PIR_KEYWORDS signal 35 2,56E-007 5,86E-005
SP_PIR_KEYWORDS disulfide bond 27 2,03E-004 7,72E-003
SP_PIR_KEYWORDS disease mutation 21 1,24E-005 7,11E-004
SP_PIR_KEYWORDS metal-binding 19 8,95E-002 4,58E-001
SP_PIR_KEYWORDS receptor 18 4,22E-004 1,37E-002
SP_PIR_KEYWORDS Secreted 17 2,39E-003 5,91E-002
SP_PIR_KEYWORDS atp-binding 11 XRCC3, MYO1A, ACVRL1, BRAF, MSH5, CDK8, CHEK2, ALK, FES, BMPR1B, EPHA3 6,28E-002 4,48E-001
SP_PIR_KEYWORDS transferase 11 SULT4A1, ACVRL1, DNTT, BRAF, CDK8, CHEK2, ALK, FES, EXT1, BMPR1B, EPHA3 8,18E-002 4,67E-001
SP_PIR_KEYWORDS Proto-oncogene 10 HLF, HHCM, BRAF, EVI2A, ETV1, SKIL, CHEK2, ALK, FES, IL2 7,22E-007 8,27E-005
SP_PIR_KEYWORDS transmembrane protein 10 CALCR, PTPRC, STS, IL2RA, TFRC, ENPP1, CYP21A2, FCGR2A, CYP1A2, CD1D 1,93E-003 5,37E-002
SP_PIR_KEYWORDS kinase 9 ACVRL1, CDKN2B, BRAF, CDK8, CHEK2, ALK, FES, BMPR1B, EPHA3 1,03E-002 1,67E-001
SP_PIR_KEYWORDS tumor suppressor 5 RECK, CDKN2B, TSC2, PMS2, EXT1 3,06E-003 6,78E-002
SP_PIR_KEYWORDS cytokine 5 IFNA1, IL26, IFNA8, TNFSF8, IL2 8,16E-003 1,57E-001
SP_PIR_KEYWORDS serine/threonine-protein kinase 5 ACVRL1, BRAF, CDK8, CHEK2, BMPR1B 8,55E-002 4,52E-001
SP_PIR_KEYWORDS Pregnancy 4 STS, PSG7, PSG3, PSG1 1,59E-006 1,21E-004
SP_PIR_KEYWORDS ATP 4 ACVRL1, BRAF, CDK8, FES 8,45E-002 4,68E-001
SP_PIR_KEYWORDS transforming protein 3 BRAF, SKIL, FES 9,66E-003 1,69E-001
SP_PIR_KEYWORDS steroid metabolism 3 SULT4A1, STS, APOA1 1,87E-002 2,65E-001
CALCR, ACVRL1, ENPP1, MMP2, SLC26A2, CDH6, CDH7, APOA1, TNFRSF18, GML, 
RECK, PTPRC, STS, MYO1A, IL2RA, BRAF, MMP16, ALK, CD1D, EPHA3, TNFSF8, 
SLC26A4, CA9, TFRC, TSC2, GIPR, FCGR2A, BMPR1B
ENPP1, IL26, PSG3, MMP16, DLK1, FGF12, PSG1, FGF20, MMP2, EPHA3, TNFSF8, IFNA1, 
APOA1, PSG7, TFRC, IMPG1, TNFRSF18, DEFA3, IGFBP1, IFNA8, THBS2, IL2
CALCR, PTPRC, MYO1A, ACVRL1, IL2RA, ENPP1, MMP16, ALK, SLC26A2, CD1D, EPHA3, 
TNFSF8, SLC26A4, CA9, TFRC, TSC2, BMPR1B
ENPP1, IL26, MMP16, DLK1, FGF12, MMP2, TNFSF8, IFNA1, APOA1, IMPG1, DEFA3, 
IGFBP1, IFNA8, IL2
XRCC3, ACVRL1, STAR, DLK1, FES, SLC26A2, MMP2, APOA1, DNTT, PMS2, RAB27B, 
STAG1, RECK, BRAF, RXRA, CDK8, PSG3, CYP1A2, PSG1, FGF20, ALK, SLC26A4, 
KLRG1, PSG7, CA9, GIPR, CTDP1, CTSF, CALCR, ENPP1, PAH, CHEK2, CDH7, IFNA1, 
IMPG1, TNFRSF18, ETV1, NDRG2, SERPINB13, IFNA8, SKIL, GML, THBS2, BRD1, PTPRC, 
MYO1A, IL2RA, CYP21A2, MSH5, PTPN13, MAGEB1, EPHA3, CD1D, TFRC, TSC2, IGFBP1, 
FCGR2A, BMPR1B, ST5
XRCC3, ACVRL1, STAR, ENPP1, PAH, CHEK2, FES, CBFA2T2, NR2E1, MMP2, SLC26A2, 
IFNA1, APOA1, NR1D1, EVI2A, PMS2, NDRG2, SKIL, TERF1, STAG1, BRD1, PTPRC, 
IL2RA, BRAF, CDK8, PTPN13, MMP16, ALK, EPHA3, KLRG1, TFRC, CA9, TSC2, DEFA3, 
IGFBP1, FCGR2A, ST5, CTDP1, CRYBA1, CTSF, SH3BP2
CALCR, ACVRL1, ENPP1, DLK1, MMP2, SLC26A2, CDH6, CDH7, APOA1, EVI2A, IMPG1, 
TNFRSF18, SERPINA2, GML, THBS2, RECK, PTPRC, STS, IL2RA, PSG3, MMP16, PSG1, 
ALK, TNFSF8, CD1D, EPHA3, KLRG1, PSG7, TFRC, CA9, GIPR, TSC2, FCGR2A, EXT1, IL2, 
CTSF
CALCR, ACVRL1, DLK1, MMP2, CDH6, CDH7, IFNA1, APOA1, EVI2A, IMPG1, TNFRSF18, 
SERPINA2, IFNA8, GML, THBS2, RECK, PTPRC, STS, IL2RA, IL26, PSG3, MMP16, PSG1, 
ALK, CD1D, EPHA3, PSG7, CA9, GIPR, DEFA3, IGFBP1, FCGR2A, BMPR1B, IL2, CTSF
ENPP1, DLK1, MMP2, IFNA1, TNFRSF18, IFNA8, GML, RAB27B, THBS2, RECK, STS, 
IL2RA, PSG3, MMP16, PSG1, CD1D, TNFSF8, KLRG1, CA9, PSG7, TFRC, GIPR, DEFA3, 
FCGR2A, IGFBP1, IL2, CTSF
PTPRC, MYO1A, STS, XRCC3, ACVRL1, STAR, ENPP1, BRAF, CYP21A2, PAH, CHEK2, 
MMP2, SLC26A2, SLC26A4, APOA1, CDKN2B, TSC2, PMS2, EXT1, BMPR1B, SH3BP2
BRD1, STS, ACVRL1, ENPP1, BRAF, CYP21A2, RXRA, PAH, MMP16, RORB, CYP1A2, 
CHEK2, MMP2, NR2E1, CBFA2T2, CA9, DNTT, NR1D1, BMPR1B
CALCR, PTPRC, ACVRL1, IL2RA, RXRA, PTPN13, RORB, ALK, NR2E1, EPHA3, KLRG1, 
NR1D1, TFRC, IMPG1, GIPR, TNFRSF18, FCGR2A, BMPR1B
IL26, PSG3, MMP16, PSG1, FGF20, MMP2, EPHA3, IFNA1, APOA1, TFRC, PSG7, IMPG1, 
TNFRSF18, DEFA3, IGFBP1, IFNA8, IL2
Table 6S
SP_PIR_KEYWORDS Antiviral defense 3 IFNA1, DEFA3, IFNA8 3,01E-002 3,73E-001
SP_PIR_KEYWORDS tandem repeat 3 PSG7, PSG3, PSG1 4,26E-002 4,44E-001
SP_PIR_KEYWORDS membrane protein 3 TSC2, PSG3, TNFSF8 4,47E-002 4,41E-001
SP_PIR_KEYWORDS Monooxygenase 3 CYP21A2, PAH, CYP1A2 4,57E-002 4,31E-001
SP_PIR_KEYWORDS Serine protease inhibitor 3 RECK, SERPINA2, SERPINB13 4,78E-002 4,14E-001
SP_PIR_KEYWORDS plasma 3 APOA1, PSG7, PSG1 6,25E-002 4,60E-001
SP_PIR_KEYWORDS microsome 3 STS, CYP21A2, CYP1A2 7,84E-002 4,75E-001
SP_PIR_KEYWORDS protease inhibitor 3 RECK, SERPINA2, SERPINB13 7,97E-002 4,69E-001
SP_PIR_KEYWORDS tyrosine-protein kinase 3 ALK, FES, EPHA3 8,48E-002 4,59E-001
SP_PIR_KEYWORDS steroidogenesis 2 STAR, CYP21A2 4,70E-002 4,24E-001
SP_PIR_KEYWORDS antiviral 2 IFNA1, IFNA8 5,95E-002 4,57E-001
SP_PIR_KEYWORDS leukocyte 2 IFNA1, IFNA8 6,36E-002 4,39E-001
SP_PIR_KEYWORDS collagen degradation 2 MMP16, MMP2 7,17E-002 4,68E-001
SP_PIR_KEYWORDS cytokine receptor 2 IL2RA, TNFSF8 7,58E-002 4,75E-001
UP_SEQ_FEATURE sequence variant 65 6,09E-003 2,03E-001
UP_SEQ_FEATURE signal peptide 35 2,99E-007 1,00E-004
UP_SEQ_FEATURE glycosylation site:N-linked (GlcNAc...) 32 9,63E-004 6,25E-002
UP_SEQ_FEATURE disulfide bond 27 1,23E-004 2,04E-002
UP_SEQ_FEATURE topological domain:Cytoplasmic 25 9,05E-003 2,42E-001
UP_SEQ_FEATURE topological domain:Extracellular 23 2,77E-003 1,24E-001
UP_SEQ_FEATURE nucleotide phosphate-binding region:ATP 11 XRCC3, MYO1A, ACVRL1, BRAF, MSH5, CDK8, CHEK2, ALK, FES, BMPR1B, EPHA3 9,41E-003 2,32E-001
UP_SEQ_FEATURE domain:Protein kinase 8 ACVRL1, BRAF, CDK8, CHEK2, ALK, FES, BMPR1B, EPHA3 4,57E-003 1,75E-001
UP_SEQ_FEATURE binding site:ATP 8 ACVRL1, BRAF, CDK8, CHEK2, ALK, FES, BMPR1B, EPHA3 9,81E-003 2,24E-001
UP_SEQ_FEATURE active site:Proton acceptor 8 ACVRL1, BRAF, CDK8, CHEK2, ALK, FES, BMPR1B, EPHA3 2,56E-002 4,63E-001
UP_SEQ_FEATURE glycosylation site:O-linked (GalNAc...) 5 IL2RA, TFRC, IMPG1, DLK1, IL2 7,23E-004 5,88E-002
UP_SEQ_FEATURE region of interest:Ligand-binding 4 TFRC, RXRA, RORB, NR2E1 3,05E-004 3,35E-002
UP_SEQ_FEATURE DNA-binding region:Nuclear receptor 4 NR1D1, RXRA, RORB, NR2E1 1,02E-003 5,52E-002
UP_SEQ_FEATURE zinc finger region:NR C4-type 4 NR1D1, RXRA, RORB, NR2E1 1,02E-003 5,52E-002
UP_SEQ_FEATURE short sequence motif:Cell attachment site 4 PSG7, PSG3, IGFBP1, THBS2 6,87E-003 2,06E-001
UP_SEQ_FEATURE domain:Ig-like C2-type 1 4 PSG7, PSG3, FCGR2A, PSG1 5,13E-002 6,46E-001
UP_SEQ_FEATURE domain:Ig-like C2-type 2 4 PSG7, PSG3, FCGR2A, PSG1 5,20E-002 6,30E-001
UP_SEQ_FEATURE domain:GS 2 ACVRL1, BMPR1B 3,04E-002 4,98E-001
UP_SEQ_FEATURE domain:STAS 2 SLC26A4, SLC26A2 4,73E-002 6,37E-001
UP_SEQ_FEATURE domain:BRCT 2 DNTT, CTDP1 5,98E-002 6,63E-001
UP_SEQ_FEATURE domain:Hemopexin-like 3 2 MMP16, MMP2 9,24E-002 8,03E-001
UP_SEQ_FEATURE region of interest:Hinge 2 RXRA, RORB 9,24E-002 8,03E-001
UP_SEQ_FEATURE domain:Hemopexin-like 4 2 MMP16, MMP2 9,24E-002 8,03E-001
UP_SEQ_FEATURE domain:Hemopexin-like 1 2 MMP16, MMP2 9,64E-002 8,02E-001
UP_SEQ_FEATURE domain:Hemopexin-like 2 2 MMP16, MMP2 9,64E-002 8,02E-001
HLF, XRCC3, ACVRL1, STAR, DLK1, FES, SLC26A2, MMP2, APOA1, DNTT, CDKN2B, 
PMS2, RAB27B, STAG1, RECK, STS, BRAF, RXRA, CDK8, PSG3, CYP1A2, PSG1, FGF20, 
ALK, SLC26A4, KLRG1, PSG7, CA9, GIPR, EXT1, CTDP1, CTSF, CALCR, ENPP1, PAH, 
CHEK2, CDH7, IFNA1, IMPG1, TNFRSF18, ETV1, NDRG2, SERPINB13, IFNA8, SKIL, GML, 
THBS2, PTPRC, BRD1, MYO1A, IL2RA, CYP21A2, MSH5, PTPN13, MAGEB1, EPHA3, 
CD1D, TFRC, TSC2, IGFBP1, FCGR2A, BMPR1B, ST5, IL2, SH3BP2
CALCR, ACVRL1, DLK1, MMP2, CDH6, CDH7, IFNA1, APOA1, EVI2A, IMPG1, TNFRSF18, 
SERPINA2, IFNA8, GML, THBS2, RECK, PTPRC, STS, IL2RA, IL26, PSG3, MMP16, PSG1, 
ALK, CD1D, EPHA3, PSG7, CA9, GIPR, DEFA3, IGFBP1, FCGR2A, BMPR1B, IL2, CTSF
CALCR, ACVRL1, ENPP1, DLK1, MMP2, SLC26A2, CDH6, CDH7, EVI2A, IMPG1, 
TNFRSF18, SERPINA2, THBS2, RECK, PTPRC, STS, IL2RA, PSG3, MMP16, PSG1, ALK, 
TNFSF8, CD1D, EPHA3, KLRG1, CA9, PSG7, TFRC, GIPR, FCGR2A, EXT1, CTSF
ENPP1, DLK1, MMP2, IFNA1, TNFRSF18, IFNA8, GML, RAB27B, THBS2, RECK, STS, 
IL2RA, PSG3, MMP16, PSG1, CD1D, TNFSF8, KLRG1, CA9, PSG7, TFRC, GIPR, DEFA3, 
FCGR2A, IGFBP1, IL2, CTSF
CALCR, ACVRL1, ENPP1, DLK1, SLC26A2, CDH6, CDH7, EVI2A, TNFRSF18, PTPRC, STS, 
IL2RA, MMP16, ALK, CD1D, EPHA3, TNFSF8, SLC26A4, KLRG1, CA9, TFRC, GIPR, 
FCGR2A, EXT1, BMPR1B
CALCR, PTPRC, ACVRL1, IL2RA, ENPP1, MMP16, DLK1, ALK, SLC26A2, CD1D, CDH6, 
EPHA3, TNFSF8, SLC26A4, CDH7, KLRG1, CA9, TFRC, EVI2A, GIPR, TNFRSF18, FCGR2A, 
BMPR1B
Table 7S
Pathway ID source members_input_overlap p-value q-value
atm signaling pathway BioCarta ATM; MDM2; RBBP8; JUN; TP73 3,23E-06 1,23E-03
Prostate Cancer Wikipathways ATM; JUN; ERG; RAD50; ABCC4; MDM2; RAF1; HSD17B2; TSC1 1,67E-05 3,16E-03
KEGG 3,16E-05 3,99E-03
Pathways in cancer - Homo sapiens (human) KEGG 1,34E-04 9,88E-03
DNA Repair Reactome XPC; LIG3; ATM; TDG; ERCC6; FANCE; FANCC; RAD50 1,48E-04 9,88E-03
Wnt Signaling Pathway Wikipathways WNT2B; PRKCH; JUN; WNT1; PRKCE; FRAT1 1,56E-04 9,88E-03
DNA damage response (only ATM dependent) Wikipathways WNT2B; WNT1; ATM; JUN; TP73; FRAT1; MDM2 2,17E-04 1,13E-02
role of brca1 brca2 and atr in cancer susceptibility BioCarta FANCE; ATM; FANCC; RAD50 2,38E-04 1,13E-02
IL-3 Signaling Pathway Wikipathways STAT5B; JUN; RAF1; IL8; HCK 3,43E-04 1,25E-02
Wnt Signaling Pathway and Pluripotency Wikipathways WNT2B; PRKCH; PPP2R1B; PRKCE; WNT1; JUN; FRAT1 3,68E-04 1,25E-02
EPO Receptor Signaling Wikipathways STAT5B; PTPRU; RAF1; EPO 3,90E-04 1,25E-02
Integrated Pancreatic Cancer Pathway Wikipathways 3,95E-04 1,25E-02
keratinocyte differentiation BioCarta PRKCH; CEBPA; JUN; RAF1; PRKCE 7,39E-04 2,16E-02
Classical Pathway with Drug Info Wikipathways 8,61E-04 2,16E-02
Private Wikipathways 8,61E-04 2,16E-02
Apoptosis Wikipathways IGF2; JUN; TP73; CFLAR; MDM2; APAF1 9,14E-04 2,16E-02
Fluoropyrimidine Activity Wikipathways ABCC4; ABCG2; TDG; CDA 9,91E-04 2,21E-02
KEGG PTGS2; ATM; CFLAR; TNFRSF11A; MALT1; IL8 1,48E-03 3,11E-02
Endochondral Ossification Wikipathways IGF2; RUNX2; STAT5B; CTSL2; PTH 1,62E-03 3,24E-02
KEGG AMPH; VAV2; PRKCE; DNM1; HCK; RAF1 1,84E-03 3,36E-02
TSH signaling pathway Wikipathways JUN; GNA12; RAF1; GNA13; PAX8 1,87E-03 3,36E-02
KitReceptor NetPath STAT5B; PTPRU; JUN; RAF1; HCK 2,00E-03 3,36E-02
TP53 network Wikipathways MDM2; ATM; TP73 2,04E-03 3,36E-02
p53 signaling pathway - Homo sapiens (human) KEGG ATM; MDM2; PPM1D; APAF1; TP73 2,28E-03 3,60E-02
Platelet activation, signaling and aggregation Reactome 2,42E-03 3,60E-02
Bladder cancer - Homo sapiens (human) KEGG PGF; MDM2; RAF1; IL8 2,47E-03 3,60E-02
Long-term depression - Homo sapiens (human) KEGG CACNA1A; PPP2R1B; GNA12; RAF1; GNA13 2,59E-03 3,64E-02
KEGG PPP2R1B; TGFB3; JUN; CFLAR; C3; IL8 2,91E-03 3,73E-02
ABC transporters - Homo sapiens (human) KEGG ABCC4; TAP1; ABCG2; ABCA3 2,93E-03 3,73E-02
hypoxia and p53 in the cardiovascular system BioCarta FHL2; MDM2; ATM 3,15E-03 3,73E-02
inhibition of cellular proliferation by gleevec BioCarta STAT5B; JUN; RAF1 3,15E-03 3,73E-02
BioCarta CACNA1A; GNA12; GNA13 3,15E-03 3,73E-02
KEGG 3,31E-03 3,80E-02
KEGG JUN; DAPP1; RAF1; MALT1; VAV2 3,71E-03 4,07E-02
AndrogenReceptor NetPath NR2C2; CEBPA; RUNX2; JUN; FHL2; AHR; MDM2 3,76E-03 4,07E-02
IL5 NetPath HCK; JUN; RAF1; STAT5B 4,03E-03 4,15E-02
Wikipathways JUN; PRKCE; LIFR 4,06E-03 4,15E-02
Integrated Breast Cancer Pathway Wikipathways RAD54L; ATM; JUN; AHR; RAD50; MDM2; TSC1 4,36E-03 4,30E-02
tpo signaling pathway BioCarta STAT5B; JUN; RAF1 4,56E-03 4,30E-02
Signaling Pathways in Glioblastoma Wikipathways PRKCH; MDM2; ATM; RAF1; TSC1 4,62E-03 4,30E-02
Cytochrome P450 - arranged by substrate type Reactome CYP27A1; CYP4A11; PTGIS; POMC 4,67E-03 4,30E-02
Reactome ATM; RAD50 4,89E-03 4,30E-02
Fanconi Anemia pathway Reactome FANCE; ATM; FANCC 5,11E-03 4,30E-02
TSH NetPath GNA12; RAF1; GNA13 5,11E-03 4,30E-02
KEGG PRKCH; CYP4A11; PRKCE; GNA12; GNA13; RAF1 5,20E-03 4,30E-02
KEGG IFNW1; IL13RA2; CSF2RA; EPO; STAT5B; IL22; LIFR 5,21E-03 4,30E-02
Androgen receptor signaling pathway Wikipathways FHL2; RUNX2; MDM2; JUN; NR2C2 5,98E-03 4,78E-02
Reactome RUNX2; TEAD4 6,23E-03 4,78E-02
brca1 dependent ub ligase activity BioCarta FANCE; FANCC 6,23E-03 4,78E-02
Homologous recombination - Homo sapiens (human) KEGG RAD54L; XRCC2; RAD50 6,31E-03 4,78E-02
TNF alpha Signaling Pathway Wikipathways JUN; RIPK3; RAF1; APAF1; CFLAR 6,59E-03 4,90E-02
Stabilization of p53 Reactome MDM2; ATM 7,71E-03 5,52E-02
Vitamin D synthesis Wikipathways CYP27A1; PTH 7,71E-03 5,52E-02
Rheumatoid arthritis - Homo sapiens (human) KEGG PGF; TGFB3; JUN; TNFRSF11A; IL8 7,95E-03 5,53E-02
BCR NetPath DAPP1; VAV2; JUN; CD5; HCK; MALT1 8,29E-03 5,53E-02
G Protein Signaling Pathways Wikipathways PRKCH; PRKCE; GNA12; AKAP1; GNA13 8,31E-03 5,53E-02
B Cell Receptor Signaling Pathway Wikipathways JUN; DAPP1; RAF1; MALT1; VAV2 8,31E-03 5,53E-02
Adipogenesis Wikipathways CEBPA; WNT1; PTGIS; AHR; STAT5B; LIFR 8,60E-03 5,62E-02
Asparagine N-linked glycosylation Wikipathways DPAGT1; MGAT5; FUT8 9,18E-03 5,80E-02
epo signaling pathway BioCarta STAT5B; EPO 9,34E-03 5,80E-02
Transcriptional misregulation in cancer - Homo 
sapiens (human)
CEBPA; ATM; ID2; MLLT3; RUNX2; ERG; IL8; MDM2; PAX8; 
HOXA9; FUT8
PGF; PTGS2; CEBPA; TGFB3; WNT1; JUN; DCC; STAT5B; 
CSF2RA; WNT2B; MDM2; RAF1; PAX8; IL8
PTGS2; WRN; LIG3; ATM; JUN; DCC; RAD50; MDM2; RAF1; 
APAF1
PTGS2; WRN; LIG3; ATM; JUN; DCC; RAD50; MDM2; RAF1; 
APAF1
PTGS2; WRN; LIG3; ATM; JUN; DCC; RAD50; MDM2; RAF1; 
APAF1
NF-kappa B signaling pathway - Homo sapiens 
(human)
Fc gamma R-mediated phagocytosis - Homo sapiens 
(human)
PRKCH; TGFB3; VAV2; PRKCE; COL1A2; GNA13; ABCC4; 
GNA12; RAF1
Chagas disease (American trypanosomiasis) - Homo 
sapiens (human)
pkc-catalyzed phosphorylation of inhibitory 
phosphoprotein of myosin phosphatase
Cytokine-cytokine receptor interaction - Homo 
sapiens (human)
IFNW1; TGFB3; IL22; EPO; TNFRSF14; CSF2RA; TNFRSF8; 
TNFRSF11A; IL8; LIFR
B cell receptor signaling pathway - Homo sapiens 
(human)
Physiological and Pathological Hypertrophy of the 
Heart
Recruitment of repair and signaling proteins to 
double-strand breaks
Vascular smooth muscle contraction - Homo sapiens 
(human)
Jak-STAT signaling pathway - Homo sapiens 
(human)
YAP1- and WWTR1 (TAZ)-stimulated gene 
expression
Table 7S
il22 soluble receptor signaling pathway BioCarta STAT5B; IL22 9,34E-03 5,80E-02
Colorectal cancer - Homo sapiens (human) KEGG JUN; TGFB3; RAF1; DCC 9,98E-03 6,10E-02
Table 8S
Pathway ID source members_input_overlap p-value q-value
KEGG IL2RA; IFNA8; IFNA1; BMPR1B; TNFSF8; IL2; IL26; TNFRSF18 3,54E-04 2,93E-02
Nuclear Receptor transcription pathway Reactome NR1D1; NR2E1; RXRA; RORB 3,55E-04 2,93E-02
AhR pathway Wikipathways CYP1A2; IGFBP1; IL2 9,12E-04 3,93E-02
Multifunctional anion exchangers Reactome SLC26A2; SLC26A4 1,19E-03 3,93E-02
inhibition of matrix metalloproteinases BioCarta RECK; MMP2 1,19E-03 3,93E-02
KEGG IL2RA; IFNA8; IFNA1; THBS2; IL2; FGF12; TSC2; FGF20 1,61E-03 4,42E-02
KEGG IL2RA; CD1D; TFRC; DNTT 2,75E-03 6,49E-02
KEGG IL2RA; IFNA1; IFNA8; IL2; IL26 3,65E-03 7,52E-02
il 2 signaling pathway BioCarta IL2RA; IL2 4,34E-03 7,66E-02
KEGG IFNA1; IFNA8; IL2 4,94E-03 7,66E-02
Estrogen metabolism Wikipathways CYP1A2; STS 5,57E-03 7,66E-02
Reactome IGFBP1; MMP2 5,57E-03 7,66E-02
Wikipathways CYP21A2; STAR 7,68E-03 8,97E-02
Semaphorin interactions Wikipathways PTPRC; FES 7,68E-03 8,97E-02
KEGG NR1D1; RORB 9,26E-03 8,97E-02
Cytokine-cytokine receptor interaction - Homo 
sapiens (human)
PI3K-Akt signaling pathway - Homo sapiens 
(human)
Hematopoietic cell lineage - Homo sapiens 
(human)
Jak-STAT signaling pathway - Homo sapiens 
(human)
Autoimmune thyroid disease - Homo sapiens 
(human)
Regulation of Insulin-like Growth Factor (IGF) 
Activity by Insulin-like Growth Factor Binding 
Proteins (IGFBPs)
Metabolism of steroid hormones and vitamins A 
and D




Transcription Factor P.value E.value Q.value Intersection Target genes
SMAD3 1.00e-5 7.10e-4 7.10e-4 9 55
TP53 3.00e-5 2.13e-3 1.06e-3 11 97
SMAD2 1.15e-3 8.16e-2 2.72e-2 4 19
JUN 1.58e-3 1.12e-1 2.80e-2 8 88
CEBPB 7.09e-3 5.03e-1 1.01e-1 3 16
EP300 9.05e-3 6.43e-1 1.07e-1 2 6
EGR1 1.14e-2 8.07e-1 1.11e-1 4 35
SMAD4 1.25e-2 8.90e-1 1.11e-1 4 36
GATA1 2.21e-2 1.57e+0 1.75e-1 3 24
CREB1 4.77e-2 3.39e+0 2.25e-1 4 54
VDR 5.05e-2 3.58e+0 2.25e-1 1 2
EBF1 5.05e-2 3.58e+0 2.25e-1 1 2
SOX9 5.05e-2 3.58e+0 2.25e-1 1 2
BRCA1 5.05e-2 3.58e+0 2.25e-1 1 2
ETS1 5.05e-2 3.58e+0 2.25e-1 4 55
CEBPA 5.06e-2 3.60e+0 2.25e-1 3 33
HBP1 5.46e-2 3.88e+0 2.28e-1 2 15
RUNX2 6.85e-2 4.86e+0 2.44e-1 2 17
DLX5 7.47e-2 5.31e+0 2.44e-1 1 3
JUND 7.47e-2 5.31e+0 2.44e-1 1 3
NANOG 7.47e-2 5.31e+0 2.44e-1 1 3
NFKB1 7.58e-2 5.38e+0 2.44e-1 4 63
YY1 9.57e-2 6.80e+0 2.61e-1 3 43
MSX2 9.84e-2 6.99e+0 2.61e-1 1 4
PPARG 9.84e-2 6.99e+0 2.61e-1 1 4
CEBPD 9.84e-2 6.99e+0 2.61e-1 1 4
NR5A1 9.91e-2 7.04e+0 2.61e-1 2 21
POU5F1 1.44e-1 1.02e+1 3.65e-1 1 6
FOXO4 1.66e-1 1.18e+1 3.96e-1 1 7
SP1 1.67e-1 1.19e+1 3.96e-1 7 178
GATA3 1.87e-1 1.33e+1 4.29e-1 1 8
E2F6 2.08e-1 1.48e+1 4.62e-1 1 9
FOXO1 2.23e-1 1.58e+1 4.80e-1 6 160
ETS2 2.48e-1 1.76e+1 5.18e-1 1 11
GATA2 2.67e-1 1.90e+1 5.41e-1 1 12
GLI2 2.74e-1 1.95e+1 5.41e-1 4 104
SMAD1 3.05e-1 2.16e+1 5.84e-1 1 14
HIF1A 4.35e-1 3.09e+1 8.13e-1 1 22
RBPJ 4.88e-1 3.46e+1 8.72e-1 3 102
E2F4 5.04e-1 3.58e+1 8.72e-1 1 27
SP3 5.04e-1 3.58e+1 8.72e-1 1 27
FOXO3 5.16e-1 3.66e+1 8.72e-1 2 67
MYC 5.73e-1 4.07e+1 9.47e-1 5 197
SREBF2 5.87e-1 4.17e+1 9.47e-1 1 34
GLI1 6.10e-1 4.33e+1 9.63e-1 3 122
NOTCH1 6.47e-1 4.59e+1 9.99e-1 1 40
STAT5A 6.82e-1 4.84e+1 1.00e+0 1 44
STAT5B 6.82e-1 4.84e+1 1.00e+0 1 44
AR 6.91e-1 4.90e+1 1.00e+0 1 45
Table 9S
SREBF1 7.29e-1 5.17e+1 1.00e+0 1 50
STAT3 7.36e-1 5.22e+1 1.00e+0 1 51
CTNNB1 7.93e-1 5.63e+1 1.00e+0 6 300
TCF7L2 7.97e-1 5.66e+1 1.00e+0 1 61
E2F1 9.14e-1 6.49e+1 1.00e+0 2 155
SMAD7 1.00e+0 7.10e+1 1.00e+0 0 10
SMAD6 1.00e+0 7.10e+1 1.00e+0 0 2
MITF 1.00e+0 7.10e+1 1.00e+0 0 25
HNF1A 1.00e+0 7.10e+1 1.00e+0 0 39
ELF1 1.00e+0 7.10e+1 1.00e+0 0 2
RELB 1.00e+0 7.10e+1 1.00e+0 0 3
SOX2 1.00e+0 7.10e+1 1.00e+0 0 11
SMAD5 1.00e+0 7.10e+1 1.00e+0 0 5
NR1H3 1.00e+0 7.10e+1 1.00e+0 0 17
NR1H2 1.00e+0 7.10e+1 1.00e+0 0 17
ID2 1.00e+0 7.10e+1 1.00e+0 0 3
NR2F1 1.00e+0 7.10e+1 1.00e+0 0 16
TCF7 1.00e+0 7.10e+1 1.00e+0 0 17
LEF1 1.00e+0 7.10e+1 1.00e+0 0 30
RELA 1.00e+0 7.10e+1 1.00e+0 0 35
STAT1 1.00e+0 7.10e+1 1.00e+0 0 25
ID3 1.00e+0 7.10e+1 1.00e+0 0 3
inhibited TFs
Transcription Factor P.value E.value Q.value Intersection Target genes
RBPJ 1.44e-2 1.02e+0 5.74e-1 7 102
HIF1A 1.74e-2 1.24e+0 5.74e-1 3 22
SMAD6 5.05e-2 3.58e+0 5.74e-1 1 2
ELF1 5.05e-2 3.58e+0 5.74e-1 1 2
NR2F1 6.14e-2 4.36e+0 5.74e-1 2 16
TCF7 6.85e-2 4.86e+0 5.74e-1 2 17
ID3 7.47e-2 5.31e+0 5.74e-1 1 3
ID2 7.47e-2 5.31e+0 5.74e-1 1 3
RELB 7.47e-2 5.31e+0 5.74e-1 1 3
NOTCH1 8.09e-2 5.74e+0 5.74e-1 3 40
SMAD5 1.21e-1 8.63e+0 7.84e-1 1 5
LEF1 1.78e-1 1.26e+1 9.50e-1 2 30
JUN 1.86e-1 1.32e+1 9.50e-1 4 88
GATA3 1.87e-1 1.33e+1 9.50e-1 1 8
FOXO1 2.23e-1 1.58e+1 1.00e+0 6 160
SMAD7 2.28e-1 1.62e+1 1.00e+0 1 10
SOX2 2.48e-1 1.76e+1 1.00e+0 1 11
GATA2 2.67e-1 1.90e+1 1.00e+0 1 12
SMAD1 3.05e-1 2.16e+1 1.00e+0 1 14
NR1H3 3.57e-1 2.53e+1 1.00e+0 1 17
NR1H2 3.57e-1 2.53e+1 1.00e+0 1 17
CTNNB1 3.58e-1 2.54e+1 1.00e+0 9 300
GLI1 3.80e-1 2.70e+1 1.00e+0 4 122
MYC 3.90e-1 2.77e+1 1.00e+0 6 197
ETS1 4.13e-1 2.93e+1 1.00e+0 2 55
NR5A1 4.20e-1 2.98e+1 1.00e+0 1 21
TP53 4.54e-1 3.22e+1 1.00e+0 3 97
Table 9S
STAT1 4.78e-1 3.39e+1 1.00e+0 1 25
MITF 4.78e-1 3.39e+1 1.00e+0 1 25
NFKB1 4.83e-1 3.43e+1 1.00e+0 2 63
GLI2 5.01e-1 3.55e+1 1.00e+0 3 104
FOXO3 5.16e-1 3.66e+1 1.00e+0 2 67
SREBF2 5.87e-1 4.17e+1 1.00e+0 1 34
RELA 5.98e-1 4.24e+1 1.00e+0 1 35
HNF1A 6.38e-1 4.53e+1 1.00e+0 1 39
YY1 6.74e-1 4.78e+1 1.00e+0 1 43
STAT5A 6.82e-1 4.84e+1 1.00e+0 1 44
STAT5B 6.82e-1 4.84e+1 1.00e+0 1 44
AR 6.91e-1 4.90e+1 1.00e+0 1 45
SREBF1 7.29e-1 5.17e+1 1.00e+0 1 50
STAT3 7.36e-1 5.22e+1 1.00e+0 1 51
CREB1 7.56e-1 5.37e+1 1.00e+0 1 54
E2F1 7.67e-1 5.45e+1 1.00e+0 3 155
TCF7L2 7.97e-1 5.66e+1 1.00e+0 1 61
SP1 9.91e-1 7.04e+1 1.00e+0 1 178
RUNX2 1.00e+0 7.10e+1 1.00e+0 0 17
PPARG 1.00e+0 7.10e+1 1.00e+0 0 4
E2F6 1.00e+0 7.10e+1 1.00e+0 0 9
SMAD2 1.00e+0 7.10e+1 1.00e+0 0 19
E2F4 1.00e+0 7.10e+1 1.00e+0 0 27
SP3 1.00e+0 7.10e+1 1.00e+0 0 27
VDR 1.00e+0 7.10e+1 1.00e+0 0 2
SOX9 1.00e+0 7.10e+1 1.00e+0 0 2
POU5F1 1.00e+0 7.10e+1 1.00e+0 0 6
SMAD4 1.00e+0 7.10e+1 1.00e+0 0 36
SMAD3 1.00e+0 7.10e+1 1.00e+0 0 55
HBP1 1.00e+0 7.10e+1 1.00e+0 0 15
GATA1 1.00e+0 7.10e+1 1.00e+0 0 24
CEBPD 1.00e+0 7.10e+1 1.00e+0 0 4
FOXO4 1.00e+0 7.10e+1 1.00e+0 0 7
ETS2 1.00e+0 7.10e+1 1.00e+0 0 11
EBF1 1.00e+0 7.10e+1 1.00e+0 0 2
EP300 1.00e+0 7.10e+1 1.00e+0 0 6
CEBPB 1.00e+0 7.10e+1 1.00e+0 0 16
CEBPA 1.00e+0 7.10e+1 1.00e+0 0 33
NANOG 1.00e+0 7.10e+1 1.00e+0 0 3
DLX5 1.00e+0 7.10e+1 1.00e+0 0 3
MSX2 1.00e+0 7.10e+1 1.00e+0 0 4
BRCA1 1.00e+0 7.10e+1 1.00e+0 0 2
JUND 1.00e+0 7.10e+1 1.00e+0 0 3
EGR1 1.00e+0 7.10e+1 1.00e+0 0 35
